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Summary 
Chronic lung disease (CLD) is a common respiratory sequalae of infants born 
extremely premature (< 32 weeks gestational age). A persistent and poorly-resolving 
neutrophilic lung inflammation has been strongly implicated in the development of 
CLD. Pathways of resolution of lung inflammation have been poorly characterised in 
preterm infants.  
Interleukin-8 (IL-8) is an key neutrophil chemokine implicated in the 
pathogenesis of CLD. Longer, and less functionally potent, isoforms of IL-8 
predominate the preterm circulation but their expression and function in the preterm 
lungs is not known. The complex of interleukin-6 (IL-6), along with the soluble IL-6 
receptor (sIL-6R), initiates IL-6 trans-signalling which experimentally has demonstrated 
downregulation of IL-8 during acute inflammation. Expression of IL-6 trans-signalling 
cytokines and their functional activity in the preterm lungs have not been studied. 
My work shows that the concentration of sgp130, a specific inhibitor of IL-6 
trans-signalling, was significantly increased in the bronchoalveolar lavage fluid (BALF) 
of preterm ventilated baboons, and human infants developing CLD later, compared to 
infants who did not. Although total IL-6 activity was detected in a specific functional 
assay, IL-6 trans-signalling activity could not be detected from the BALF samples or by 
using a complex from recombinant cytokines.  
I have shown that the long isoform of IL-8, IL-877 was a minor proportion of 
total IL-8 in the preterm ventilated BALF, although significant expression of IL-877 was 
detected in vitro from lung cells. Preterm BALF efficiently converted exogenously 
added recombinant IL-877 to shorter isoforms, mainly by the activity of serine 
proteases from neutrophils and the clotting cascade. BALF from CLD infants converted 
significantly more IL-877, compared to BALF from No-CLD infants. Among the 
neutrophil serine proteases, proteinase-3 (Pr-3) converted IL-877 to functionally more 
potent isoforms; Pr-3 antigen and thrombin activity was also significantly increased in 
BALF from CLD infants, making them attractive targets for intervention. 
 
 
v 
 
Publications 
1. Chakraborty M, Kotecha S. Pulmonary surfactant in newborn infants and 
children. Breathe. 2013;9(6):476-88. 
2. Chakraborty M, McGreal EP, Davies PL, Nowell MA, Jones S, Kotecha S. Role of 
interleukin-6, its receptor and soluble gp130 in chronic lung disease of prematurity. 
Neonatology. 2013;104(3):161-7. 
3. McGreal EP, Chakraborty M, Winter VT, Jones SA, Coalson JJ, Kotecha S. 
Dynamic Expression of IL-6 Trans-Signalling Molecules in the Lungs of Preterm Baboons 
Undergoing Mechanical Ventilation. Neonatology. 2011 Mar 2;100(2):130-8. 
4. Beeton ML, Maxwell NC, Davies PL, Nuttall D, McGreal E, Chakraborty M, et al. 
Role of pulmonary infection in the development of chronic lung disease of prematurity. 
Eur Respir J. 2011 Jun;37(6):1424-30. 
5. Chakraborty M, McGreal EP, Kotecha S. Acute lung injury in preterm newborn 
infants: mechanisms and management. Paediatric Respiratory Reviews. [Review]. 2010 
Sep;11(3):162-70; quiz 70. 
 
 
Submitted 
Serine Proteases Regulate Interleukin-877 Function in the development of 
Bronchopulmonary Dysplasia in Preterm Ventilated Infants 
Chakraborty M, McGreal EP, Williams A, Davies PL, Powell W, Abdulla S, Voitenok NN, 
Hogwood J, Gray E, Spiller OB, Chambers RC, Kotecha S.  
 
 
 
 
 
 
 
 
vi 
 
Abbreviations 
2ME 2-mercaptoethanol 
AA Amino acid 
AAT Alpha-1 antitrypsin 
ATIII Antithrombin III 
BALF Broncho alveolar lavage fluid 
BPD    Bronchopulmonary dysplasia 
BSA Bovine serum albumin 
BSF-2 B-cell stimulatory factor-2 
CBD Cytokine binding domain 
CF Cystic fibrosis 
CG Cathepsin-G 
CLC cardiotrophin like cytokine 
CLD    Chronic lung disease 
CNTF ciliary neurotrophic factor 
COPD    Chronic obstructive pulmonary disease 
COPD Chronic obstructive pulmonary disease 
CPAP Continuous positive airways pressure 
CRP C-reactive protein 
CT-1 cardiotrophin-1 
CTGF    Connective tissue growth factor 
CTGF Connective tissue growth factor 
D Dalton 
DNA Deoxyribonucleic acid 
DS sIL-6R Differential spliced sIL-6R 
E.coli Escherichia coli 
ELISA Enzyme linked immuno sorbent assay 
EMAP II Endothelial monocyte-activating polypeptide II 
ENA-78 Epithelial cell-derived neutrophil activating peptide-78 
ERK Extracellular signal-regulated kinase 
FGF Fibroblast growth factor 
vii 
 
FGFR Fibroblast growth factor receptor 
FITC Fluorescein isothiocyanate   
fMLP N-Formyl-L-methionyl-L-leucyl-L-phenylalanine 
FNIII Fibronectin type-III 
FRC Functional residual capacity 
GCP Granulocyte chemotactic protein 
GM-CSF Granulocyte macrophage colony stimulating factor 
GRO Growth regulated oncogene 
GWAS genome wide association study 
H IL-6 Hyper IL-6 
HFOV High frequency oscillatory ventilation 
HGF Hybridoma growth factor 
HRPO Horse radish peroxidase 
HSF Hepatocyte stimulating factor 
ICAM Inter-cellular adhesion molecule 
IFN-γ Interferon-γ 
Ig Immunoglobulin 
IL-1β Interleukin-1β 
IL-6 Interleukin-6 
IL-6R Interleukin-6 receptor 
IL-8 Interleukin-8 
Jak Janus activated kinase 
JNK c-Jun N-terminal kinase 
LFA-1 Lymphocyte function-associated antigen-1 
LIF leukaemia inhibitory factor 
LPC Lipophosphatidyl choline 
LPS Lipopolysaccharide 
Mac-1 Macrophage-1 antigen 
MAPK Mitogen activated protein kinase 
MAPK Mitogen-activated protein kinase 
MCP Monocyte chemoattractant protein 
viii 
 
mg milligram 
 MIP Macrophage inflammatory protein 
ml millilitre 
MTS [3-(4,5-dimethyl-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium, inner salt 
N Normal 
NaCl Sodium chloride 
NE Human neutrophil elastase 
NEC Necrotising enterocolitis 
NF-κB Nuclear factor-κB 
ng nanogram 
NICHD National Institute of Child Health and Human 
Development 
NK Natural killer (cells) 
nm nanometre 
ONS    Office for National Statistics 
OSM oncostatic-M 
PBS Phosphate buffered saline 
PCR    Polymerase chain reaction 
PDA Patent ductus arteriosus 
PDGF-A Platelet derived growth factor-A 
PECAM-1   Platelet endothelial cell adhesion molecule-1 
PEEP Positive end expiratory pressure 
PES Phenazine ethosulfate 
pg picogram  
PHA Phytohaemagglutinin 
PI3K Phosphoinositide 3-kinase 
PIAS Protein inhibitor of activated STAT 
PICD Phagocytosis-induced cell death 
PMA Phorbol myristate acetate 
PMN Polymorphonuclear neutrophils 
ix 
 
PMSF Phenylmethanesulfonyl fluoride 
Pr-3 Proteinase 3 
PS Phosphatidyl serine 
RA Retinoic acid 
RDS    Respiratory distress syndrome 
rh recombinant human 
RIA Radio immuno assay 
rm recombinant mouse 
RNA Ribonucleic acid 
ROS Reactive oxygen species 
RT Room temperature 
sIL-6R Soluble IL-6R 
siRNA short interfering ribo nucleic acid 
SNP single nucleotide polymorphism 
SOCS Suppressor of cytokine signalling 
STAT Signal transducer and activator of transcription 
TAF Tracheal aspirate fluid 
TGF-β Transforming growth factor-β 
TLR Toll-like receptor 
TMB Tetramethyl benzidine 
TNF-α Tumour necrosis factor-α 
Tyk Tyrosine kinase 
Tyr Tyrosine 
VCAM Vascular cell adhesion molecule 
VEGF    Vascular endothelial growth factor 
VEGF Vascular endothelial growth factor 
VEGFR    Vascular endothelial growth factor receptor 
VEGFR Vascular endothelial growth factor receptor 
VLBW Very low birth weight 
μg microgram 
μl microlitre 
x 
 
Table of Contents 
1. INTRODUCTION------------------------------------------------------------------------------------------------------------------------------------------------ 1 
1.1. INTRODUCTION ----------------------------------------------------------------------------------------------------------- 2 
1.2. DEFINITIONS OF BRONCHOPULMONARY DYSPLASIA / CHRONIC LUNG DISEASE ------------------------------------- 2 
1.3. EPIDEMIOLOGY ----------------------------------------------------------------------------------------------------------- 5 
1.4. NORMAL LUNG DEVELOPMENT ----------------------------------------------------------------------------------------- 8 
1.5. LUNG PATHOLOGY IN CLD --------------------------------------------------------------------------------------------- 10 
1.6. RISK FACTORS FOR CLD ------------------------------------------------------------------------------------------------ 11 
1.6.1. Antenatal Factors -------------------------------------------------------------------------------------------- 13 
Infection ------------------------------------------------------------------------------------------------------------------------------ 13 
Glucocorticoids --------------------------------------------------------------------------------------------------------------------- 17 
Genetic Factors --------------------------------------------------------------------------------------------------------------------- 18 
1.6.2. Post-Natal Causes ------------------------------------------------------------------------------------------- 19 
Ventilator Induced Lung Injury ------------------------------------------------------------------------------------------------- 19 
Surfactant Deficiency ------------------------------------------------------------------------------------------------------------- 21 
Oxygen Toxicity --------------------------------------------------------------------------------------------------------------------- 23 
PDA and Fluids ---------------------------------------------------------------------------------------------------------------------- 24 
Neonatal Infection ----------------------------------------------------------------------------------------------------------------- 27 
1.7. INFLAMMATION – A SHORT SUMMARY ------------------------------------------------------------------------------- 28 
1.8. RESOLUTION OF ACUTE INFLAMMATION ------------------------------------------------------------------------------- 30 
1.9. INFLAMMATION IN BPD ------------------------------------------------------------------------------------------------ 33 
1.10. LUNG DEVELOPMENT DISORDERS IN BPD ---------------------------------------------------------------------------- 37 
1.11. MODULATION OF LUNG INFLAMMATION IN PRETERM INFANTS – TWO POTENTIAL PATHWAYS ------------------ 40 
1.12. INTERLEUKIN-6 BIOLOGY ----------------------------------------------------------------------------------------------- 42 
1.12.1. Structure of IL-6 ---------------------------------------------------------------------------------------------- 42 
1.12.2. Functions of IL-6 ---------------------------------------------------------------------------------------------- 43 
1.12.3. The IL-6 Receptor System ---------------------------------------------------------------------------------- 43 
1.12.4. Receptor Signalling ------------------------------------------------------------------------------------------ 45 
1.12.5. Cis- and trans-signalling ----------------------------------------------------------------------------------- 46 
1.12.6. IL-6 in Disease and Inflammation ----------------------------------------------------------------------- 48 
1.13. INTERLEUKIN-8 BIOLOGY ----------------------------------------------------------------------------------------------- 49 
1.13.1. Early discovery of Interleukin-8 structure and function ------------------------------------------- 49 
1.13.2. Isoforms of IL-8 ----------------------------------------------------------------------------------------------- 50 
1.13.3. Conversion of longer isoform of IL-8 to shorter isoforms ----------------------------------------- 53 
1.13.4. Functional activity of different isoforms of IL-8 ------------------------------------------------------ 53 
1.13.5. IL-8 in preterm infants and in CLD/BPD ---------------------------------------------------------------- 56 
1.13.6. Summary ------------------------------------------------------------------------------------------------------- 56 
xi 
 
1.14. SUMMARY AND BACKGROUND OF THE PROJECT ---------------------------------------------------------------------- 57 
1.15. HYPOTHESIS AND AIMS OF THE PROJECT ------------------------------------------------------------------------------ 58 
1.15.1. IL-6 trans-signalling in the preterm lung -------------------------------------------------------------- 59 
1.15.2. IL-8 isoforms in the preterm lung ------------------------------------------------------------------------ 59 
2. MATERIALS AND METHODS ----------------------------------------------------------------------------------------------------------------------------- 60 
2.1. BUFFERS AND SOLUTIONS ---------------------------------------------------------------------------------------------- 61 
2.1.1. --------------------------------------------------------------------------------------------------------------------------- 61 
2.1.2. Phosphate Buffered Saline (PBS) ------------------------------------------------------------------------ 61 
2.1.3. Assay diluent for total IL-8 ELISA (PBS + 10% foetal calf serum) -------------------------------- 61 
2.1.4. Protease-free bovine serum albumin (BSA) stock solution --------------------------------------- 61 
2.1.5. ELISA wash buffer -------------------------------------------------------------------------------------------- 61 
2.1.6. ELISA wash buffer for IL-877 ELISA ----------------------------------------------------------------------- 61 
2.1.7. Tris buffer for all protease experiments (TBS BSA) -------------------------------------------------- 61 
2.1.8. Sodium citrate solution------------------------------------------------------------------------------------- 62 
2.1.9. Dextran solution --------------------------------------------------------------------------------------------- 62 
2.1.10. Percoll solution ----------------------------------------------------------------------------------------------- 62 
2.1.11. Purified human neutrophil elastase and cathepsin G buffer solution (for diluting 
lyophilised powder) -------------------------------------------------------------------------------------------------------- 62 
2.2. CYTOKINES, CHEMOKINES AND INFLAMMATORY STIMULI ------------------------------------------------------------ 63 
2.3. ANTIBODIES ------------------------------------------------------------------------------------------------------------- 64 
2.4. OTHER REAGENTS ------------------------------------------------------------------------------------------------------- 65 
2.5. ENZYME LINKED IMMUNOSORBENT ASSAY (ELISA) ------------------------------------------------------------------ 66 
2.5.1. Human IL-6 ELISA -------------------------------------------------------------------------------------------- 66 
2.5.2. Human sIL-6R ELISA ----------------------------------------------------------------------------------------- 67 
2.5.3. Human Differentially Spliced (DS) sIL-6R ELISA ------------------------------------------------------ 67 
2.5.4. Human sgp130 ELISA --------------------------------------------------------------------------------------- 68 
2.5.5. Human IL-8 ELISA -------------------------------------------------------------------------------------------- 69 
2.5.6. Human IL-877 ELISA ------------------------------------------------------------------------------------------ 70 
2.5.7. Human monocyte chemotactic protein-1 (MCP-1) ELISA ----------------------------------------- 70 
2.5.8. Human total matrix-metalloprotease-9 (MMP-9) ELISA ------------------------------------------ 71 
2.5.9. Proteinase-3 ELISA ------------------------------------------------------------------------------------------- 72 
2.6. PRIMATE (BABOON) MODEL OF CLD ---------------------------------------------------------------------------------- 72 
2.6.1. Animal Management --------------------------------------------------------------------------------------- 72 
2.6.2. Tracheal Aspirate and Lavage Fluids and Cell Counts ---------------------------------------------- 73 
2.6.3. Differential Cell Counts of Baboon Cytospins --------------------------------------------------------- 74 
2.6.4. ELISA ------------------------------------------------------------------------------------------------------------ 74 
2.7. CLD IN PRETERM VENTILATED INFANTS ------------------------------------------------------------------------------- 74 
xii 
 
2.7.1. Patient Groups ------------------------------------------------------------------------------------------------ 74 
2.7.2. BALF Collection and Processing -------------------------------------------------------------------------- 75 
2.8. B9 CELL ASSAY----------------------------------------------------------------------------------------------------------- 75 
2.8.1. Introduction --------------------------------------------------------------------------------------------------- 75 
2.8.2. B9 cells and initial thawing-------------------------------------------------------------------------------- 76 
2.8.3. Subcultures ---------------------------------------------------------------------------------------------------- 76 
2.8.4. Assays ----------------------------------------------------------------------------------------------------------- 76 
2.9. RHEUMATOID ARTHRITIS SYNOVIAL FIBROBLAST (RASF) CULTURE AND STIMULATION ---------------------------- 77 
2.10. CORD-BLOOD COLLECTION FROM TERM INFANTS --------------------------------------------------------------------- 78 
2.10.1. Subjects and Consenting ----------------------------------------------------------------------------------- 78 
2.10.2. Cord blood collection and initial processing ---------------------------------------------------------- 79 
2.11. PERIPHERAL VENOUS BLOOD COLLECTION FROM HEALTHY ADULT VOLUNTEERS ------------------------------------ 79 
2.12. PURIFICATION OF POLYMORPHONUCLEAR LEUCOCYTES AND MONONUCLEAR CELLS FROM CORD AND ADULT 
BLOOD 80 
2.12.1. Cell purification by discontinuous Percoll gradient ------------------------------------------------- 80 
2.12.2. Processing of PMNs ----------------------------------------------------------------------------------------- 82 
2.12.3. Processing of MNCs ----------------------------------------------------------------------------------------- 82 
2.12.4. Preparation of PMN cytospins --------------------------------------------------------------------------- 82 
2.13. STIMULATION OF PURIFIED PMNS AND MNCS----------------------------------------------------------------------- 82 
2.14. PROCESSING OF IL-877-------------------------------------------------------------------------------------------------- 83 
2.14.1. Conversion of IL-877 by BALF ------------------------------------------------------------------------------ 83 
2.14.2. Conversion of IL-877 by purified neutrophil serine proteases ------------------------------------- 83 
2.14.3. Neutrophil Degranulation Assay ------------------------------------------------------------------------- 84 
2.15. AIRWAY EPITHELIAL CELL CULTURE AND STIMULATION -------------------------------------------------------------- 84 
2.15.1. Culture of transformed epithelial cells ----------------------------------------------------------------- 84 
2.15.2. Small airway epithelial cells (SAEC) --------------------------------------------------------------------- 85 
2.15.3. Airway Epithelial cell stimulations ---------------------------------------------------------------------- 87 
2.16. THROMBIN FUNCTIONAL ASSAY ---------------------------------------------------------------------------------------- 87 
2.17. STATISTICAL ANALYSIS -------------------------------------------------------------------------------------------------- 88 
2.17.1. Primate (baboon) model of CLD ------------------------------------------------------------------------- 88 
2.17.2. CLD in ventilated preterm infants ----------------------------------------------------------------------- 88 
2.17.3. B9 cell assay for IL-6 ---------------------------------------------------------------------------------------- 88 
2.17.4. Processing of IL-877 ------------------------------------------------------------------------------------------ 89 
3. EXPRESSION OF IL-6, SIL-6R AND SGP130 IN THE PRETERM LUNG --------------------------------------------------------------------------- 90 
3.1. OVERVIEW --------------------------------------------------------------------------------------------------------------- 91 
3.2. AIMS OF THE PROJECT (EXPRESSION IN THE PRETERM BABOON LUNG) --------------------------------------------- 91 
3.3. EFFECT OF VENTILATION ON LUNG INFLAMMATION IN PRETERM BABOONS ---------------------------------------- 92 
xiii 
 
3.4. EXPRESSION OF IL-6, SIL-6R AND SGP130 --------------------------------------------------------------------------- 92 
3.5. RATIOS OF TRANS-SIGNALLING MOLECULES --------------------------------------------------------------------------- 94 
3.6. CELL COUNTS ------------------------------------------------------------------------------------------------------------ 96 
3.7. EXPRESSION OF CHEMOKINES ------------------------------------------------------------------------------------------ 97 
3.8. SUMMARY OF RESULTS IN PRETERM VENTILATED BABOONS ---------------------------------------------------------- 98 
3.9. EXPRESSION IN HUMAN PRETERM INFANTS: AIMS OF THE PROJECT ------------------------------------------------ 99 
3.10. CLINICAL SUBJECTS ------------------------------------------------------------------------------------------------------ 99 
3.11. INFLAMMATORY MARKERS ------------------------------------------------------------------------------------------- 100 
3.12. EXPRESSION OF IL-6, SIL-6R AND SGP130 ------------------------------------------------------------------------- 102 
3.13. MOLAR RATIOS OF IL-6 TRANS-SIGNALLING MOLECULES ----------------------------------------------------------- 103 
3.14. EXPRESSION OF DS SIL-6R ------------------------------------------------------------------------------------------- 104 
3.15. DISCUSSION ----------------------------------------------------------------------------------------------------------- 108 
3.15.1. Summary ----------------------------------------------------------------------------------------------------- 108 
3.15.2. Expression of cytokines and chemokines in the preterm baboon lung ---------------------- 109 
3.15.3. Cellular infiltrate in the lungs of preterm ventilated baboons --------------------------------- 110 
3.15.4. Expression of the chemokines IL-8 and MCP-1 in preterm ventilated human infants --- 111 
3.15.5. Expression of IL-6, sIL-6R and sgp130 in preterm ventilated human infants--------------- 113 
3.15.6. Ratio of IL-6 trans-signalling molecules in preterm ventilated human infants ------------ 117 
3.15.7. Expression of DS sIL-6R ----------------------------------------------------------------------------------- 121 
3.16. SUMMARY OF CHAPTER ---------------------------------------------------------------------------------------------- 122 
4. FUNCTIONAL ACTIVITY OF IL-6 IN THE PRETERM VENTILATED LUNGS--------------------------------------------------------------------- 123 
4.1. OVERVIEW ------------------------------------------------------------------------------------------------------------- 124 
4.2. OVERALL HYPOTHESIS AND AIMS OF THE PROJECT ------------------------------------------------------------------ 125 
4.3. SENSITIVITY OF B9 CELLS TO IL-6 CIS-SIGNALLING ------------------------------------------------------------------ 125 
4.4. SPECIFICITY OF B9 CELLS TO IL-6 ------------------------------------------------------------------------------------ 127 
4.5. SENSITIVITY OF B9 CELLS TO IL-6 TRANS-SIGNALLING -------------------------------------------------------------- 128 
4.6. MODIFICATIONS OF THE ASSAY TO MEASURE IL-6 TRANS-SIGNALLING -------------------------------------------- 129 
4.7. IL-6 FUNCTIONAL ACTIVITY IN PRETERM BALF ---------------------------------------------------------------------- 137 
4.8. IL-6 TRANS-SIGNALLING IN B9 CELLS USING RECOMBINANT MOLECULES------------------------------------------ 141 
4.9. DISCUSSION ----------------------------------------------------------------------------------------------------------- 143 
4.9.1. Summary of Chapter -------------------------------------------------------------------------------------- 143 
4.9.2. The B9 cells as an IL-6 bioassay ------------------------------------------------------------------------ 143 
4.9.3. Modifications for trans-signalling --------------------------------------------------------------------- 145 
4.9.4. IL-6 bio-activity in BALF ---------------------------------------------------------------------------------- 146 
4.9.5. Other IL-6 trans-signalling assays --------------------------------------------------------------------- 148 
4.10. SUMMARY ------------------------------------------------------------------------------------------------------------- 152 
xiv 
 
5. REGULATION OF INTERLEUKIN-877 EXPRESSION AND FUNCTION IN THE LUNGS OF PRETERM 
VENTILATED INFANTS -------------------------------------------------------------------------------------------------------------------------------------------- 153 
5.1. OVERVIEW AND BACKGROUND --------------------------------------------------------------------------------------- 154 
5.2. AIMS OF THE PROJECT ------------------------------------------------------------------------------------------------ 154 
5.3. MODIFICATION AND VALIDATION OF THE IL-877 ELISA ------------------------------------------------------------ 155 
5.4. CLINICAL CHARACTERISTICS OF THE PATIENT COHORT --------------------------------------------------------------- 158 
5.5. EXPRESSION OF IL-877 IN THE PRETERM LUNG ---------------------------------------------------------------------- 159 
5.6. EXPRESSION OF IL-877 FROM SPECIFIC CELL-TYPES ----------------------------------------------------------------- 162 
5.6.1. Expression in lung epithelial cells ---------------------------------------------------------------------- 162 
5.6.2. Expression in neonatal PMN and MNC--------------------------------------------------------------- 164 
5.7. CONVERTASE ACTIVITY OF BALF ------------------------------------------------------------------------------------- 167 
5.8. CONVERSION OF IL-877 BY PURIFIED NEUTROPHIL PROTEASES ----------------------------------------------------- 170 
5.8.1. Conversion of IL-877 by purified neutrophil proteases at different concentrations ------- 171 
5.8.2. Conversion of IL-877 by purified neutrophil proteases over time ------------------------------ 172 
5.9. FUNCTIONAL ACTIVITY OF IL-8 AFTER INCUBATION WITH PROTEASES --------------------------------------------- 174 
5.9.1. Establishing the neutrophil degranulation assay-------------------------------------------------- 174 
5.9.2. Functional activity of IL-8 isoforms after processing by proteases --------------------------- 175 
5.10. PROCESSING OF RHIL-872 BY PROTEINASE-3 ------------------------------------------------------------------------ 178 
5.11. EXPRESSION OF PROTEINASE-3 IN PRETERM VENTILATED INFANT BALF ------------------------------------------- 179 
5.12. ACTIVITY OF THROMBIN IN PRETERM VENTILATED INFANT BALF -------------------------------------------------- 180 
5.13. DISCUSSION ----------------------------------------------------------------------------------------------------------- 181 
5.13.1. Summary ----------------------------------------------------------------------------------------------------- 181 
5.13.2. Expression of IL-8 isoforms in preterm BALF -------------------------------------------------------- 181 
5.13.3. Expression of IL-877 from individual cell types ------------------------------------------------------ 182 
5.13.4. Conversion of IL-877 by preterm BALF: effect of neutrophil serine proteases -------------- 183 
5.13.5. Conversion of IL-877 by preterm BALF: effect of thrombin and the coagulation cascade187 
5.14. LIMITATIONS ---------------------------------------------------------------------------------------------------------- 189 
5.15. SUMMARY ------------------------------------------------------------------------------------------------------------- 190 
6. FINAL SUMMARY ------------------------------------------------------------------------------------------------------------------------------------------ 191 
6.1. INTRODUCTION -------------------------------------------------------------------------------------------------------- 192 
6.2. MODULATION OF INFLAMMATION BY IL-6 TRANS-SIGNALLING ---------------------------------------------------- 193 
6.2.1. Data from the baboon model of BPD ----------------------------------------------------------------- 194 
6.2.2. Data from human preterm infants -------------------------------------------------------------------- 195 
6.2.3. Data from the IL-6 functional assay ------------------------------------------------------------------ 196 
6.2.4. Role of sgp130 ---------------------------------------------------------------------------------------------- 198 
6.3. MODULATION OF INFLAMMATION BY IL-8 ISOFORMS -------------------------------------------------------------- 200 
xv 
 
6.4. LIMITATIONS AND UNRESOLVED QUESTIONS ------------------------------------------------------------------------ 202 
6.5. SCIENTIFIC UNCERTAINTIES SURROUNDING CLD/BPD ------------------------------------------------------------- 204 
6.6. KEY POINTS ------------------------------------------------------------------------------------------------------------ 207 
7. REFERENCES ------------------------------------------------------------------------------------------------------------------------------------------------- 208 
8. APPENDICES ------------------------------------------------------------------------------------------------------------------------------------------------- 246 
8.1. ETHICAL APPROVALS -------------------------------------------------------------------------------------------------- 247 
8.1.1. Ethical Approval for Collection of BALF from Preterm Infants --------------------------------- 247 
8.1.2. Ethical Approval for Collection of Cord Blood from Term Infants ----------------------------- 249 
8.2. PARENT INFORMATION LEAFLETS AND CONSENT FORMS ---------------------------------------------------------- 252 
8.2.1. BALF Collection from Preterm Infants ---------------------------------------------------------------- 252 
8.2.2. Cord Blood Collection from Term Infants ------------------------------------------------------------ 257 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xvi 
 
List of Figures 
Figure 1-1: Change in Incidence of BPD.. .......................................................................... 7 
Figure 1-2: Lung Growth abnormalities in CLD ............................................................... 11 
Figure 1-3: Factors affecting lung growth ....................................................................... 12 
Figure 1-4: Potential sites of bacterial infection in the uterus. ...................................... 15 
Figure 1-5: Possible effects of glucocorticoids on the developing lung in utero ............ 18 
Figure 1-6: Pressure-volume curve showing low and high volume injury zones............ 20 
Figure 1-7: Structure of the human Il-6/IL-6R_/gp130 hexameric complex................... 45 
Figure 1-8: IL-6 trans-signalling ....................................................................................... 47 
Figure 1-9: (A) Amino acid sequence of IL-872 and (B) different isoforms of IL-8 resulting 
from variable a.a. sequence at the NH2-terminal. .......................................................... 52 
Figure 1-10: Overview of the naturally occurring CXCL8 isoforms. ................................ 55 
 
Figure 2-1: Representative layer and bands after purification of leukocytes through a 
discontinuous Percoll gradient.. ..................................................................................... 81 
 
Figure 3-1: Pulmonary inflammation due to gentle ventilation. .................................... 92 
Figure 3-2: Expression of trans-signalling molecules. ..................................................... 93 
Figure 3-3: Molar ratio of trans-signalling molecules. .................................................... 95 
Figure 3-4: Cell counts in TAF. ......................................................................................... 96 
Figure 3-5: Expression of chemokines. ........................................................................... 98 
Figure 3-6: Inflammatory markers in the preterm lung. ............................................... 101 
Figure 3-7: Expression of IL-6 trans-signalling molecules. ............................................ 102 
Figure 3-8: Molar ratio of trans-signalling molecules. .................................................. 104 
Figure 3-9: Expression of total and DS sIL-6R in preterm BALF.. .................................. 106 
Figure 3-10: Correlation between the expressions of DS sIL-6R (y-axis) with total sIL-6R 
(x-axis) in preterm BALF ................................................................................................ 106 
Figure 3-11: Expression of total and DS sIL-6R in newborn circulation. ....................... 107 
Figure 3-12: Correlation between the expressions of DS sIL-6R (y-axis) with total sIL-6R 
(x-axis) in term newborn infant circulation. ................................................................. 108 
 
Figure 4-1: Representative dose response curve of B9 cells to rhIL-6. ........................ 126 
Figure 4-2: Inhibition of B9 cell proliferation in the presence of anti human IL-6 
monoclonal antibody. ................................................................................................... 127 
Figure 4-3: Specificity of B-9 cells. ................................................................................ 128 
Figure 4-4: Sensitivity of B9 cells to IL-6 trans-signalling.. ............................................ 129 
Figure 4-5: Schematic representation of modification of the B9 cell assay to measure 
IL-6 trans-signalling in clinical samples ......................................................................... 130 
Figure 4-6: (a) Dose-response of 15A7 antibody. (b) Inhibition of B9 cell proliferation in 
the presence of 15A7 antibody. .................................................................................... 131 
Figure 4-7: Cross-reaction of 15A7 antibody with human sIL-6R. ................................ 132 
Figure 4-8: (a) Dose-response of 2B10 antibody (b) Inhibition of B9 cell proliferation in 
the presence of 2B10 antibody.. ................................................................................... 133 
Figure 4-9: Testing cross-reaction of 2B10 antibody with human sIL-6R. .................... 134 
Figure 4-10: Testing cross-reaction of 2B10 antibody with human sIL-6R in RASF cells
 ....................................................................................................................................... 135 
xvii 
 
Figure 4-11: IL-6 trans-signalling in the presence of 2B10 antibody ............................ 136 
Figure 4-12: Dose-response of sgp130Fc. ..................................................................... 137 
Figure 4-13: Panel of controls. ...................................................................................... 139 
Figure 4-14: IL-6 functional activity in preterm BALF. .................................................. 140 
Figure 4-15: IL-6 trans-signalling with recombinant molecules. ................................... 142 
 
Figure 5-1: Validation of the IL-877 ELISA. ..................................................................... 155 
Figure 5-2: Validation of the commercial ELISA.. .......................................................... 156 
Figure 5-3 : Modification of IL-877 ELISA. ...................................................................... 157 
Figure 5-4: Expression of IL-8 and IL-877 in preterm BALF. ........................................... 160 
Figure 5-5: Proportion of IL-877. .................................................................................... 161 
Figure 5-6: Gestation and IL-877 expression. ................................................................. 162 
Figure 5-7: Expression of IL-877 from airway epithelial cells.. ....................................... 163 
Figure 5-8: Expression of IL-877 from immune cells.. .................................................... 165 
Figure 5-9: Expression of IL-8 and IL-877 from immune cells. ....................................... 166 
Figure 5-10: Panel of controls…………………………………………………………………………………..168 
Figure 5-11: Convertase activity of preterm BALF. ....................................................... 169 
Figure 5-12: Convertase activity in No CLD and CLD infants. ....................................... 170 
Figure 5-13: Protease dose-response. .......................................................................... 171 
Figure 5-14: Dose-response of conversion of IL-877 by purified proteases. ................. 172 
Figure 5-15: Time-course of conversion of IL-877 by purified proteases....................... 173 
Figure 5-16: Establishing the neutrophil degranulation assay. .................................... 175 
Figure 5-17: Functional activity of IL-8 isoforms. .......................................................... 177 
Figure 5-18: Processing of rhIL-872 by purified proteinase-3. ....................................... 178 
Figure 5-19: Expression of proteinase-3 in preterm BALF. ........................................... 179 
Figure 5-20: Activity of thrombin in preterm BALF. ...................................................... 180 
 
Figure 6-1: Regulation of innate and acquired immunity by IL-6 trans-signalling........ 194 
 
 
 
 
 
 
 
 
 
 
 
 
xviii 
 
List of Tables 
Table 1-1: Summary of stages of lung development.   ..................................................... 9 
Table 1-2: Isoforms of IL-8 from different cellular sources. ........................................... 51 
 
Table 2-1: List of cytokines, chemokines and other inflammatory stimuli ..................... 63 
Table 2-2: List of antibodies. FITC = Fluorescein Isothiocyanate .................................... 64 
Table 2-3: List of other reagents used. ........................................................................... 65 
Table 2-4: Details of all experimental conditions in conversion of IL-877 by BALF. ........ 83 
Table 2-5: List of transformed airway epithelial cells with culture conditions ............... 85 
 
Table 3-1: Concentrations of IL-6, sIL-6R & sgp130 in pg/ml and the molar ratios 
(human equivalents) of sIL-6R/IL-6 & sgp130/sIL-6R represented as medians (IQR) at 
each time-point. .............................................................................................................. 95 
Table 3-2: Cell counts (millions/ml) and ratios of PMN/MNC in TAF represented as 
medians (IQR) at each timepoint. ................................................................................... 97 
Table 3-3: Clinical characteristics of the study population. .......................................... 100 
Table 3-4: Inflammatory markers in the lung.. ............................................................. 101 
Table 3-5: Expression of IL-6 trans-signalling molecules and their ratios. ................... 104 
Table 3-6: Clinical characteristics of the study population used for measuring DS sIL-6R
 ....................................................................................................................................... 105 
 
Table 4-1: Availability of free IL-6 and sIL-6R/IL-6 complex in a mixture of cytokines.150 
 
Table 5-1: Patient and clinical characteristics. .............................................................. 158 
Table 5-2: Expression of IL-8 and IL-877. ........................................................................ 159 
Table 5-3: Expression of IL-8 from airway epithelial cells.. ........................................... 164 
Table 5-4: Expression of IL-8 from innate immune cells.. ............................................. 167 
 
 
 
1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1. Introduction 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2 
 
1.1. Introduction 
 
Preterm infants, born before 37 completed weeks of gestation, are about 7-
10% in number of all live births in the UK (Office for National Statistics, ONS). Of all live 
births, about 1-2% are born before 32 completed weeks of gestation (ONS). This group 
of newborn infants (≤ 32 weeks gestational age) require significant support in the first 
few weeks to months after birth, resulting is substantial cost to the health care 
services (Mangham et al., 2009). National epidemiological studies, on infants born at < 
27 weeks gestational age, suggest that survival of this group of infants is increasing in 
the UK, and a large percentage of them continue to require significant resources due 
to complications of preterm birth (Costeloe et al., 2012). This adds to the health care 
burden of society.  
   The most common insufficiency, and long term complication, of preterm 
infants is that of the respiratory system. In this chapter, I will discuss the most 
common respiratory complication of preterm infants, chronic lung disease (CLD). I will 
start with a discussion on the definitions of CLD, and the difficulties and controversies 
surrounding it. Then I will proceed to provide an overview of the risk factors for CLD, as 
per current understanding, and argue that non-resolving inflammation of the preterm 
lungs is the final common pathway involved in the pathogenesis of this condition. My 
research is on two pathways of modulation of inflammation, and I will introduce these 
pathways in the following sections. I will end the chapter with the hypothesis for this 
project, along with detailed aims of the research work that I have carried out. 
    
1.2. Definitions of Bronchopulmonary Dysplasia / Chronic Lung Disease 
 
Preterm infants born at early gestations (≤32 weeks) are surviving in increasing 
numbers (Fanaroff et al., 2007). This is most evident in the group of infants born with 
extremely low birth weight (≤1000g) or gestation of less than 28 weeks (Costeloe et al., 
2012). Respiratory insufficiency, characterised by Respiratory Distress Syndrome (RDS) 
– an inflammatory condition in the lungs of preterm infants contributed by inadequate 
surfactant production resulting in respiratory failure with small volume lungs and 
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ground-glass appearance in chest radiographs – is the most common challenge faced 
by these infants. Chronic lung disease (CLD) or bronchopulmonary dysplasia (BPD) is 
the term used to describe an evolving condition of the lung in infants, the majority of 
who are born preterm (mainly ≤32 weeks gestation). CLD results in pulmonary 
insufficiency requiring supplemental oxygen or respiratory support, and with long-term 
respiratory sequelae (Kotecha and Silverman, 1999). CLD and BPD are commonly used 
interchangeably, with CLD describing the clinical picture and BPD describing the 
pathology of the condition. 
The clinical definition of CLD has been evolving since the first description of 
BPD in 1967 by Northway and his colleagues (Northway et al., 1967). Their 
retrospective case series described four stages of the disease from birth: stage I from 
two to three days, stage II from four to ten days, stage III from ten to twenty days and 
stage IV beyond one month after birth. Of note, the infants described in this study 
were more mature than the current population of preterm infants who are at 
maximum risk for CLD. 
In 1979 Bancalari and colleagues (Bancalari et al., 1979) suggested that the 
term BPD be used to describe the more advanced stages of the disease, i.e. after 28 
days (stage IV in Northway and colleagues’ original description), as they were unable 
to clinically and radiologically distinguish the earlier stages (stages I, II and III) from 
severe RDS. Also, some of their patients seemed to develop stage IV of the disease 
without apparently going through the earlier stages. The term “chronic lung disease” 
was also coined in the same year by Tooley who suggested it be used for preterm 
infants after 30 days of life with radiological lung abnormalities, respiratory failure and 
supplemental oxygen requirement (Tooley, 1979).  
In a retrospective study of infants born preterm who were followed up for at 
least two years, Shennan and colleagues (Shennan et al., 1988) concluded that oxygen 
requirement at 36 weeks corrected gestational age was a better predictor of long term 
pulmonary outcome, especially in infants born extremely prematurely. They suggested 
that the 28 day criterion be used for more mature infants born at ≥ 30 weeks 
gestational age as in the population of Northway’s (Northway et al., 1967) original 
study. For more preterm infants (< 30 weeks gestational age at birth), the modified 
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criteria seemed to be a better predictor of long-term morbidity. Shennan’s study was 
conducted on infants whose mothers did not receive antenatal corticosteroids to 
mature the lungs, and the infants did not have exogenous surfactant replacement after 
birth (these are discussed in later sections). Thus, it may be argued that the current 
population of preterm infants, most of who have the benefit of antenatal 
corticosteroids and postnatal surfactant therapy, are not comparable to Shennan’s 
cohort. More recent long-term follow up studies of preterm infants have attempted 
answer this question. The 36-week corrected gestational age cut-off point was 
revalidated in the Trial of Indomethacin Prophylaxis in Preterms (TIPP) cohort of 
infants, where the authors concluded that oxygen requirement at any other time-point 
(from 32 weeks to 40 weeks corrected gestational age) was not superior as a predictor 
of CLD, compared to 36 week time-point; indeed, supplemental oxygen requirement at 
36 weeks corrected gestational age was found to be an accurate predictor of long term 
pulmonary and neurodevelopmental outcome in their cohort of patients (Davis et al., 
2002). Thus, the definition proposed by Shennan et al seemed to be appropriate in 
preterm infants born in the pre-natal steroid and surfactant era (after early to mid 
1990s).  
The current population of infants who are at high risk for BPD are born at 
extremely preterm (< 28weeks gestational age) with very low birth-weight (Coalson, 
2003). There are also significant differences in the lung pathology of these infants 
(Coalson, 2003, Husain et al., 1998) from the ones described in the original description 
of Northway. They seem to have fewer but larger alveoli (alveolar simplification) and a 
sparse capillary network (Coalson, 2003). The term “new BPD” was coined by Jobe 
(Jobe, 1999) to reflect the current pathology.  
A modification of the definition of BPD, stratified by gestational age at birth, 
was proposed in 2001 by the NIH Workshop on BPD (Jobe and Bancalari, 2001b). The 
authors graded the condition into mild, moderate and severe CLD depending on 
oxygen requirement, and stratified by gestational age (< 32 or ≥ 32 weeks gestational 
age at birth). This classification was found to be a valid predictor of adverse long-term 
pulmonary outcome as the severity of the disease increased (Ehrenkranz et al., 2005). 
Importantly, this definition acknowledged the group of patients who did not need 
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supplemental oxygen at 36 weeks corrected gestational age but had residual lung 
disease (e.g. needing continuous positive airway pressure, or CPAP, in air). One of the 
important reasons for proposing a unified definition was to allow for comparisons to 
be made between different units and centres. 
A “room air challenge test”, to confirm supplemental oxygen requirement at 36 
weeks corrected gestational age, was proposed by Walsh and colleagues (Walsh et al., 
2003). Application of this test in a prospective trial resulted in reduction of calculated 
BPD rates (Walsh et al., 2003, Walsh et al., 2004) when compared to the traditional 
clinical definitions. It also seemed valid in predicting long-term pulmonary outcomes. 
The Bronchopulmonary Dysplasia Group, in their summary proceedings in 2006 (Walsh 
et al., 2006), proposed using the severity based definition (Jobe and Bancalari, 2001b) 
and augmenting it with the physiologic test to confirm oxygen requirements (Walsh et 
al., 2003).  
In summary, definition of CLD has changed several times to describe the 
evolving condition more accurately. Currently, respiratory support including 
supplemental oxygen requirement at 36 weeks corrected gestational age, has become 
the most common definition used for the condition. This is also the definition most 
commonly used by researchers to describe the condition, and is used to define CLD in 
this thesis.  
 
1.3. Epidemiology 
 
As the definition of CLD has evolved, so has the reported incidence of the 
condition. In the original description of BPD by Northway (Northway et al., 1967), the 
authors reported a 100% rate of pulmonary disease beyond four weeks of age in 
survivors. In his report of 14 years of retrospective data from 1969 to 1978, Tooley 
(Tooley, 1979) published an incidence of 25-40% of BPD in survivors in babies born 
with a birth weight between 750 and 1500gm. In their review of BPD in 1985, 
O’Brodovich and Mellins (O'Brodovich and Mellins, 1985) remark that there were no 
prospective trials until that date which set out to calculate the incidence of BPD. From 
retrospective studies, the reported range was from 2% to 68% and the incidence 
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seemed to increase with decreasing birth weight. It needs to be emphasised that both 
of these reviews are selective, and probably did not represent the true scale of the 
problem at that time. 
In the current population of infants, the incidence rates of CLD vary greatly 
between centres and regions, but can affect up to 25% of infants born at < 32 weeks 
gestational age (Gortner et al., 2011) to more than 40% of infants born before 28 
weeks gestational age (Stoll et al., 2010). UK data from the Trent and Yorkshire regions 
(The Neonatal Survey, 2008) report an incidence of CLD (supplemental oxygen at 36 
weeks corrected gestational age) of up to 30% in preterm infants ≤ 32 weeks who have 
received mechanical ventilation. Due to differences in the definition of CLD, the 
reported incidence rates have varied as well (Fenton et al., 1996, Manktelow et al., 
2001, Oh et al., 2005). In addition, the changing pathology of CLD (Husain et al., 1998, 
Willet et al., 1999) brings into question the validity and applicability of either of the 
traditional definitions in the current population of preterm infants. Implementing 
modified definitions (Jobe and Bancalari, 2001b, Walsh et al., 2003) have resulted in 
decreasing the calculated rates of CLD in the same population of preterm infants from 
35% (using oxygen or respiratory support at 36 weeks) to 25% (using the physiologic 
room-air test) (Walsh et al., 2004). However, if the 36-week corrected gestational age 
definition is used purely as a predictor of long-term outcome (as in the original study 
by Shennan et al), several studies in the current population of preterm infants have 
shown its limited applicability (Lefkowitz and Rosenberg, 2008). 
Recent reviews suggest that the incidence of CLD may be decreasing. In a large 
review of all neonatal admissions nationwide (USA) over a 14-year period (1993 – 
2006), a steady and statistically significant decline in the incidence of CLD was noted 
over the study period (Stroustrup and Trasande, 2010). This was accompanied by a 
decline in the use of invasive ventilation and an increase in the use of non-invasive 
respiratory support (Figure 1.1). A similar study from Spain, involving infants born 
between 1997 – 2009, concluded that there was a significant increase in survival of 
infants (birth-weight < 1000 g) without significant CLD (Botet et al., 2012). Factors 
reported by the authors to be associated with this outcome included a reduction in 
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endo-tracheal intubation rate, a reduction in duration of mechanical ventilation and 
(surprisingly) delivery by Caesarean section.     
 Figure 1-1: Change in Incidence of BPD. Percentage change in the annual 
incidence of BPD and related management of preterm infants in neonatal units in the 
USA from 1993 to 2006. With permission from (Stroustrup and Trasande, 2010). 
 
Neurodevelopmental outcome and respiratory morbidity of infants born 
prematurely is of primary concern for neonatologists. CLD has been shown to be a risk 
factor for adverse respiratory outcome (Greenough, 2012, Greenough, 2008) with 
prolonged oxygen requirements, persistent respiratory symptoms leading to repeated 
hospitalisations and abnormalities in lung function tests. Long term follow-up studies 
have concluded that severe CLD is an independent risk factor for neurological deficits 
in preterm infants (Majnemer et al., 2000). The incidence of moderate to severe 
cerebral palsy (CP), mental development index (MDI) <70, psychomotor development 
index (PDI) <70 and neurodevelopmental impairment (NDI) are all increased in infants 
with CLD (Doyle and Anderson, 2009). It needs to be remembered, however, that long-
term follow-up studies as above are from cohorts of preterm infants who were born a 
few decades earlier, and clinical care for preterm infants has changed since then. Thus, 
application of such studies to the current population of babies may not be entirely 
appropriate and new cohort studies need to be conducted for data that are more 
relevant. 
A recent systematic review of respiratory morbidity in adult survivors of CLD 
concluded that impairment of respiratory function (defined variously) continues into 
8 
 
adulthood (Gough et al., 2012). In a meta-analysis, children who were born preterm 
were found to have significantly impaired lung function, when compared to control 
infants born at term (Kotecha et al., 2013). However, there is a lack of data on non-
pulmonary outcomes of CLD survivors into adulthood. Obvious caveats of such a 
conclusion are heterogeneity between the different studies. Also, a large number of 
survivors included in them were born when antenatal corticosteroids and postnatal 
surfactant replacement were not routine. It has also been suggested that CLD/BPD 
could be the precursor of adult chronic obstructive pulmonary disease (COPD) (Baraldi 
and Filippone, 2007). Studies which have followed a current (representative) cohort of 
preterm infants into adulthood are awaited.  
In summary, CLD is a problem mainly of infants born extremely preterm, 
leading to significant long-term respiratory morbidity and is associated with 
neurodevelopmental disorders, regardless of the definition used to describe CLD. 
Respiratory and neurodevelopmental outcomes are used extensively as end-points in 
research and clinical trials on neonates. Thus, understanding the causes and 
mechanisms of CLD forms the first steps towards attempts to treat or prevent it in the 
future.  
 
1.4. Normal Lung Development 
 
Extremely preterm infants, who are born at < 28 weeks gestational age, have 
lungs which are in the late canalicular or early saccular stages of development process 
(table 1.1). Further development of their airways and synthesis of surfactant is 
initiated at later gestations, while the process of alveolarisation and capillary 
maturation are primarily postnatal events in humans.  
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Table 1-1: Summary of stages of lung development.  [Modified from (Wert, 2004, 
Snyder, 2004, Tuyl and Post, 2004, Roth-Kleiner and Post, 2003)] 
 
Stage Duration Key Events 
Embryonic 3-7 
weeks 
Airway: Lung bud arises from ventral foregut endoderm 
             Initiation of branching morphogenesis 
             Bronchi formation 
             Trachea and oesophagus separate 
Vessels: Pulmonary arteries bud off sixth pair of aortic    
arches 
             Pulmonary veins develop as outgrowths of left 
atrium 
Pseudoglandular 5-17 
weeks 
Airway: Acinar tubules and buds form in peripheral lung 
             Ciliated, goblet, neuroepithelial, basal cells 
differentiate  
             Cartilage, mucous glands, smooth muscle 
develop 
             Pleuroperitoneal cavity closes  
Vessels: Pulmonary arteries parallel  airway branching               
Canalicular 16-26 
weeks 
Airway: Acinar tubules and buds expand 
             Air-blood barrier forms 
             Alveolar type I and type II cells differentiate 
             Lamellar bodies form in type II cells 
Vessels: Capillary network form 
Saccular 24-38 
weeks 
Airway: Air spaces expand to form saccules 
             Mesenchyme thins and condenses 
             Elastin deposited at sites of secondary crest  
formation 
             Surfactant synthesised and secreted by type II  
cells 
             Foetal lung fluid and foetal breathing 
Vessels: Septal walls contain double capillary  network                
Alveolar and 
microvascular 
maturation 
36 weeks 
to 2nd  
postnatal 
year 
Alveolar: Secondary septa form, subdividing saccules  
into alveoli 
              Alveolar septal walls thin, with loss of 
connective tissue 
               Alveolar surface area increases 
               Collagen, elastin and fibronectin deposited 
               Surfactant production increases in type II cells 
Vessels: Double capillary network fuses into single  
network 
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1.5. Lung Pathology in CLD 
 
In the original description of BPD (Northway et al., 1967), four stages of the 
disease was described. The pathology was characterised by alveolar atelectasis, 
necrosis of alveolar epithelium and thickening of capillary basement membrane in the 
early stages, progressing to areas of emphysematous over-inflation, severe airway 
changes including smooth-muscle hypertrophy, fibrosis and generalised thickening of 
capillary basement membranes. Vascular changes, indicative of pulmonary 
hypertension, were also noted. The infants included in these early descriptions were 
more mature than preterm infants seen now; they did not receive the benefits of 
antenatal steroids or postnatal surfactant replacement therapy. Clinical care of 
preterm infants has also changed significantly since then. 
CLD is now seen mainly in infants born extremely preterm (< 28 weeks 
gestation with birth weights < 1000g) (Fanaroff et al., 2007) and the term “new” BPD 
has been coined to describe the lung condition in this population (Jobe, 1999). 
Significant differences have been noted in the lung pathology of the current 
population of preterm infants compared to those reported in early descriptions. Most 
of the severe changes observed in earlier cohorts were absent in the current 
population of infants (Coalson, 2006, Coalson, 2003). “New” BPD/CLD is characterised 
by milder airway changes with less fibrosis but abundance of large airspaces with 
decreased surface area, suggesting an interruption or dysregulated alveolarisation 
(Husain et al., 1998), and dysmorphic blood vessels (Figure 1.2). These changes were 
observed more diffusely all over the lung, suggesting that the use of surfactant keeps 
the airways open leading to milder but more widespread injury (Husain et al., 1998).  
Studies describing lung pathology of CLD in the modern era are only few in 
number. As mortality in the current population of CLD infants is rare, this reduces the 
possibility of further similar histological studies. Moreover, infants with CLD who die 
likely represent the severe end of the spectrum, and their histology may not be 
representative of less severe CLD. Indirect studies using surrogate markers like 
pulmonary diffusion capacity have suggested that current infants with CLD may indeed 
have decreased alveolar surface area but not lung volume (Balinotti et al., 2010). In 
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spite of a lack of data, currently CLD is considered a disease of lung growth 
abnormality.  
 
Figure 1-2: Lung Growth abnormalities in CLD. (A) In the saccular stage, the walls of the 
airspaces are thicker with interstitium and a double network of capillaries. (B) Normal 
alveolarisation results in thinning of the interstitium, development of a single layer of 
capillaries in the walls and elongation of secondary septa, which increase the surface 
area for gas exchange. (C) In CLD, the interstitium remains thick and the capillary 
network in underdeveloped and dysmorphic. The secondary septa are blunted, 
resulting in large and simplified alveoli. Reproduced with permission from (Ahlfeld and 
Conway, 2012) 
    
1.6. Risk Factors for CLD 
 
Northway and colleagues (Northway et al., 1967) suggested that possible 
mechanisms leading to CLD could include impaired pulmonary healing after severe 
RDS, oxygen toxicity during that process, mechanical ventilation and poor bronchial 
drainage due to intubation. Bancalari and colleagues (Bancalari et al., 1979) implicated 
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RDS with positive pressure ventilation along with the toxic effects of oxygen as 
important pathogenetic factors in the development of CLD. A review of CLD by 
O’Brodovich and Mellins (O'Brodovich and Mellins, 1985) suggested several 
mechanisms contributing to the development of lung injury including (a) quantitative 
and qualitative inadequacy of surfactant (b) pulmonary oedema and inflammation 
including release of neutrophil derived proteases and generation of toxic oxygen 
radicals (c) oxygen toxicity playing a role in the genesis of chronic lung injury, inhibiting 
normal lung development and promoting dysplasia and (d) assisted mechanical 
ventilation. 
The pathology of BPD has undergone change since these descriptions with a 
shift from persistent inflammation, fibrosis and small airway disease (“old” BPD) to 
dilated distal airways and decreased alveolarisation (“new” BPD) (Jobe and Ikegami, 
1998). Presented below is a short review of the current understanding about the main 
risk factors implicated in the development of CLD (Figure 1.3). 
 
 
 Figure 1-3: Factors affecting lung growth. Summary of factors which have an 
impact on lung growth ante-natally (top half), and post-natally after preterm delivery, 
that can contribute to the development of CLD. Reproduced with permission from 
(Kotecha, 2000). 
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1.6.1. Antenatal Factors 
Infection    
About 50 - 80% of preterm births are spontaneous in origin (Goldenberg et al., 
2000) and infection/inflammation of the uterus has been widely suggested as the 
triggering cause. Intrauterine infections have been noted to increase in incidence with 
decreasing gestation (Goldenberg et al., 2000, Goncalves et al., 2002, Yoon et al., 
2000). Bacteria causing infection in the uterus are most often of upper-vaginal origin 
and can lead to preterm labour in early gestations (Goldenberg et al., 2000, Goncalves 
et al., 2002).  Bacteria act on decidua and foetal membranes through pattern 
recognition receptors (Kim et al., 2004b, Harju et al., 2005) leading to production of 
cytokines and chemokines. They can also stimulate production of prostaglandins. 
Leucocytes attracted to these sites of inflammation are activated and release 
proteases. Prostaglandin stimulates uterine contraction and proteases can rupture 
membranes (Athayde et al., 1998) leading to onset of preterm labour (Goldenberg et 
al., 2000). Ascending bacteria from the vagina can infect the decidua, membranes and 
the foetus (Figure 1.4) (Romero and Mazor, 1988) leading to infection resulting in a 
systemic inflammatory response syndrome (Athayde et al., 1998).  
The association of intrauterine infection and neonatal morbidity have been the 
focus of several studies. The incidence of neonatal sepsis was found to be higher in 
neonates with evidence of foetal inflammation (Yoon et al., 2000). Studies have also 
shown the increased incidence of neurological and gastrointestinal morbidity in such 
neonates (Viscardi et al., 2004, Goepfert et al., 2004). Watterberg and colleagues 
(Watterberg et al., 1996) showed that foeti exposed to the effects of chorioamnionitis 
had a decreased incidence of RDS but an increased incidence of CLD with increased 
levels of inflammatory markers (interleukin-1β, thromboxane B2, leukotriene B4, 
prostaglandin E2) in the lung. Matsuda and colleagues (Matsuda et al., 1997) 
demonstrated positive association of necrotising funisitis (stage four in intrauterine 
infection sequence) with CLD. These two studies collectively suggested that 
inflammation initiated in the uterus can affect respiratory outcome in preterm infants.  
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Clinical trials in human neonates since Watterberg have confirmed the above 
association (Been et al., 2009). A case control study by Van Marter and colleagues (Van 
Marter et al., 2002) demonstrated the effect of postnatal factors that modify 
respiratory outcome in preterm infants who have been exposed to chorioamnionitis. 
They found intra-uterine infection to decrease the risk of BPD if babies were ventilated 
for less than 7 days postnatally. However, if the duration of ventilation was more than 
7 days, or there was postnatal sepsis, then the risk increased. This suggests that post-
natal modifying factors affect respiratory outcome started by inflammation in the 
uterus and introduced the concept of “multiple hits” on the lung having additive 
effects (Inatomi et al., 2012). 
Subsequent observational studies on the effect of chorioamnionitis on 
respiratory morbidity after birth have not reported significant association (Laughon et 
al., 2009, Soraisham et al., 2009). Histologic chorioamnionitis of maternal side (by 
placental pathology) decreases odds ratio of RDS (Been et al., 2009, Kaukola et al., 
2009); however, foetal involvement seemed to increase odds ratio for RDS (Been et al., 
2009). No effect on the incidence of CLD was observed.  
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Figure 1-4: Potential sites of bacterial infection in the uterus. Reproduced with 
permission from (Goldenberg et al., 2000). 
 
Animal models of intrauterine infection/inflammation have helped to 
understand the effects of intra-uterine inflammation. Introduction of Ureaplasma 
urealyticum into the amniotic fluid of pregnant mice induces lung inflammation in the 
newborn pups (Normann et al., 2009). Intra-amniotic injection of endotoxin in such a 
model resulted in a selective inflammatory response in the lung (Kramer et al., 2002, 
Willet et al., 2000). The overall effect has been to accelerate maturation of the existing 
lung structure but at the cost of simplification of the alveoli and growth arrest, the 
histological pattern that characterises the “new” BPD (Kramer, 2008, Kramer et al., 
2009). An increased expression of transforming growth factor-β1 (TGF-β1), a cytokine 
involved in lung growth and remodelling, and suppression of connective tissue growth 
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factor (CTGF), which modulates fibrosis and promotes vascular development, 
highlights the potential link between inflammation and altered lung development 
(Kunzmann et al., 2007). Increased expression of cytokines which inhibit vascular 
development (interferon γ inducible protein 10, TGF-1) and reduced expression of 
vascular markers (vascular endothelial growth factor [VEGF], vascular endothelial 
growth factor receptor-2 [VEGFR-2], platelet endothelial cell adhesion molecule-1 
[PECAM-1]) support the model of inflammation-induced alteration of lung 
development (Kramer et al., 2009). In pregnant baboons, experimental introduction of 
intrauterine Ureaplasma results in lung inflammation in newborn preterm baboons. 
This inflammation resolves in baboons who clear the airway Ureaplasma but persists in 
the animals who are unable to clear the microbe (Afshar et al., 2003); TGF- β1 
expression is increased in the lungs of such animals, indicating a pro-fibrotic response 
(Viscardi et al., 2006a). 
Upper-vaginal bacteria are the commonest cause of intra-uterine infection. 
Mollicutes have been identified as the single most common class of bacteria infecting 
the uterus ranging from 6-12% in amniotic fluid in mid trimester collected for genetic 
tests (Kramer et al., 2009) to 23% from cord blood cultures of preterm neonates 
delivered between 23-32 weeks (Goldenberg et al., 2008). These bacteria can cause 
inflammation of the uterus and preterm labour occurs more commonly in women with 
a positive polymerase chain reaction (PCR) for bacterial genes (Schelonka and Waites, 
2007). Mollicutes have also been implicated in neonatal respiratory morbidity such as 
pneumonia (Schelonka and Waites, 2007) and BPD (Schelonka and Waites, 2007, 
Maxwell et al., 2009, Colaizy et al., 2007).     
In summary, intra-amniotic inflammation may decrease the incidence of RDS by 
maturing the lung. Its effect on CLD is debatable with conflicting data from studies. 
Early studies suggest the association of chorioamnionitis with arrest of lung-growth 
resulting in a BPD-like pathology. This was enhanced by post-natal injurious factors, 
such as ventilation and infection, which perpetuate inflammation. However, the exact 
mechanism of these effects has not yet been elucidated. 
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Glucocorticoids 
 
As with intra-uterine infection which matures the preterm lung structure, 
glucocorticoids also have similar effects. The use of a single course of steroids to 
women with threatened preterm labour has been one of the most effective therapies 
so far to decrease respiratory morbidity in babies born extremely preterm (Roberts 
and Dalziel, 2006). Use of the drug has reduced the incidence of RDS significantly but 
has had little effect on CLD, probably due to increased survival of extremely premature 
infants who are most at risk of BPD (Crowley, 1995). The mechanism of action of 
glucocorticoids given antenatally seems to be brought about by the maturational 
effect of the drugs on the developing lung (Figure 1.5) (Bolt et al., 2001). The increase 
in the secretion of surfactant proteins and lipids seems to be the key effect which has 
decreased the incidence of RDS in preterm infants. However, similar to the effect of 
chorioamnionitis on the developing lung, it leads to global growth arrest and lung 
“simplification” (Bolt et al., 2001, Vyas and Kotecha, 1997). Studies conducted on 
animal models have confirmed the effect of a course of antenatal steroids on alveolar 
development (Jobe, 2003). This has been shown to be reversible, if preterm delivery is 
avoided.  
Currently, the benefits of using steroids for lung maturation in preterm infants 
outweighs its negative effects on lung growth and development, and has been 
recommended in routine care.  
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Figure 1-5: Possible effects of glucocorticoids on the developing lung in utero. 
Reproduced with permission from (Bolt et al., 2001)] 
 
Genetic Factors 
 
Complex diseases like diabetes, heart disease and atherosclerosis, to name a few, 
have been reported to be caused by an interaction of genetic and environmental 
factors (Bhandari et al., 2006). Recent studies on twin populations have suggested that 
genetic factors could affect the susceptibility to BPD (Lavoie et al., 2008, Bhandari et 
al., 2006, Parker et al., 1996). Several small studies have looked at gene 
polymorphisms and their effect on the outcome of BPD (Bhandari et al., 2006) with 
mixed results. Studies which have looked at difference in outcome between male and 
female babies showed that being female is advantageous especially after preterm birth 
(Ingemarsson, 2003).  
The main approach in these studies has been to look at “candidate genes” which 
could affect the course or outcome of BPD. However, with the potential of modern 
genetic techniques using a genome-wide approach, possible associations of genes with 
BPD may become more apparent. Recently, such a study, looking at genome-wide 
associations with BPD, did not identify any single nucleotide polymorphisms associated 
19 
 
with BPD (at a pre-specified significance level). Additionally, the study could not 
replicate significance levels of some polymorphisms identified previously in the 
literature to be associated with BPD (Wang et al., 2013a). In contrast, other genome-
wide association studies have found increased expression of mast-cell (Bhattacharya et 
al., 2012) and susceptibility (Hadchouel et al., 2011) genes in BPD.  
The main pathology noted in the “new” CLD is a dysregulation of alveolar growth 
and development (Coalson, 2006). Several genetic signals work in close concert for 
alveolar development to take place. Thus, this suggests that preterm birth and 
subsequent events alter the genetic signalling pathways controlling alveolar 
development in infants who develop CLD. Currently, pulmonary inflammation is 
strongly implicated in the pathogenesis of CLD (Ryan et al., 2008). The link between 
inflammation and alteration of genetic signals needs further elucidation (Ahlfeld and 
Conway, 2012). 
 
1.6.2. Post-Natal Causes 
Ventilator Induced Lung Injury 
Preterm infants often need assistance to initiate and establish breathing. The 
target is to establish a functional residual capacity in the lungs. Residual fluid present 
in the lungs at birth impedes this process. The deficiency of surfactant in these infants 
increases surface tension in the airspaces, which prevents them from being “opened” 
up at birth, and makes them more prone to collapse. Ventilation of such lungs causes 
shear stress and has been termed atelectrauma (Attar and Donn, 2002). On the 
pressure-volume hysteresis curve (Figure 1.6), this has been termed the “low-volume 
injury zone” (Jobe and Ikegami, 1998). The use of high tidal volumes during 
resuscitation to open up alveoli can cause damage leading to long-term sequelae 
(Bjorklund et al., 1997). This is termed volutrauma and occurs in the “high-volume 
injury zone” (Jobe and Ikegami, 1998). Preterm babies are more prone to volutrauma 
because of their compliant chest wall, which allows uncontrolled expansion. If chest-
wall expansion is restricted, then lung injury can be limited even at high pressures 
(Hernandez et al., 1989). Similar stresses can occur during prolonged ventilation.  
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Figure 1-6: Pressure-volume curve showing low and high volume injury zones. 
Reproduced with permission from (Jobe and Ikegami, 1998)].  
 
The use of animal models has been invaluable to study the effects of 
conventional ventilation on the lung. It is widely accepted that mechanical ventilation 
can actually worsen lung conditions, especially if they have been injured before 
(Dreyfuss and Saumon, 1998, Dreyfuss et al., 1995), by altering fluid balance, 
increasing endothelial and epithelial permeability and causing severe tissue damage. 
Pulmonary oedema produced by mechanical ventilation (Webb and Tierney, 1974) is 
thought to be mainly due to alterations in alveolar-capillary permeability resulting in 
increased efflux of solutes through the epithelium (Marks et al., 1985, Nolop et al., 
1986) and increased epithelial pore radius (Egan et al., 1976). Changes in permeability 
have been confirmed by electron-microscopic studies of ventilated rabbits with 
discontinuities in alveolar type I cells (John et al., 1982) and alterations of endothelial 
and epithelial barriers (Dreyfuss et al., 1985). Increased pressures during mechanical 
ventilation were traditionally considered the cause of such changes (barotrauma). 
However, it has been shown that an increase in lung volume (volutrauma) due to the 
high pressures was the main factor causing damage (Dreyfuss et al., 1988). Repeated 
collapse of alveoli at the end of expiration and re-expansion at the beginning of 
inspiratory breaths (as happens the absence of surfactant) can cause severe structural 
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and functional damage (Taskar et al., 1997). The use of positive end expiratory 
pressure (PEEP) reduced oedema formation and cell damage (Dreyfuss et al., 1988). 
Ventilation of preterm lungs causes pulmonary inflammation resulting in influx of 
leucocytes and production of mediators of inflammation (Chakraborty et al., 2010), 
that results in lung damage and is termed biotrauma (Tremblay and Slutsky, 1998). 
Studies on rabbits and rats have shown that the use of PEEP can help to reduce 
inflammatory cell recruitment into the lungs during prolonged ventilation  (Markos et 
al., 1993). Similar benefits were seen with high frequency oscillatory ventilation 
(HFOV) (Matsuoka et al., 1994). High volume ventilation with no PEEP resulted in 
increased cytokine concentrations in the lung (Tremblay et al., 1997). Similar patterns 
of cytokine expression have been observed in human preterm infants after ventilation, 
with higher concentrations observed in those who develop CLD later than in those who 
resolve their inflammation (Kotecha et al., 1995, Munshi et al., 1997). This suggests 
that cytokines and chemokines, along with the inflammatory cells they attract, play a 
role in lung injury and damage. Indeed, ventilation at physiological settings for a short 
period of time has been shown to be able to produce changes in lung morphology in 
foetal sheep that resemble CLD (Allison et al., 2008).  
Clinicians have realised that mechanical ventilation of preterm infants through an 
endo-tracheal tube has adverse effects on the lungs mediated by multiple factors, 
including ventilation itself (by mechanisms as above) and infection, which adds to lung 
inflammation. Prolonged ventilation along with post-natal infection, in preterm infants 
born on a background of chorioamnionitis has been shown to make them more prone 
to develop CLD (Van Marter et al., 2002). Several non-invasive ventilatory strategies, 
using continuous positive airways pressure (CPAP), have had encouraging results on 
respiratory outcomes of these preterm infants (Jobe, 2011).  
 
 
Surfactant Deficiency 
Surfactant is a lipid-rich complex which is produced in the lung by type II alveolar 
epithelial cells. It lowers surface-tension in the alveoli and thus make them less likely 
to collapse at the end of expiration. In newborn babies, this is of immense importance 
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as it allows them to establish an effective functional residual capacity (FRC) and helps 
to transform a fluid filled space to an air-filled one. Attempts to ventilate a surfactant 
deficient lung, resulting in repeated opening and closing of the airspace, causes severe 
functional impairment of the lung as well as histological damage with formation of 
hyaline membrane (Taskar et al., 1997). Use of positive end expiratory pressure (PEEP) 
prevents collapse of the surface film of surfactant as well as loss of surfactant into the 
airways (Dreyfuss and Saumon, 1998), thus preserving its function.    
Preterm infants who are at high risk of lung damage (≤ 28 weeks gestation) 
produce inadequate quantities of surfactant due to an immature stage of lung 
development. This has been identified as the primary cause of RDS (also sometimes 
known as surfactant deficiency lung disease), and provides the rationale for exogenous 
replacement of surfactant. Since the mid 1980s, several well designed clinical trials and 
their recent meta-analysis have established the effectiveness of this therapy in 
neonatology (Sweet and Halliday, 2009). Evidence supports the early use of surfactant 
in babies with or at risk of RDS with extubation to CPAP rather than a selective later 
administration of surfactant (Stevens et al., 2007). This approach results in the 
decreased need for mechanical ventilation later, decreased pulmonary air-leaks and 
the decreased need for supplementary oxygen at 28 days. However, no change in 
incidence of CLD (at 36 weeks corrected gestational age) was reported, suggesting that 
long-term lung damage occurred with either strategy. When used as a prophylactic 
measure in infants at risk of RDS, there was a decreased incidence of air leaks and 
mortality was lowered, compared to rescue therapy with surfactant (Soll and Morley, 
2001). However lung damage, as evidenced from the incidence of oxygen requirement 
at 28 days, remained unaffected.  
In summary, replacement of surfactant has resulted in significant short-term 
benefits for preterm infants with RDS. However, its use has not been able to prevent 
long-term lung injury in this population of babies. It is likely that this is due to the 
increased survival of a population of extremely preterm infants who are at maximum 
risk of developing CLD. The effects of surfactant on survival seem to be more than its 
effect on preventing lung-injury in small preterm babies. Though RDS and its related 
treatment strategies (mechanical ventilation and oxygen) are risk factors for lung 
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damage, other factors which contribute to it (see sections 1.6.2.1-.5) may be equally 
important in causing injury. Thus, prevention or effective treatment of RDS with 
exogenous surfactant has not been able to prevent lung damage completely. 
 
Oxygen Toxicity 
The use of oxygen in neonatology has a long history, as reviewed by Sola et al  
(Sola et al., 2007). In their report from the NICHD workshop in 2005, the authors noted 
that oxygen was administered to premature infants as a stimulant in the late 19th 
century (Higgins et al., 2007), and administration of intragastric oxygen was practiced 
in the first half of the 20th century (Sola et al., 2007). In the initial description of BPD in 
1967 (Northway et al., 1967), the authors proposed that oxygen-induced damage to 
the lung was one of the key causative factors in the pathogenesis of the disease. 
Gerschman and colleagues (Gerschman et al., 1954)  suggested that the injurious 
products of oxygen are the reactive oxygen species (ROS). These compounds can 
interact with and alter cell components including protein, lipid, carbohydrates and 
DNA (Saugstad, 2003). Uncoupling of respiration from ATP synthesis in the 
mitochondria by free-radicals can lead to cell death (Ciencewicki et al., 2008). 
The body contains both extracellular and intracellular defences against ROS. A 
number of substances including vitamin C, urate and bilirubin make up the 
extracellular defences. The major intracellular antioxidant is glutathione. These 
systems maintain a balance between pro- and anti-oxidant effects in the body. The 
term oxidative stress is used to describe the state when the anti-oxidant effects 
become ineffective or overwhelmed leading to local tissue damage.  
Preterm infants are at increased risk of oxidative stress for several reasons. They 
are often exposed to high concentrations of oxygen as part of their respiratory 
support. The normal defences against oxidant stress in preterm babies are also less 
efficient. Vitamin C levels decline in the first few days of life and intracellular defences 
undergo developmental changes in the later part of pregnancy (Saugstad, 2003). 
Preterm animals are unable to efficiently upregulate their anti-oxidant enzymes like 
superoxide dismutase, catalase and glutathione peroxidise making them susceptible to 
oxidative stress (Frank and Sosenko, 1991).  
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Evidence has accumulated over the last few years for the role of oxidative stress 
in CLD. Markers of peroxidation have been found in tracheal lavage fluid and urine of 
babies who went on to develop BPD (Saugstad, 2003). Lipid peroxidation (Pitkanen et 
al., 1990, Inder et al., 1994) and surfactant oxidation have been implicated in BPD. ROS 
have the ability to oxidise proteins (Saugstad, 2003) which has been detected at higher 
concentrations in infants who develop BPD (Inder et al., 1994, Gladstone and Levine, 
1994, Varsila et al., 1995). Animal studies seem to show that hyperoxia may be the 
most important trigger for the pathologic changes seen in BPD and it possibly 
potentiates the effects of other contributory factors (Weinberger et al., 2002).  
In summary, oxygen is potentially toxic to cells due to its free radicals. It has pro-
inflammatory effects in the lung and this has been associated with the development of 
CLD in preterm infants, who are at increased risk of oxidative stress and have limited 
antioxidant mechanisms.  
 
PDA and Fluids     
The majority of body water in very low birth weight (VLBW) infants is contained 
in the extracellular fluid compartment (Friis-Hansen, 1957, Friis-Hansen, 1961). 
Excessive extracellular fluid volume can lead to increased interstitial fluid in the lung 
causing pulmonary oedema, which can interfere with gas exchange necessitating 
respiratory support. Excessive fluid can also lead to persistent patency of the ductus 
arteriosus with similar implications due to increased pulmonary blood flow.  
Several studies have looked at respiratory outcomes in these small babies in 
relation to their  fluid intake in the first few days of life with mixed results. Van Marter 
and colleagues (Van Marter et al., 1990) found that infants who later developed CLD 
had consistently higher fluid intake (crystalloids, colloids and total) in the first few days 
of life which resulted in a net weight gain compared to babies who did not develop 
CLD who had lower intakes and a net weight loss. Tammela and Koivisto (Tammela and 
Koivisto, 1992) randomised babies to a “dry” group with fluid restriction between 20%-
47% in the first week and 25% thereafter compared to a control group with normal 
fluid regimen as practiced in the hospital. No significant difference was found in the 
number of babies with CLD in either group. However, babies in this study were more 
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mature (mean gestational age 31 weeks) than the population of infants who develop 
CLD nowadays.   
More recently, Marshall and colleagues (Marshall et al., 1999) found an 
increased risk of CLD with increased fluid intake and lower weight loss in their study 
population. The cohort study of Oh and colleagues (Oh et al., 2005) found that the 
group of infants who went on to develop CLD had a higher fluid intake and lost less 
weight in the first few days of life. However, a randomised trial of fluid (crystalloids 
and colloids) restriction of at least 20% between two groups of matched preterm 
infants did not find a difference in the incidence of CLD between the groups (Kavvadia 
et al., 2000).  In their meta-analysis of all trials of fluid restriction, Bell and Accaregui 
(Bell and Acarregui, 2008) recommended a careful restriction of fluids in preterm 
infants which improves weight loss and reduces the risk of patent ductus arteriosus 
(PDA) and necrotising enterocolitis (NEC). They also noted a trend towards reduction 
of CLD, which was not statistically significant. However, this analysis was based on 
randomised trials only, most of which were conducted in the pre surfactant and 
prenatal steroids era, and thus were on more mature infants than we see today. As a 
result, direct extrapolation of this data on to preterm infants seen currently may not 
be appropriate. A large retrospective observational study (Wadhawan et al., 2007) 
concluded that the incidence of CLD and/or death (treated as a competing variable for 
CLD) was significantly lower in extremely preterm infants if they lost weight (below 
their birth weight) in the first ten days of life.  
In summary, although infants who lose weight early seem to have a better 
outcome in observational studies, fluid restriction as an intervention has not had an 
effect on the incidence of CLD. Further studies would be needed to confirm the role of 
fluids in the development of CLD.  
Physiologically, a PDA can have the same effect on pulmonary mechanics as 
water overload. There is also a possibility of histopathological changes in the vascular 
network due to the “abnormal” increase in blood flow (at that gestation) resulting in 
pulmonary hypertension due to intimal fibrosis and medial hypertrophy (Bancalari et 
al., 2005). With the use of pulmonary surfactant on preterm infants, the signs and 
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symptoms of a PDA can appear earlier due to improved oxygenation resulting in 
decreased pulmonary vascular resistance (Bancalari et al., 2005).   
Early reports of the effect of PDA on respiratory status were provided by 
Cotton and colleagues (Cotton et al., 1978b) who demonstrated benefits of early 
surgical closure of PDA in a randomised trial (Cotton et al., 1978a). Benefits of closing 
the duct with indomethacin was shown in the trial of Merritt and colleagues (Merritt et 
al., 1981) who were also able to demonstrate a decrease in the incidence of CLD. 
Several studies have reported the adverse effects of a PDA on respiratory status 
including the need for prolonged respiratory support (Cotton et al., 1978b), increased 
risk of pulmonary haemorrhage (Alfaleh et al., 2008), adverse effects on pulmonary 
mechanics (Clyman et al., 2009) and increased risk of CLD (Brown, 1979). Closure of 
the duct has been shown to prevent deterioration in pulmonary function (Clyman et 
al., 2009). Studies on the effects of water and electrolyte balance in preterm neonates 
on PDA and respiratory function have had mixed results. Bell and colleagues showed 
an increase in the incidence of PDA with increased volume of fluid intake (Bell et al., 
1980) but the same effect was not demonstrated in several studies (Lorenz et al., 1982, 
Kavvadia et al., 2000, Wadhawan et al., 2007). The effect of fluid management on CLD 
has also been mixed with some studies showing decreased incidence of BPD with 
restriction of fluid intake (Marshall et al., 1999, Wadhawan et al., 2007, Oh et al., 2005) 
while others demonstrating no effect of fluid management on CLD (Lorenz et al., 1982, 
Bell et al., 1980, Kavvadia et al., 2000). Of note, two important studies reported the 
synergistic effects of PDA and infection on the incidence of CLD (Rojas et al., 1995, 
Gonzalez et al., 1996). The latter trial showing an increase in prostaglandins levels with 
infection which may explain the persistence of the duct in such infants.  
Recent authors have argued that there is an association between the presence of 
a PDA and the incidence of CLD but this is probably not a cause-and-effect relationship 
(Laughon et al., 2004, Bose and Laughon, 2006). Thus, although the presence of a PDA 
has been associated with an increase in the incidence of CLD, treatment has not been 
able to decrease the incidence of CLD (Schmidt et al., 2001, Schmidt et al., 2006, 
McCurnin et al., 2005c) in human or animal studies. Systematic reviews with meta-
analysis of trials reached similar conclusions (Mosalli and Alfaleh, 2008, Cooke et al., 
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2003) even when surgical and medical methods of closure were compared (Malviya et 
al., 2003). In summary, the current prevailing opinion suggests treatment of a PDA 
when it becomes symptomatic, but its effect on long-term respiratory outcome is still 
unclear.  
 
Neonatal Infection 
Microbial agents stimulate the immune system and cause inflammation at sites 
of infection. Receptors on the cells of the immune system are activated by recognising 
patterns of repeating molecular structure on the surface and nuclear material of these 
organisms (Medzhitov et al., 1997). Activation of Toll-like and other innate immune 
receptors leads to a sequence of events (see section 1.7) resulting in an influx of 
inflammatory cells to the site of inflammation. Experimental introduction of intra-
uterine infection in animals has resulted in a selective inflammatory response in the 
lungs of the foetus (Kramer et al., 2002, Willet et al., 2000), priming the lungs to 
further damage. When such lungs are exposed to post-natal injurious factors like 
infection, ventilation or PDA, there seems to be an additive effect to the damage 
produced (Van Marter et al., 2002, Rojas et al., 1995, Gonzalez et al., 1996).  
Cohort studies of preterm infants have demonstrated the role of infection in the 
development of CLD. In a recent cohort of preterm infants, our group have shown that 
the presence of infection, both early and late, were significantly associated with the 
development of CLD (Beeton et al., 2011). Inflammatory cytokines and chemokines, 
which are commonly associated with CLD, were increased in concentration of lung-
fluid from infants with evidence of infection, who went on to develop CLD later. Post-
natal infection was also associated with the episodic rise of proteases in lung-fluid of 
infants who develop CLD (Davies et al., 2010).  
In recent years, Ureaplasma Spp. have gained importance in their association 
with neonatal lung inflammation. Mollicutes are the single most common class of 
bacteria cultured from uterine samples (Kramer et al., 2009, Goldenberg et al., 2008). 
Transmission of Ureaplasmas from the mother to the foetus and thus the neonate, as 
evidenced by its culture from very early endo-tracheal samples, has been 
demonstrated (Sanchez, 1993). Several studies have looked at the association of 
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infection with this bacteria with long-term lung damage and the results have been 
mixed. A recent meta-analysis (Schelonka et al., 2005) demonstrated a positive 
association of this organism with CLD although there was increased variability between 
included studies; also, studies with smaller number of subjects demonstrated greater 
effects. This organism has been shown to affect different steps in the inflammatory 
cascade (Li and Tullus, 2002) including inflammatory cell infiltration and expression of 
inflammatory mediators (Schelonka and Waites, 2007). Apoptosis of lung epithelial 
cells has also been demonstrated in-vitro due to this organism (Li et al., 2002).  
Experimental intra-uterine Ureaplasma introduced in the preterm baboon model 
of CLD (Yoder et al., 2003b) results in an early rise of pro-inflammatory mediators in 
the tracheal aspirates of infants. Animals that remained colonised with the bacteria 
had persistent presence of mediators of inflammation in the lung with worse lung 
function while those infants who were able to clear their infection resolved their 
inflammation after 48 hours and had improved lung function. The authors suggested 
that difference in response of the immune system may determine outcome after 
colonization with this organism. In a separate study of the same model, TGF-β1 was 
noted to be increased in infected animals indicating a cytokine expression pattern 
promoting pro-fibrotic responses (Viscardi et al., 2006a).  
In summary, several different insults have been implicated in the pathogenesis of 
CLD. There is insufficient evidence to suggest that one risk factor is more injurious than 
the next. It is more likely that CLD is the cumulative effect of multiple risk factors 
acting on the lungs of preterm infants. 
 
1.7. Inflammation – A Short Summary 
 
Inflammation is defined as the response of living tissue to injury (Ryan and 
Majno, 1977) by the immune system of the body which consists of two interacting 
arms, the innate immune system and the adaptive immune system (Janeway et al., 
2005). The actions of both of these arms are effected by cells, which originate in the 
bone marrow from two common progenitor cells, the lymphoid progenitor and the 
myeloid progenitor. The lymphoid progenitor gives rise to T and B-lymphocytes, which 
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are part of adaptive immunity, and natural killer (NK) cells, which are considered part 
of innate immunity. The myeloid progenitor gives rise to granulocytes (innate 
immunity), monocytes/macrophages (both innate and adaptive immunity) and 
dendritic cells (adaptive immunity). Dendritic cells can arise from the common 
lymphoid progenitor as well and has similar antigen presenting functions for the 
adaptive immune system. 
The innate immune system forms the first line of the body’s defence against 
injury (infectious and non-infectious). It produces an immediate response within 
minutes to hours of an injury and then an early induced response between 4-96 hours 
before the adaptive immune response becomes active (Janeway et al., 2005). When 
injury is due to micro-organisms, receptors on the cells of the immune system are 
activated by recognising patterns of repeating molecular structure on the surface and 
nuclear material of these organisms (Medzhitov et al., 1997). Macrophages residing in 
tissues are the cells initially activated by pattern-recognition receptors (macrophage 
mannose receptor, Toll-like receptors). Activation of these receptors (mainly Toll-like 
receptors in case of microorganisms) leads to a sequence of events resulting in an 
influx of neutrophils to the site of inflammation (Kolaczkowska and Kubes, 2013). The 
first step in this process involves production of cytokines and chemokines, which have 
local and systemic effects. Cytokines like IL-1β and TNF-α activate endothelial cells of 
blood vessels to express cell adhesion molecules (selectins) and intercellular adhesion 
molecules (ICAM-1 and -2). Adhesion molecules arrest the flow of neutrophils in the 
blood vessel and firmly attach them to the endothelial cells. The neutrophils then pass 
through in-between two endothelial cells (diapedesis) and migrate down the 
concentration gradient of the chemokines to the site of infection. Chemokines like 
interleukin-8 create a concentration gradient to guide inflammatory cells to the site of 
inflammation. Both cytokines and chemokines “prime” neutrophils for activation on 
reaching sites of inflammation.  
Neutrophils function as phagocytic cells at sites of inflammation. They 
recognise microorganisms by the same process as described for macrophages earlier, 
i.e. by pattern recognition receptors on the cell surface (toll-like receptors). 
Phagocytosis is also facilitated by another arm of the innate immune system, the 
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complement system, which promotes the uptake and destruction of pathogens 
(Kobayashi et al., 2005). This also involves the production of reactive oxygen species, 
which are part of the mechanism involved in killing pathogens. The other major 
function of these cells is the production of cytokines and chemokines as part of the 
acute phase reaction. Activated neutrophils trigger cytoplasmic granules, containing 
several enzymes and antimicrobial peptides, to fuse with the phagocytosed pathogen 
and result in their killing. 
The receptors of the cells in the innate immune system are germline encoded 
and can recognise molecular patterns in microorganisms, which are common to many 
pathogens. Thus, they have low specificity. Pathogens have also evolved strategies to 
evade recognition by cells of the innate immune system by various methods, and this 
has created the need for another family of cells, which can respond to them in a 
specific manner. The adaptive immune system is formed by T- and B-lymphocytes and 
their related antigen presenting cells. This system has a memory and can learn to 
respond to most challenges to the body, which are perceived as injurious. B-cells 
respond primarily by the production of specific antibodies and T-cells have helper and 
cytotoxic functions. T helper cells (CD4) produce two types of responses; TH1 
responses, which are directed towards intracellular pathogens and TH2 responses, 
which are involved in activating B-cells. Both T- and B-cells need to be exposed to 
antigens for a period before they can respond with an immune reaction. Newborn 
infants are born with naïve lymphocytes, which have not been exposed to “non-self” 
antigens before.  
 
1.8. Resolution of acute Inflammation 
 
Acute inflammation, as summarised above, is characterised by an influx of 
polymorphonuclear neutrophils (PMN) through sequential and regulated steps. These 
cells are part of the innate immune system and protect the body against danger e.g. 
invading microorganisms. However, PMNs themselves and their products can be 
involved in perpetuation of inflammation if they are not effectively removed (Si-Tahar 
et al., 2009). Programmed cell-death (apoptosis) of PMNs and their removal from the 
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site of inflammation by phagocytes are thought to be key steps in the resolution of 
inflammation (Savill et al., 1989).  
A key step at the beginning of resolution is granulocyte apoptosis, a process of 
programmed cell-death. Apoptosis is considered a non-inflammatory process where 
the cell maintains its membrane integrity for a period of time. Several pathways are 
known to affect the survival of PMNs in an inflammatory milieu (Kennedy and DeLeo, 
2009, Rossi et al., 2007). Inflammatory cytokines (IL-1β, TNF-α, GM-CSF, IFN-γ), TLR 
activation and modulation by bacterial pathogens can all lead to increased survival of 
these cells (Colotta et al., 1992). Among the intracellular pathways involved in 
inflammation, nuclear factor-κB (NF-κB) is a key regulator of PMN apoptosis along with 
mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K) 
pathways (Rossi et al., 2007). Ingestion of bacteria by PMNs can lead to apoptosis by 
phagocytosis-induced cell death (PICD) (Kennedy and DeLeo, 2009) which can override 
delays due to pro-inflammatory factors (Watson et al., 1996). Thus, inflammation, and 
the resulting intra-cellular signalling pathways, can lead to increased survival and 
delayed removal of innate immune cells.    
The apoptotic PMNs are able to maintain membrane integrity for a period of 
time during which they need to be cleared from the site of inflammation. 
Macrophages are professional phagocytes which are the main cells involved in this 
clearing process (Savill et al., 1989),. These cells are attracted to sites of apoptosis, 
preferentially recognise apoptotic cells and phagocytose them to clear sites of 
inflammation. Apoptotic cells are known to express signals which attract phagocytes to 
them. Candidate molecules attracting macrophages to sites of apoptotic cells include 
endothelial monocyte-activating polypeptide II (EMAP II) (Weigert et al., 2009), a 
heterodimer of thrombospondin and CD36 (Moodley et al., 2003) and chemotactic 
lipids like lysophosphatidylcholine (LPC) by coupling to G protein coupled receptors 
(Mueller et al., 2007).  
Specific recognition of apoptotic cells by phagocytes occur by recognition of 
cell-surface changes during apoptosis. Phospatidylserine (PS), which is normally 
present in the inner cell-membrane is one of the essential molecules which gets 
externalised on the cell surface during apoptosis (Martin et al., 1995). Receptors on 
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phagocytic cells interact with PS through bridging molecules leading to specific 
recognition.  Other candidate molecules include calreticulin (Gardai et al., 2005) and 
CD31 (PECAM-1) which seems to have a dual role (Brown et al., 2002). Thus, ligation of 
CD31 on viable leucocytes causes their detachment from macrophages while the 
opposite happens on ligation of CD31 on apoptotic cells. Recognition of apoptotic cells 
leads to the formation of a phagocytic-synapse on the cell surface with a variety of co-
receptors being involved in the process (Vandivier et al., 2006) resulting in 
internalisation and removal of the apoptotic cell. Phagocytosis of apoptotic cells 
results in a down-regulation of pro-inflammatory activity of macrophages and causes 
these cells to express anti-inflammatory cytokines (Fadok et al., 1998a, Fadok et al., 
1998b). Thus, apoptosis of innate immune cells and their subsequent phagocytosis are 
essential steps in the resolution of inflammation.  
In the lung, clearance of apoptotic cells by macrophages after pneumonia is 
seen (Haslett, 1999). The ineffective clearance of PMNs by phagocytes can lead to 
chronic disease. Increased numbers of apoptotic cells have been found in patients with 
cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD); high levels of 
neutrophil elastase in CF patients inhibits efferocytosis (Vandivier et al., 2006). 
Preterm infants with RDS have apoptotic neutrophils in their lungs which get cleared 
by macrophage phagocytosis (Grigg et al., 1991). However, infants who develop CLD 
later seem to have an abundance of viable PMNs in the lung which failed to enter 
apoptosis (Kotecha et al., 2003, Oei et al., 2003). Persistence of neutrophils in the 
lungs of preterm infants may contribute to perpetuation of inflammation and 
continued injury to the lungs. 
In summary, apoptosis of PMNs and their subsequent removal are key steps 
during resolution of inflammation. A complex system exists which ensures efficient 
working of these steps. Disordered regulation of resolution has the potential to lead to 
chronic disease. A clear understanding of these processes involved in resolution of lung 
inflammation in preterm infants could result in new approaches to prevent 
development of chronic lung disease. 
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1.9. Inflammation in BPD 
 
A vast body of evidence implicating inflammation in the pathogenesis of BPD 
has accumulated over the last three decades. Researchers have looked at various 
stages in the inflammatory cascade as also their temporal profile to link it with the 
disease process. Presented below is a summary of the evidence, in the sequence it is 
thought to take place in the inflammatory cascade. 
 
Early Cytokines and Chemokines: Tumour necrosis factor- (TNF-α) belongs to a family 
of cytokines of the same name which is produced by alveolar macrophages in response 
to stimuli by pathogens. It upregulates expression of adhesion molecules on 
endothelial cells, epithelial cells and on leucocytes. It can also induce production of IL-
1β and IL-8 (see below). Preterm neonatal monocytes have decreased capacity (25%) 
of producing TNF-α (Metinko, 2004). TNF-α is detected in aspirates of epithelial lining 
fluid in ventilated preterm neonates (Ambalavanan et al., 2009, Jonsson et al., 1997b). 
However, its bioactivity may be low compared to its immune levels (Bagchi et al., 
1994). 
Interleukin-1 (IL-1β) is an early response cytokine produced by alveolar 
macrophages (in response to danger stimuli) and to a lesser extent by endothelial cells 
and fibroblasts. It up-regulates expression of adhesion molecules on endothelial cells 
and PMNs and also “primes” them for activation when they reach a site of 
inflammation (Metinko, 2004). It also induces IL-6 and IL-8 production from cells. IL-1β 
is detected in increased concentration in BALF from intubated preterm infants in the 
first day of life who went on to develop BPD (Rozycki, 1994). It is also associated with 
an increased risk of BPD (or death) when present in TAF of ventilated preterm infants 
(Ambalavanan et al., 2009). IL-1β expression in mouse lung produces a pathology 
similar to BPD (Bry et al., 2007) which could be due to suppression of the retinoic acid 
pathway during alveologenesis (Bry and Lappalainen, 2006). IL-1 receptor antagonist 
(IL-1ra) is a natural protein synthesized by mononuclear cells, which binds to the IL-1 
receptor and inhibits its action. Sub-optimal expression of the antagonist has been 
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implicated in the pathogenesis of airway inflammation in babies who develop BPD 
(Kakkera et al., 2005).  
IL-8 (CXCL-8) is an early response chemokine, which is a key chemoattractant 
for PMNs to sites of inflammation. It is produced by a variety of cells including alveolar 
macrophages, endothelial cells, epithelial cells, fibroblasts etc. on induction by danger 
stimuli. In-vitro, IL-8 seems to be the dominant CXC chemokine produced by alveolar 
macrophages and accounts for most of the chemotactic activity on PMNs (Goodman et 
al., 1998). It has consistently been detected in increased quantities from epithelial 
lining fluid in lungs of ventilated preterm infants who later develop BPD (Kotecha et al., 
1995, Ambalavanan et al., 2009) and has been observed to increase before the peak of 
inflammatory cell influx (Munshi et al., 1997). High levels of IL-8 in lung at birth 
correlate well with increased duration of ventilation in small preterm babies (De Dooy 
et al., 2007).     
 
Arrest of circulating leucocytes: Circulating neutrophils and monocytes express 
adhesion molecules called integrins (LFA-1 or CD11a/CD18, Mac-1 or CD11b/CD18) and 
L-selectin (CD62L)  which attach to endothelial cell adhesion molecules (ICAM-1 or 
CD54, ICAM-2 or CD102, VCAM-1 or CD106) for to stop them from flowing away. These 
molecules are up-regulated by early response cytokines TNF-α and IL-1β. Soluble forms 
of these adhesion molecules exist which are formed by alternative splicing of the 
trans-membrane domains. Endothelial cells also contain P-selectin (also in platelets) 
(CD62P) and E-selectin (CD62E) which attach to ligands on neutrophils to arrest their 
flow. Arrested cells pass between cells out of the capillaries and travel to sites of 
inflammation down the concentration gradient of chemokines. 
Concentration of soluble L-selectin (Ballabh et al., 2003) and expression of L-
selectin by PMNs (Ballabh et al., 2004) was found to be low in peripheral blood in 
infants who develop BPD. However, the concentration of soluble L-selectin in BALF was 
reported as increased persistently in the same group of infants in another study 
(Kotecha et al., 1998) suggesting the preferential retention of PMNs expressing low 
levels of L-selectin in peripheral circulation. Expression of CD62L on PMNs was further 
decreased after dexamethasone therapy (Ballabh et al., 2004, Waisman et al., 1998) in 
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this population of patients. In infants who developed BPD later, soluble E-selectin 
concentrations was increased in cord blood (Kim et al., 2004a) and in peripheral blood 
(Ramsay et al., 1998, Ballabh et al., 2003) and concentration was suppressed after 
dexamethasone therapy (Ballabh et al., 2003). ICAM-1 concentrations was similarly 
raised in peripheral blood (Ballabh et al., 2003, Ramsay et al., 1998) and in epithelial 
lining fluid (Kotecha et al., 1995, Kojima et al., 1993) of infants who developed BPD. 
However, it was not significantly affected by dexamethasone therapy (Ballabh et al., 
2003). In summary, these molecules demonstrate dynamic expression on cells, in 
blood and in epithelial lining fluid, which may be an indicator of inflammatory cell 
recruitment to sites of inflammation. However, the stimulus for recruitment comes 
from the inflammatory site and seems to be the initiator of expression of these 
molecules. Measuring them may be useful as a marker of cell recruitment over time. 
 
Influx of inflammatory cells: An influx of inflammatory cells into the lung epithelial 
lining fluid recovered by aspiration is seen early in patients of RDS (Merritt et al., 1983, 
Ogden et al., 1983, Ogden et al., 1984b). This was also noted to be persistently high in 
infants who went on to develop BPD later. Most of this influx consisted of PMNs 
(Merritt et al., 1983, Ogden et al., 1983). These studies were done before use of 
surfactants and prenatal steroids were prevalent; ventilation strategies were different 
as well. However, similar results have been reported in studies in which infants have 
benefitted from both surfactant and prenatal steroids (Kotecha et al., 1995, Arnon et 
al., 1993, Munshi et al., 1997). However, surfactant use seemed to be associated with 
an increase in MNC numbers (Arnon et al., 1993). Studies in the last decade have 
confirmed the association between prolonged infiltration of PMNs and CLD (Kotecha et 
al., 2003). 
 
Cytokine and chemokine expression: Persistence of cytokine and chemokine expression 
in the lung has been observed in preterm infants who develop BPD (Ryan et al., 2008, 
Bose et al., 2008, Speer, 2006, Ambalavanan et al., 2009). Inflammatory cells including 
macrophages and neutrophils are a major source of these cytokines (Cassatella, 1995) 
along with cells in the lung including airway and alveolar epithelial cells, endothelial 
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cells and fibroblasts. Cytokines bind to specific receptors on target cell surfaces and 
mediate intracellular signalling by up regulating or down regulating genes and their 
transcription factors (NF-κB) (Shimotake et al., 2004). Chemokines are expressed by 
the same cells in response to cytokine stimulation and they direct cellular influx to the 
site of inflammation. 
 
Protease and Antiprotease Balance: Proteases are enzymes which hydrolyses peptide 
bonds and degrade proteins (Papoff, 2000). Inflammatory cells, mainly neutrophils, are 
the major source of proteases in the lung epithelial lining fluid which potentially can 
cause damage. The functions of these enzymes are regulated by anti-proteases, which 
maintain the balance in this system during health. An imbalance between elastase and 
its inhibitor α1-proteinase inhibitor (α1-PI) has been noted in the airways of preterm 
infants (Speer, 2006). Increased urinary concentrations of desmosine, a degradation 
product of elastin, has also been identified in such infants and is thought to be a 
consequence of proteolytic damage. Elastin deposition is an essential step in the 
formation of secondary septa in the airspaces that develop into mature alveoli, which 
is not well formed in babies with BPD. Similar imbalances have been observed in 
cysteine and serine proteases and their inhibitors (Altiok et al., 2006, Yasumatsu et al., 
2006) as well as in the matrix metalloproteinases and their inhibitors (Curley et al., 
2004, Curley et al., 2003, Fukunaga et al., 2009).  
 
Resolution of Inflammation: Traditionally, the resolution of inflammation was thought 
to be a passive process related to the phagocytosis of microbes (cessation of stimulus 
for inflammation) resulting in decreased production of pro-inflammatory molecules 
and recruitment of neutrophils. Recent evidence suggest that this may be an active 
process brought about by lipid-derived mediators which are involved in switching the 
profile of inflammatory response to that of resolution (Serhan, 2008, Serhan et al., 
2008, Serhan and Savill, 2005). These mediators act by decreasing further recruitment 
of PMNs to the site of inflammation/infection and also by increasing uptake of 
apoptotic PMNs by macrophages to enhance resolution. Phagocytosis of pathogens is 
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a common inducer of apoptosis of PMNs which overrides anti-apoptotic signals from 
cytokines or other bacteria derived factors (Kennedy and DeLeo, 2009).    
Studies on the resolution of lung inflammation in preterm babies are limited. 
There is evidence of delayed neutrophil apoptosis in infants who develop CLD later 
(Kotecha et al., 2003). This suggests that inappropriate suppression of neutrophil 
apoptosis may contribute to lung inflammation by delaying resolution in this group of 
patients. The exact mechanism of this delay is unknown. No studies looking at pro-
resolving mediators in preterm lungs have been done so far. 
 
Summary: CLD in preterm babies is a multi-factorial disease which is probably starts in 
utero, initiating lung inflammation and setting it up for further injury after birth. 
Several factors contribute to lung inflammation after birth and perpetuate the injury. 
Inflammation seems to be the final common pathway causing lung damage. An 
imbalance between pro- and anti-inflammatory pathways favouring the former seems 
to perpetuate this process. There is an arrest of growth of alveoli and vessels as a 
result of this damage. Further research into the mechanisms of injury is the first step 
towards understanding this condition better, and may lead to effective treatment 
strategies. 
 
1.10. Lung Development Disorders in BPD 
 
Human lung development in the foetus occurs in overlapping stages and is 
summarised in table 1. Most infants who develop BPD are born at a late canalicular or 
early saccular stage of lung development (24-30 weeks). In this stage, there is 
functional surface for gas exchange but it is not well developed. Extensive 
development in the distal airspace structure and microvasculature occurs during this 
stage of lung development. The major part of development of the gas exchange 
surface occurs after birth in human infants. The mesenchyme of the developing lung, 
including cells (fibroblasts), structural proteins (collagen, elastin, fibronectin and 
laminin) and it’s supportive network proteoglycans and glycosaminoglycans), are 
integral to both early and late lung development (Ahlfeld and Conway, 2012). During 
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the canalicular stage, the distal airways and it’s related vasculature continue to 
develop accompanied by thinning of the mesenchyme. Maturity of the lung epithelial 
cells also takes place including differentiation into distinct cellular types in preparation 
for gas exchange. These changes continue in the saccular stage with further thinning of 
the mesenchyme and development of the pulmonary acinus. The primary septa of the 
acini are primed for development into the secondary septa, a development which 
occurs during the alveolar stage. The important changes are the thinning of the 
mesenchyme, maturation of the capillary network from a double layered to a single 
layer, and deposition of elastin at the tips of the secondary crests. Our limited 
knowledge of lung pathology suggests that these changes are altered in preterm infant 
who develop CLD, leading to simplified large airspaces. 
Studies in animal models have increased our understanding of lung 
developmental disorders involved in the pathogenesis of CLD. The primate model of 
CLD in premature baboons have provided insights in development disorders of the 
lung (Coalson et al., 1999a). These animals received similar clinical management as 
current preterm human infants, including prenatal steroids, early postnatal surfactant 
replacement, gentle ventilation and judicious use of oxygen. Lung pathology in these 
animals showed an interstitium of variable thickness and hypercellularity, focal 
deposition of elastin and collagen and dysmorphic microvasculature. Rodent models of 
CLD have also provided us with valuable insight into the lung developmental disorders 
resulting from injury before the alveolar stage. A short summary of selected growth 
factors implicated in the developmental disorders of the preterm lung follows. 
The mesenchymal structural protein elastin has a vital role in alveolar 
development where it is localised to the growing secondary septal tips (Willet et al., 
1999, Burri, 2006). Myofibroblasts are the major source of elastin in the mesenchyme, 
both in animals (Dickie et al., 2008) and humans (Leslie et al., 1990). Platelet derived 
growth factor A (PDGF-A) acts as an important chemoattractant for fibroblasts, and 
retinoic acid & sonic hedgehog have been proposed as molecules which establish a 
morphogen gradient of PDGFA to sites of secondary septation (Bourbon et al., 2005). 
Humans developing CLD show disorganised elastin deposition in their saccular wall 
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(Thibeault et al., 2003); however, the mechanisms by which elastin is involved in 
secondary septal formation is  poorly understood.  
Fibroblast growth factors (FGF) signalling through their receptors, especially 
FGFR-3 and -4, also seems critical for alveolar growth and development. Delayed 
expression of PDGF-A and reduced expression of FGFR-4 have been documented in 
neonatal rats exposed to hypoxia (Bourbon et al., 2005). FGF-7 (keratinocyte growth 
factor) is a potent stimulus of adult alveolar type II cells, and its concentration been 
found to be lower in infants who develop CLD compared to those who did not (Danan 
et al., 2002). It has also been shown to protect lung epithelium from oxidative stress, 
mechanical ventilation and infection (Bourbon et al., 2005, Franco-Montoya et al., 
2009).  
Several molecular signals are involved in this process resulting in a cross-talk 
between the developing airways and the surrounding mesenchyme. Transforming 
growth factor- (TGF-β) is an early modulator of lung growth, which acts by inhibiting 
or limiting fibroblast growth factor (FGF) signalling. It limits epithelial bud formation 
during branching morphogenesis (pseudoglandular stage) (Wert, 2004). 
Overexpression of TGF-β in the late saccular and early alveolar stage also inhibits 
alveolarisation with significant fibrosis (Gauldie et al., 2003). Elegantly designed 
experiments of antibody-mediated TGF-β inhibition demonstrated the attenuation of 
defects in alveologenesis after chronic exposure to 85% oxygen.    
Vascular growth and airway morphogenesis run parallel in human lung 
development and the former process may be important for normal alveolarisation 
(Thebaud, 2007). Vascular endothelial growth factor (VEGF) with its receptors VEGFR-1 
and -2 is a specific mitogen and survival factor for vascular endothelial cells (Thebaud, 
2007). VEGF increases cell division in human foetal lung Type II cells and probably plays 
a key role in the process of alveolarisation (Snyder, 2004). The involvement of VEGF in 
the pathogenesis of BPD is suggested by the fact that its inhibition blocks 
alveolarisation and when it is ectopically administered it enhances alveolarisation 
(Thebaud and Abman, 2007). Levels of VEGF in lung fluid in preterm infants who 
develop BPD have been found to be lower than in those who recover from RDS (Lassus 
et al., 2001). Exogenous replacement of VEGF in animal models of lung injury resulted 
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in improved capillary formation and alveolar development (Thebaud and Abman, 
2007).   
Retinoic acid (RA) signalling in the lung enhances alveologenesis while vitamin 
A deficiency delays alveolar development (Bourbon et al., 2005). Levels of vitamin A 
has been found to be lower in babies who develop CLD (Shenai et al., 1985) and it has 
been shown to have modest benefits when supplemented in a preterm population 
(Tyson et al., 1999). More consistent benefits with improvement of alveologenesis has 
been found in animal models (Bourbon et al., 2005). The post natal formation of alveoli 
is largely prevented by glucocorticoids, an effect which was partially reversed by RA 
treatment in an animal model (Bourbon et al., 2005).  
In summary, the process of normal lung development involves complex 
interaction of the growing airways with its surrounding mesenchyme, with each stage 
being modulated by several molecular mechanisms. Interruption of this process, as by 
preterm birth, can have implications in the form of alveolar simplification and paucity 
of vessels as seen in BPD. However, the molecular mechanisms which lead from 
inflammation in the lungs to dysregulated growth is yet to be determined.   
 
1.11. Modulation of Lung Inflammation in Preterm Infants – Two Potential 
Pathways 
 
Persistent inflammation has been strongly implicated in the development of 
CLD in preterm infants. This inflammation is characterised by a poorly resolving 
neutrophilia, suggesting a prolongation of acute inflammation, and poor recruitment 
of mononuclear cells suggesting an inadequate resolution phase (see section 1.9). 
Measurement of several cytokines, chemokines and other mediators of inflammation 
also support this pattern of cellular influx in infants at risk of developing CLD later. 
Thus, pathways which can down-regulate the recruitment of neutrophils and up-
regulate the influx of mononuclear cells could result in modulating lung inflammation 
in ventilated preterm infants. 
Researchers at Cardiff University have been studying the specific pro-resolution 
effects of IL-6 signalling. In an experimental animal model of peritonitis, they have 
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shown that IL-6 trans-signalling (see section 1.12.5) can down-regulate the expression 
of IL-8, one of the key chemokines involved in recruitment of neutrophils to sites of 
inflammation, and up-regulate the expression of monocyte chemoattractant protein-1 
(MCP-1), a chemokine involved in attracting mononuclear cells (Hurst et al., 2001). This 
changed the pattern of inflammation from a primarily neutrophil mediated acute 
inflammation to a mononuclear cell mediated resolution. Thus, IL-6 trans-signalling 
could attenuate lung inflammation in CLD, which exhibits dysregulation at both the 
stages (persistent neutrophil influx and poor recruitment of mononuclear cells), and 
provides an attractive mechanism to resolve pulmonary inflammation in infants at risk 
of CLD. Although IL-6 concentration has been measured in the lungs of ventilated 
preterm infants (see section 1.12.6), detailed studies on the trans-signalling pathway 
has not been conducted yet. 
IL-8 is one of the main chemokines implicated in the recruitment and activation 
of neutrophils at sites of inflammation. Concentration of IL-8 in the lungs of ventilated 
preterm infants, who later develop CLD, have been consistently shown to be higher 
than in infants who do not (resolved RDS, see section 1.9). This is in keeping with the 
persistent influx of neutrophils observed into the lungs of CLD infants. Variations in the 
numbers of amino acids at the amino-terminal of the IL-8 molecule leads to the 
formation of several isoforms of IL-8 (see section 1.13.2 and table 1.2). The most 
common biological isoform involved in inflammation is the 72-amino acid molecule IL-
872, which is functionally much more potent (both in attracting neutrophils and in 
activating them) than the next common isoform, the 77-amino acid molecule IL-877 
(see section 1.13.4). IL-877 is the major isoform found in the circulation of preterm 
infants (Maheshwari et al., 2009). Although concentration of total IL-8 have been 
measured in the lungs of preterm ventilated infants, the expression of IL-877 has not 
been studied. Potentially, modulation of expression of the IL-8 isoforms could result in 
modulating neutrophil influx into the preterm lung and change the pattern if 
inflammation. 
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1.12. Interleukin-6 Biology  
 
Interleukin-6 (IL-6) is a multifunctional cytokine in biology (Kishimoto, 2006). It 
has important roles in normal physiology (when it is well regulated) as well as in 
pathology (defective regulation). Before the current name came into use, the molecule 
has been previously known as B cell stimulatory factor-2 (BSF-2), hybridoma growth 
factor (HGF) and hepatocyte-stimulating factor (HSF). All of these molecules were 
found to have the identical cDNA sequence and the name IL-6 was proposed (Akira et 
al., 1993).  
Although IL-6 is commonly regarded as a pro-inflammatory cytokine, recent 
evidence has brought to light the pro-resolution effects of IL-6 (section 1.11.6). CLD is 
characterised by a persistent and poorly-resolved neutrophilic inflammation in the 
lungs of preterm infants. Thus, the pro-resolution effects of IL-6 signalling could be an 
effective pathway in modulating inflammation in the lungs of preterm infants at risk of 
CLD. Although the concentration of IL-6 itself has been measured in the lungs of 
preterm infants (sections 1.9 and 1.11.6), molecules in the IL-6 signalling pathway 
which are involved in resolution of acute inflammation have not. 
 
1.12.1. Structure of IL-6 
The IL-6 molecule is 184 amino acids (AA) in length and is secreted as a 212 AA 
long precursor by multiple cell types as a 21-28 kDa molecule (Heinrich et al., 1998, 
Van Snick, 1990). The range of molecular weights is due to post-translational 
glycosylation and phosphorylation in cells. Human IL-6 gene is located on chromosome 
7p21 (Bowcock et al., 1988). There is about 65% homology between human IL-6 and 
mouse or rat IL-6 at the gene level (42% at protein level), mainly due to the conserved 
central portion (Akira et al., 1993). Human IL-6 has biologic activity on murine cells but 
mouse IL-6 does not have biologic activity on human cells (Coulie et al., 1989). IL-6 has 
a four α-helical structure, A-D, with connecting loops (Xu et al., 1996); receptor 
recognition epitopes are mainly located in the beginning of the A-helix and the ends of 
the AB loop and D-helix (Kalai et al., 1997).  
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1.12.2. Functions of IL-6 
A large variety of cells in the body produce IL-6 including cells of the immune 
system (macrophages, PMNs, lymphocytes), endothelial cells, fibroblasts, bone cells 
(chondrocytes, osteoblasts) and some tumour cells. Most cells secrete IL-6 after 
appropriate stimulation which is usually well regulated; tumour cells are able to 
produce IL-6 constitutively (Akira et al., 1993). Multiple stimuli are known to affect the 
production of IL-6, by exerting both positive and negative control. Some stimuli are 
known to be cell specific exerting positive control in some cell types and negative 
control in others. 
IL-6 produced by T-cells act as B-cell differentiation factor. It can augment IL-2 
receptor expression resulting in T-cell growth and cytotoxic T-cell differentiation 
(Kishimoto, 2006). IL-3 and IL-6 have synergistic effects on the formation of 
multilineage blast cell colonies (Ikebuchi et al., 1987). IL-6 can act as thrombopoietin to 
control the late stages of megakaryocyte differentiation into platelets (Hill et al., 1990) 
in times of haematopoietic stress. IL-6 stimulates osteoclast formation & recruitment 
and bone resorption. Skin keratinocytes produce IL-6 when induced by IL-4 and IL-6 
can stimulate proliferation of normal human keratinocytes (Grossman et al., 1989). 
Ultraviolet light can induce increased production from skin (Kirnbauer et al., 1991) and 
it may function as a regulator of systemic sunburn reaction. Endothelial cells, when 
induced by IL-6, produce increased platelet derived growth factor (PDGF) in vitro which 
in turn proliferation and migration of vascular smooth muscle cells as well as being 
chemotactic for monocytes and PMNs resulting in priming them (Akira et al., 1993). It 
can induce endothelial expression of adhesion molecules and production of MCP-1 
(Romano et al., 1997). IL-6 is one of the primary cytokines involved in the “acute phase 
response” resulting in the production of several plasma proteins by the liver including 
C-reactive protein (CRP), fibrinogen and complement proteins.      
  
1.12.3. The IL-6 Receptor System 
IL-6 exerts its biological actions by a low-affinity attachment to a specific cell-
surface receptor, the IL-6 receptor α (IL-6Rα, an 80kD ligand-binding subunit, gp80) 
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which dimerises another cell-surface molecule gp130 (IL-6Rβ, a 130kD signal-
transduction subunit, CD130) (Rose-John et al., 2007). Both receptor subunits are 
transmembrane proteins. The IL-6R precursor is 468 AA in length which matures to a 
449 AA protein including a 339 AA extracellular part, a 28 AA transmembrane part and 
an 82 AA intracellular part (Heinrich et al., 1998, Van Snick, 1990). The extracellular 
chain contains a cytokine binding domain (CBD) and two fibronectin-type-III-like 
domains (FNIII). gp130, the signal-transducing subunit, is common to other members 
of the IL-6 family. Its precursor is secreted as a 918 AA protein which matures to a 896 
AA protein including an extracellular part of 597 AA, a transmembrane part of 22 AA 
and an intracellular part of 277 AA (Van Snick, 1990, Heinrich et al., 1998). The 
intracellular domain of gp130 is essential for signal transduction. Cytokine binding by 
gp130 occurs through three membrane-distal domains, D1-D3 while three membrane 
proximal FNIII domains are involved in receptor activation (Bravo et al., 1998, Chow et 
al., 2001).  
IL-6 has three distinct receptor binding sites (Simpson et al., 1997). Site 1 is 
formed by the C-terminal residues of helix D and the C-terminal part of the AB loop; 
this site determines the specificity of binding to IL-6R. Site 2 is formed by residues near 
the middle of helices A and C and is the universal gp130 binding site which happens 
only in the presence of IL-6R. There is also a site 3 formed by the end of the CD loop, 
the N-terminus of the D helix and the N-terminal part of the AB loop; this is a second 
binding site for gp130 by IL-6. Thus, in the homodimer of the signalling complex, two 
different binding epitopes of gp130 are involved in ligand recognition. 
Site 1 on IL-6 binds to the CBD on IL-6R as the first step in the interaction 
(Heinrich et al., 1998). Site 2 on IL-6 in the IL-6R/IL-6 complex then engages with D2-D3 
on the gp130 molecule to form an intermediate trimolecular nonsignalling complex. 
This is followed by dimerisation of the complex by interaction of site 3 on IL-6 with D1 
(Ig like domain) on the gp130 molecule. The final signal complex is of a hexameric 
architecture consisting of two molecules each of IL-6, IL-6R and gp130 (figure 1.7) 
(Boulanger et al., 2003). The complex of IL-6R/IL-6 is essential to recruit gp130 
efficiently. 
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Figure 1-7: Structure of the human Il-6/IL-6R_/gp130 hexameric complex (Boulanger et 
al., 2003).  
1.12.4. Receptor Signalling 
Binding of IL-6/IL-6R complex to gp130 results in activation of intra-cytoplasmic 
kinases, of which the Janus Activated Kinases (Jaks) are the best studied. These 
tyrosine kinases are associated with the cytoplasmic tail of gp130 and induces tyrosine 
phosphorylation. IL-6 signalling leads to the activation of Jak1, Jak2 and Tyk2 among 
which Jak1 seem to be crucial (Guschin et al., 1995). STATs (signal transducers and 
activators of transcription) are the one of the main transcription factors involved in 
intracellular signalling via activation of IL-6 receptors. Of the seven STAT genes 
identified so far, protein products of the STAT1 and STAT3 genes are known to be 
involved in IL-6 signalling. There are specific docking sites for STATs on the phospho-
tyrosine residues on the cytoplasmic tail of gp130 (Stahl et al., 1995). Phospho-STAT1 
(Tyr701) and 3 (Tyr705) are able to form homo- and hetero-dimers which is essential for 
DNA binding (Heinrich et al., 1998) after active translocation into the nucleus (Heinrich 
et al., 2003). STATs bind to specific DNA sequences and modulate transcription of 
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target genes. SOCS (suppressor of cytokine signalling) proteins are cytoplasmic 
molecules which are involved in a negative feedback loop to control intra-cellular 
signalling by IL-6. They are activated by IL-6 binding to its receptors and act by 
inhibiting tyrosine phosphorylation of gp130 (Naka et al., 1997). Other proteins like 
PIAS (protein inhibitor of activated STAT) are directly involved in STAT inhibition by 
blocking DNA binding and gene activation (Chung et al., 1997).  
Homodimerisation of IL-6 receptors not only activate the JAK/STAT signalling 
pathways but also can induce the MAPK (mitogen activated protein kinase) cascade. 
Several members of the MAPK family are known to be activated by IL-6 signalling 
including ERK1/2 (cell survival effects) as well as p38 and JNK (stress related activation) 
(Heinrich et al., 2003). Another pathway activated by IL-6 signalling is the PI3K/Akt 
(phosphoinositide-3-kinase) pathway which is involved in proliferation of myeloma 
cells in the presence of IL-6 (Hideshima et al., 2001). 
 
1.12.5. Cis- and trans-signalling  
The downstream sequence of events when IL-6 binds to its membrane-bound 
receptor subunits (IL-6R and gp130) resulting in intracellular signal transduction is 
termed cis-signalling. gp130 is ubiquitously expressed on almost all cells of the body 
(Saito et al., 1992). However, expression of the membrane-bound IL-6R is restricted to 
mainly hepatocytes and leucocytes (Jones et al., 2001, Jones, 2005). A soluble form of 
the IL-6R (sIL-6R) was detected in human urine (Novick et al., 1989), in human serum 
and culture supernatants of human mononuclear cell (Honda et al., 1992). sIL-6R can 
be generated by limited proteolysis of the membrane-bound receptor (Mullberg et al., 
1993b) which could be prevented by a metalloprotease inhibitor (Mullberg et al., 
1995). It can also be generated by an alternative splicing mechanism where the 
transmembrane domain is deleted (Horiuchi et al., 1994a). Both the recombinant (Taga 
et al., 1989) and the soluble (Mackiewicz et al., 1992) forms of IL-6R interact with IL-6 
and the complex was found to be biologically active. Commonly, in biology, the 
complex of a ligand and its soluble receptor are inhibitory in function. However, the 
complex of sIL-6R/IL-6 is an exception where they can bind to gp130 on the cell-
membrane and initiate intra-cellular signalling. IL-6 signalling via its complex with sIL-
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6R through membrane-bound gp130 has been termed trans-signalling. Effectively, this 
vastly widens the repertoire of cells which can respond to IL-6 signalling. Several 
investigators have since explored the effects of trans-signalling on cells and tissues of 
the body (Jones et al., 2001).  
A soluble form of the gp130 subunit (sgp130) is normally present at relatively 
high levels in body fluids (Narazaki et al., 1993). This was shown to associate 
preferentially with the complex of sIL-6R/IL-6, but no association was demonstrated in 
the absence of either sIL-6R or IL-6 (Yasukawa et al., 1992). Further exploration of the 
role of sgp130 in IL-6 signalling showed it to be a selective inhibitor of the sIL-6R/IL-6 
complex, i.e. trans-signalling but not of IL-6 via membrane-bound IL-6R (cis-signalling). 
It can competitively bind to the complex and prevent its association with the 
membrane-bound gp130 (signal-transducer) when present in a molar excess (Jones et 
al., 2005). It has been proposed that since sgp130 is present in serum at high levels, it 
acts as the natural inhibitor of IL-6 trans-signalling (Jostock et al., 2001a), although an 
effect on IL-6 cis-signalling has also been recently suggested (Garbers et al., 2011). 
 
Figure 1-8: IL-6 trans-signalling (with permission from Rose-John et.al. 2007) 
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1.12.6. IL-6 in Disease and Inflammation 
 
The traditional view of IL-6 is as an acute-phase response cytokine which has 
pro-inflammatory effects, both local and systemic. Several diseases have been shown 
to be associated with elevated concentrations of IL-6 (Jones et al., 2005). IL-6 signalling 
has also been implicated in various chronic disease processes like myeloma, 
rheumatoid arthritis, and Crohn’s disease (Jones, 2005). The systemic effects of IL-6 as 
an acute phase reactant can be explained by signalling through its membrane-bound 
receptors, i.e. cis-signalling. However, since the expression of the ligand-binding 
subunit (IL-6R) is restricted to only a few cell types, the local effects of IL-6 can only be 
explained by trans-signalling through the soluble receptor (sIL-6R) (Rose-John et al., 
2006). 
The anti-inflammatory roles of IL-6 are less well known. IL-6 can decrease 
neutrophil infiltration and production of cytokines in animal models of acute lung 
inflammation (Ulich et al., 1991, Xing et al., 1998). IL-6 trans-signalling is involved in 
directing leukocyte trafficking to inflammatory sites, regulation of leukocyte apoptosis 
and directing maturation of T-cell subsets (Jones, 2005). More specifically, IL-6 trans-
signalling has been shown to effect the transition of inflammatory infiltrate from 
predominantly neutrophilic to mononuclear cells in an animal model of acute 
inflammation, thus initiating resolution (Hurst et al., 2001). This is effected by changing 
the expression of chemokines from those predominantly attracting neutrophils (e.g. IL-
8, GRO-α) to those which predominantly attract mononuclear cells (e.g. MCP-1) 
(Kaplanski et al., 2003). However chronic diseases, which are characterised by a 
persistent infiltrate of mononuclear cells, can also be adversely controlled by the 
effects of IL-6 trans-signalling.  
IL-6 has been studied in the context of CLD in preterm infants. IL-6 has been 
found in increasing concentrations in lung fluid of preterm infants who later develop 
CLD (Kotecha et al., 1996b, Jonsson et al., 1997b, Choi et al., 2006b). The increase in 
concentration of IL-6 was found to precede the influx of neutrophils to the lung 
(Munshi et al., 1997). As discussed before, CLD is characterised by a persistent 
neutrophilia (Kotecha et al., 2003) leading to inflammation and lung damage. IL-6 
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trans-signalling, with its ability to switch leukocyte infiltrate to a mononuclear cell 
population during acute inflammation may have important implications for CLD. The 
modifying effects of the soluble receptors (sIL-6R and sgp130) on IL-6 signalling in the 
lung have not been studied extensively. In a recent report, no differences were found 
in the concentration of sIL-6R and sgp130 in the lung fluid of preterm infants who 
developed CLD compared to infants who did not (von Bismarck et al., 2008a). I 
hypothesised that the pattern of inflammation in the lungs of preterm infants 
developing CLD was due to a lack of IL-6 trans-signalling. 
 
1.13. Interleukin-8 Biology 
 
1.13.1. Early discovery of Interleukin-8 structure and function 
Interleukin-8 (IL-8), also known as CXCL8 (2003) was discovered in the 
laboratory in the late 1980’s by researchers while looking for a chemotactic factor and 
activator of neutrophils (PMN). This was first detected in human mononuclear 
leukocytes by stimulating them with lipopolysaccharide (LPS) (Yoshimura et al., 1987a) 
and/or phorbol myristate acetate (PMA) (Schroder et al., 1987) and also by stimulating 
human lymphocytes with phytoheamagglutinin (PHA)/ Concavalin A/ LPS (Schroder et 
al., 1988). The estimated molecular weight of the molecule was around 10 kD and 
attracted PMNs selectively. Amino-terminal sequencing by several groups of 
investigators revealed an identical protein which was different from other known 
proteins (Yoshimura et al., 1987b, Walz et al., 1987, Van Damme et al., 1988). The 
complete sequence of the molecule was finally detected to consist of 72 AA with 
identical NH2-terminal sequence as determined previously with a molecular weight of 
8 kD (Matsushima et al., 1988). All of these proteins detected had selective activity to 
attract PMNs but not monocytes. 
Researchers soon established that IL-8 is secreted by almost all nucleated cells 
of the body, along with its various functions including attracting and activating 
neutrophils (Baggiolini et al., 1989, Remick, 2005). It was suggested that IL-8 acts by 
binding to specific cell-surface receptors on neutrophils (Baggiolini et al., 1989) and 
two receptors called CXCR1 and CXCR2 were soon established (Baggiolini, 1993). Since 
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then, IL-8 has been found to be a key mediator of acute inflammation at all sites in 
humans. 
 
1.13.2. Isoforms of IL-8 
Studies on Staphylococcal enterotoxin A stimulated human peripheral blood 
leucocytes (Schmid and Weissmann, 1987) had established the upregulation of the IL-8 
gene which was predicted to transcribe a 99 AA pre-protein consisting of a 22 AA signal 
sequence and a 77 AA mature protein (later shown to be identical to IL-8). This 
upregulated cDNA clone, called 3-10C, was used by several researchers to express the 
protein in E.coli (Lindley et al., 1988a) & 293 (human kidey cell-line) cells (Gimbrone et 
al., 1989) and to detect mRNA in retinal pigment epithelial cells (Elner et al., 1990) & 
dermal fibroblasts (Mielke et al., 1990). As predicted earlier (Schmid and Weissmann, 
1987), all of these investigators detected primarily the 77 AA protein.  
The cDNA for  MDNCF (Monocyte Derived Neutrophil Chemotactic Factor, an 
old name for IL-8) was screened and cloned from stimulated monocytes (Matsushima 
et al., 1988). This predicted a 99 AA pre-protein with a 27 AA signal sequence resulting 
in a 72 AA mature protein starting with serine. This cDNA sequence was used to 
express the protein (72 AA) in E.coli (Furuta et al., 1989) and detect mRNA in 
stimulated endothelial cells (Strieter et al., 1989a) and fibroblasts (Strieter et al., 
1989b).  
Thus, the two main isoforms of IL-8 were established as the 77 and 72 AA 
proteins, IL-872 and IL-877 (Figure 1.8). Within the next two years, several investigators 
discovered different isoforms of IL-8 from various cell-types which differed in the AA 
sequence at the NH2-terminal (table 1.2). However, the function of the different 
isoforms were not known.  
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Reference Cell type Isoforms 
(Yoshimura et al., 1989a) Monocytes 79 a.a. – 6% 
77 a.a. – 38% 
72 a.a – 36% 
(Lindley et al., 1988a) Monocyte 77 a.a. – 17% 
72 a.a. – 70% 
70 a.a. – 8% 
69 a.a. – 5% 
(Gregory et al., 1988) Lymphocytes 77 a.a. – 30% 
72 a.a. – 70% 
(Van Damme et al., 1989b) Mixed mononuclear cells 77 a.a. – 20% 
72 a.a. – 55-70% 
79, 71, 70 & 69 a.a. – rest 
(Gimbrone et al., 1989) Endothelial cells 77 a.a. – 90% 
72 a.a. – rest 
(Schroder et al., 1990) Dermal fibroblasts 77 a.a. – 85-90% 
79 a.a. - rest 
 Table 1-2: Isoforms of IL-8 from different cellular sources. 
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 Figure 1-9: (A) Amino acid sequence of IL-872 and (B) different isoforms of IL-8 
resulting from variable a.a. sequence at the NH2-terminal. From the top in figure (B), 
the isoforms are IL-872, IL-877, IL-870 and IL-869 (Lindley et al., 1988a). (T = peptides 
obtained by tryptic digestion, A = peptides obtained by cleavage with 75% formic acid) 
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1.13.3. Conversion of longer isoform of IL-8 to shorter isoforms 
 The ability of different proteases to convert IL-877 to shorter isoforms was 
demonstrated by researchers. Conversion to IL-872 was demonstrated in the presence 
of -thrombin (Hebert et al., 1990a), plasmin (Nakagawa et al., 1991b), by cathepsin-L 
(Ohashi et al., 2003) and in the presence of R-gingipain (proteinase from 
Porphyromonas gingivalis, an oral anaerobic rod strongly associated with active 
periodontitis) (Dias et al., 2008). Matrix metalloproteinase-9 (MMP-9) is another 
proteinase which converted IL-877 to IL-871 (Van den Steen et al., 2000).  
 
 
1.13.4. Functional activity of different isoforms of IL-8 
 Conversion of IL-877 to IL-872 by -thrombin resulted in difference of potency of 
the isoforms in functional assays (Hebert et al., 1990a). IL-872 was found to be 10-times 
more potent in inhibiting adhesion of neutrophils to IL-1 stimulated endothelial-cell 
monolayers. In the presence of R-gingipains, the chemotactic activity of IL-877 was 
found to be higher than untreated IL-877, as it is converted to IL-872 (Dias et al., 2008). 
After conversion of IL-877 by MMP-9 to IL-871, a 10-fold lower concentration was able 
to achieve half-maximal binding to neutrophil receptors. Also, IL-871 was able to 
mobilise intracellular calcium at 20-times lower concentration compared to IL-877. 
Similar differences in functional potency were observed by the authors in release of 
gelatinase-B from neutrophils and chemotaxis of neutrophils, with the shorter isoform 
being more potent. 
  To assess possible functional differences in the two main IL-8 isoforms, Huber 
et al. looked at neutrophil invasion through a blood-vessel wall construct (Huber et al., 
1991). Whilst differences in potency were noted between the two isoforms, both 
caused PMN attachment to endothelial cells and subsequent migration to basal layers. 
This is in contrast to an earlier report (Gimbrone et al., 1989) suggesting that the 77-aa 
isoform is a specific inhibitor of PMN-endothelial cell interaction. This potential 
contrast can be explained by the difference in the two models systems: Huber et al 
created a chemotactic gradient by using conditioned media on one side of the cellular 
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construct and not stimulating the endothelial cells directly. On the other hand, 
Gimbrone et al stimulated endothelial cells to produce IL-877, thus abolishing the 
chemotactic gradient. However, the physiological relevance of either of these 
observations are not entirely clear; the model used by Gimbrone et al. is probably 
more physiologic as endothelial cells are stimulated by IL-1 and TNF- during an 
inflammatory cascade. In an extension of the study, preloaded intravenous IL-8 (both 
isoforms) inhibited intradermal accumulation of PMNs in rabbits, when challenged 
with cytokines (Hechtman et al., 1991). No differences in potency were noted between 
the two isoforms.  
 In a detailed in vitro study of functional activity of the different isoforms (Clark-
Lewis et al., 1991), the authors showed  a significant difference in potency between IL-
877 and IL-872 in their ability to release elastase from neutrophils and in displacing 
radio-iodine conjugated IL-8 from receptor binding sites. Other important findings 
from this study was confirming the essential role of the E-L-R sequence at position 69-
67 (from the COOH-terminal) for functional activity, as this region is involved in binding 
to the receptor. A truncated form of IL-8 with missing AA from the COOH terminal was 
also found to be functionally active, although less potent compared to the full protein, 
but nonetheless confirming the non-essential nature of the COOH-terminal amino 
acids for function.  
 In a direct comparison between the functional activity of IL-872 and IL-877 in 
vitro, the shorter protein was found to have significantly increased potency in 
elevating cytoplasmic calcium and in displacing bound IL-8 from cell-surface receptors 
(Nourshargh et al., 1992). However, no significant difference in potency was noted in 
accumulation of neutrophils at sites of injection in vivo. The authors speculated on the 
possibility of IL-877 being cleaved by proteases in vivo to shorter isoforms, resulting in a 
lack of difference in functional activity. 
 More recent studies on functional activity of IL-8 isoforms (Mortier et al., 
2011b, Proost et al., 2008) confirmed the differences in potency of the main isoforms 
in vivo. Importantly, the authors also demonstrated a higher angiogenic potency of IL-
872 in rabbit corneal micropockets (Proost et al., 2008) and accumulation of 
neutrophils after intra-peritoneal injection compared to IL-877 (Proost et al., 2008, 
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Mortier et al., 2011b). Thus, the differences in potency between the two major 
isoforms in vitro was reflected by functional differences in vivo. The authors proposed 
a classification of IL-8 isoforms based on their functional activity (figure 1.9) 
 
 Figure 1-10: Overview of the naturally occurring CXCL8 isoforms. Several NH2-
terminally modified isoforms of CXCL8 have been purified from the conditioned 
medium of leukocytes, fibroblasts and endothelial cells. The NH2-terminal and COOH-
terminal sequences of these isoforms are depicted in the one-letter code (B = 
citrulline). Based on the criteria formulated by Von Heijne (von Heijne, 1983), the 99 
amino acid precursor molecule may be cleaved by signal peptidases between Cys20 and 
Glu21 or between Gly22 and Ala23, the latter being more probable. CXCL8(1-77) can be 
cleaved by a number of proteases, resulting in the listed NH2-terminally truncated 
forms. These NH2-terminal modifications differently affect the ability of CXCL8 to 
recruit neutrophils. The in vivo neutrophil-attracting activity is defined in the boxes at 
the right (Mortier et al., 2011b).  
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1.13.5. IL-8 in preterm infants and in CLD/BPD 
 IL-8 has been extensively studied in lung fluid from preterm ventilated infants 
(Ryan et al., 2008, Bose et al., 2008). Significantly increased IL-8 in lung fluid from 
infants who later develop CLD, compared to infants who don’t, has been a consistent 
finding in all studies. However, the isoforms of IL-8 in the preterm lung has never been 
looked at.  
 Until the early 2000s, an assay to selectively and easily detect IL-877 did not 
exist. The earlier ELISAs (Ko et al., 1992), as well as commercially available ELISA were 
able to detect “total” IL-8. In 2002, a specific monoclonal antibody was developed for 
IL-877 which was used to detect this isoform in an ELISA (Nashkevich et al., 2002a). 
Based on the ELISA, a recent study on circulating IL-8 in preterm infants (Maheshwari 
et al., 2009) suggested that IL-877 may be the dominant isoform compared to term 
infants and adults. The authors suggested that IL-8 expression is regulated by 
developmental changes taking place in the foetus, with more mature and active form 
predominating at later gestations (term) and during adulthood. If this is reflected in 
the preterm lung, it can have profound effects on the functional activity of IL-8 as the 
long isoform (IL-877) is significantly less potent than the more common shorter isoform 
(IL-872).  
  
1.13.6. Summary 
 IL-8 is one of the most potent pro-inflammatory chemokines involved in 
attracting and activating neutrophils to sites of inflammation. In preterm ventilated 
infants, the lung is a common site of inflammation and IL-8 concentrations are found 
to be consistently high in infants who develop CLD. The different isoforms of IL-8 have 
confirmed differences in functional potency, both in vitro and in vivo. However, this 
aspect of inflammation has not been studied in the preterm lungs. Potentially, a better 
understanding of the expression of different IL-8 isoforms may result in novel 
pathways of modulation of lung inflammation in preterm infants.   
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1.14. Summary and Background of the Project 
 
CLD is a disease which is prevalent primarily in survivors after extreme preterm 
birth. These infants need respiratory support in the short- to medium-term, and have 
been noted to develop long-term respiratory sequelae. Extreme prematurity and 
extremely low birth weight are the two main risk factors for development of this 
condition. However, several clinical risk factors have been implicated to contribute to 
the development of CLD including chorioamnionitis, mechanical ventilation, post-natal 
infection and oxygen toxicity among others. Inflammation seems to be the final 
common pathway which leads to lung injury, and subsequent interruption of lung 
growth at an immature stage. The pattern of inflammation in CLD shows a persistent 
influx of acute inflammatory cells, mainly PMNs, and low numbers of mononuclear 
cells. Thus a persistent and poorly resolved neutrophilia is characteristic in the lungs of 
preterm infants who develop CLD later. Better understanding of the pathways of 
resolution of inflammation in the preterm lungs could lead to potential therapeutic 
targets to modulate the process with possible clinical benefits for these infants.  
 IL-6 trans-signalling has already been shown to have a pro-resolution effect on 
experimental inflammation, by down-regulating expression of IL-8 (a key chemokine 
involved in recruiting PMNs to sites of inflammation) and up-regulating MCP-1 (a 
chemokine involved in recruiting mononuclear cells), which switches the influx of cells 
from mainly neutrophils to mononuclear cells. Thus, if effective, IL-6 trans-signalling 
could potentially reverse the two key defects in the inflammatory pathway in the 
preterm lungs, viz. persistent influx of PMNs and inadequate recruitment of 
mononuclear cells. Expression and functional activity of the members of the IL-6 trans-
signalling pathway have not been explored in detail in the preterm lung. 
 Interleukin-8 is a key chemokine which attracts neutrophils to sites of 
inflammation along a chemical gradient. It has been strongly implicated in the 
pathogenesis of CLD, which shows a pattern of persistent neutrophilic lung 
inflammation. Modulation of the biological effects of IL-8 could be a key step in 
limiting inflammation and its effects on lung injury in preterm infants. The long isoform 
of IL-8, IL-877 is functionally less potent compared to the most common isoform IL-872. 
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Since several enzymes expressed at sites of inflammation can convert IL-877 to shorter 
isoforms, understanding these processes could be provide us with new approaches 
toward modulating IL-8 activity and inflammation in the preterm lung.  
 Modelling human diseases in appropriate animals to study mechanisms and 
gather evidence of efficacy of new interventions is a well established strategy. Rodents 
have been used as a common animal model for several human diseases, specifically 
murine models, due to the availability and ease of genetic knockouts. Several 
researchers have used animal models to study effects of risk factors on lung 
development in newborn rodents (Auten et al., 2001, Choi et al., 2013, Franco-
Montoya et al., 2009) and lambs (Kramer et al., 2002, Willet et al., 2000). However, the 
most physiologically relevant model of CLD is the primate model in preterm baboons 
(Coalson et al., 1999b). These animals are delivered preterm at gestational age 2/3rd of 
term (equivalent to extreme prematurity in human infants) after antenatal steroids, 
receive exogenous surfactant replacement after birth and are ventilated gently in 
sufficient oxygen to maintain adequate saturations. After a variable period of time, 
these animals are sacrificed and their lungs are studied histologically, showing changes 
similar to human CLD. As this care reflects current clinical practice in human infants 
closely, in animals that are evolutionally closest to our species, this makes the baboon 
model of CLD the most relevant for research.      
  
1.15. Hypothesis and Aims of the project 
 
On the above background, the main hypothesis of my project is that 
modulation of neutrophil infiltration into the preterm lungs may be regulated by 
1. the effects of IL-6 trans-signalling  
2. altering functional effects of IL-8 isoforms.  
Since limited information is available about the effects of these two pathways 
in the preterm lungs, my project was designed to start as an observational study, to 
proceed to identifying potential therapeutic targets at the molecular level in 
appropriate laboratory-based in-vitro models. 
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 The specific aims of the project are detailed below.   
1.15.1. IL-6 trans-signalling in the preterm lung 
 To determine the expression of the IL-6, sIL-6R, sgp130, IL-8 and MCP-1 in 
broncho-alveolar lavage fluid (BALF) from ventilated preterm baboons and 
human infants. To determine the concurrent pattern of influx of inflammatory 
cells in BALF from preterm ventilated baboons and human infants.  
 To analyse possible correlations between expression of the IL-6 trans-signalling 
molecules, the related chemokines and influx of inflammatory cells.  
 To compare expression in the human infants between those who develop CLD 
and those who do not. 
 To develop a sensitive and specific bioassay to measure IL-6 functional activity 
(cis- and trans-signalling) in BALF from preterm ventilated infants. 
 To compare functional activity between infants who develop CLD and those 
who do not.   
 
1.15.2. IL-8 isoforms in the preterm lung 
 To determine the expression of total IL-8 and IL-877 in BALF from preterm 
ventilated infants. 
 To compare the expression of total IL-8 and IL-877 in infants who develop CLD 
with those who do not.   
 To determine the functional potential of BALF to convert IL-877 to shorter 
isoforms and identify possible proteases involved in the mechanisms of 
conversion.  
 To determine the effect of proteases, potentially involved in the above 
conversion, on IL-877 in-vitro and determine the functional relevance of this 
conversion on PMNs.   
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2. Materials and Methods 
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2.1. Buffers and Solutions 
2.1.1.  
2.1.2. Phosphate Buffered Saline (PBS) 
10 x concentrated stock solution (Fisher Scientific, Loughborough, UK) was used 
to prepare a working solution of 1 x concentration by diluting the stock 1 in 10 in de-
ionised water (dH2O). Freshly prepared before use. 
 
2.1.3. Assay diluent for total IL-8 ELISA (PBS + 10% foetal calf serum) 
PBS (1 x) was mixed with 10% (v/v) of heat inactivated (see later) foetal calf 
serum (FCS, Sigma-Aldrich Company Ltd., Gillingham, UK) and stored frozen at -20°C 
(henceforth called PBS FCS). 
 
2.1.4. Protease-free bovine serum albumin (BSA) stock solution 
10% BSA (w/v) (Sigma-Aldrich Company Ltd., Gillingham, UK) was diluted in PBS 
(1x) and stored frozen at -20°C (henceforth called BSA).   
 
2.1.5. ELISA wash buffer 
PBS (1 x) was supplemented with 0.05% (v/v) Tween-20 solution (Fisher 
Scientific, Loughborough, UK) and stored at 4°C. 
 
2.1.6. ELISA wash buffer for IL-877 ELISA  
ELISA wash buffer as before with 300 mM sodium chloride (NaCl) (Fisher 
Scientific, Loughborough, UK).  
 
2.1.7. Tris buffer for all protease experiments (TBS BSA) 
50 mM tris(hydroxymethyl)aminomethane (Tris) (Fisher Scientific, 
Loughborough, UK) with 154 mM NaCl, pH 7.4, and 0.05% (w/v) BSA. Freshly prepared 
before use. 
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2.1.8. Sodium citrate solution  
3.8% (w/v) sodium citrate (citrate) (Fisher Scientific, Loughborough, UK) was 
dissolved in 0.9% NaCl solution (Fresenius Kabi, Runcorn, UK). Solution was sterile 
filtered by passing through a low protein-binding polyethersulfone (PES) membrane 
with a pore-size of 0.22 μm (Elkay Labs, Basingstoke, UK) and stored at room 
temperature. 
 
2.1.9. Dextran solution  
6% Dextran (w/v) from Leuconostoc mesenteroides (dextran), average mol wt 
425,000 to 575,000 D (Sigma Aldrich Company Ltd., Gillingham, UK) was dissolved in 
0.9% NaCl solution. Solution was sterile filtered by passing through a low protein-
binding polyethersulfone (PES) membrane with a pore-size of 0.22 μm and stored at 
4°C. 
 
2.1.10. Percoll solution  
90% working solution (v/v) was prepared from Percoll stock solution (100%), 
density 1.125 – 1.135 g/ml (Sigma Aldrich Company Ltd., Gillingham, UK) by diluting 
with 0.9% NaCl solution. Solution was prepared sterile and stored at 4°C. Henceforth, 
Percoll refers to the 90% solution. 
 
2.1.11. Purified human neutrophil elastase and cathepsin G buffer solution 
(for diluting lyophilised powder) 
50 mM sodium acetate (Fisher Scientific, Loughborough, UK) pH 5.5 with 150 
mM NaCl.  
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2.2. Cytokines, Chemokines and Inflammatory Stimuli 
 
Molecule Company 
Typical stock 
concentration 
Recombinant human interleukin-6 
(rh IL-6) 
R & D Systems, Abingdon, UK 30 μg/ml 
Recombinant human soluble 
interleukin-6 receptor (rh sIL-6R) 
R & D Systems, Abingdon, UK 30 μg/ml 
Hyper interleukin-6 (Hyper IL-6) 
 
Generous gift from Prof Stefan 
Rose-John 
30 μg/ml 
Recombinant human soluble gp130 
(rh sgp130) 
R & D Systems, Abingdon, UK  120 μg/ml 
Recombinant human soluble gp130 
Fc chimera (rh sgp130Fc) 
Generous gift from Prof Stefan 
Rose-John 
120 μg/ml 
Recombinant human interleukin-1β 
(rh IL-1β) 
Peprotech EC, London, UK 100 μg/ml 
Recombinant human interleukin-8 
(72 a.a.) (rh IL-872) 
Peprotech EC, London, UK 100 μg/ml 
Recombinant human interleukin-8 
(77 a.a.) (rh IL-877) 
Peprotech EC, London, UK 100 μg/ml 
Lipopolysaccharide (LPS) from 
Escherichia Coli 0127:B8 
Sigma Aldrich Company Ltd., 
Gillingham, UK 
10 mg/ml 
N-Formyl-L-methionyl-L-leucyl-L-
phenylalanine (fMLP) 
Sigma Aldrich Company Ltd., 
Gillingham, UK 
10 μM 
 
Table 2-1: List of cytokines, chemokines and other inflammatory stimuli 
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2.3. Antibodies 
Antigen Clone Isotype Conjugate Company 
Stock 
conc. 
Dilution 
factor 
Human 
IL-6 
MQ2-
13A5 
Rat IgG1, 
κ 
 BioLegend, 
London, UK 
1 mg/ml  
Isotype 
control 
RTK2071 Rat IgG1, 
κ 
 BioLegend, 
London, UK 
0.5 mg/ml  
Mouse 
sIL-6R 
D7715A7 Rat IgG2b, 
κ  
 BioLegend, 
London, UK 
1 mg/ml  
Isotype 
control 
RTK4530 Rat IgG2b, 
κ 
 BioLegend, 
London, UK 
0.5 mg/ml  
Mouse 
sIL-6R 
2B10   NovImmune, 
Switzerland 
6 mg/ml  
Isotype 
control 
Y13   NovImmune, 
Switzerland 
4 mg/ml  
Human 
CD14 
M5E2 Mouse 
IgG2a, κ 
FITC BioLegend, 
London, UK 
 1/100 
Isotype 
control 
MOPC-
173 
Mouse 
IgG2a, κ 
FITC BioLegend, 
London, UK 
 1/100 
Human 
IL-877 
N11 Mouse 
IgG1, κ 
 Generous gift 
from Prof  N 
Voitenok, 
Moscow 
1.9 mg/ml 1/360 
Human 
IL-877 
H6 Mouse 
IgG1, κ 
 Generous gift 
from Prof  N 
Voitenok, 
Moscow 
  
Table 2-2: List of antibodies. FITC = Fluorescein Isothiocyanate 
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2.4. Other Reagents 
 
Molecule/ Reagent Company Typical 
Stock 
Solution 
Purified human neutrophil elastase 
(HNE) 
Athens Research & 
Technology, Athens, USA 
500 μg/ml 
(16.9 μM) 
Purified human neutrophil cathepsin G 
(CG) 
Athens Research & 
Technology, Athens, USA 
500 μg/ml 
(16.9 μM) 
Purified human neutrophil proteinase-3 
(Pr-3) 
Athens Research & 
Technology, Athens, USA 
1000 μg/ml 
(33.8 μM) 
Purified human plasma alpha-1 
antitrypsin (AAT) 
Talecris Plasma Resources, 
NC, USA 
50 mg/ml 
(1.0 mM) 
Purified human plasma antithrombin III 
(ATIII) 
Merck Chemicals Limited, 
Nottingham, UK 
1.0 mg/ml 
Phenylmethanesulfonyl fluoride (PMSF) Sigma Aldrich Company Ltd., 
Gillingham, UK 
200 mM 
1, 10 phenanthroline Sigma Aldrich Company Ltd., 
Gillingham, UK 
500 mM 
[3-(4,5-dimethyl-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium, inner salt; 
MTS] and an electron coupling reagent 
(phenazine ethosulfate; PES) 
Promega UK, Southampton, 
UK 
Ready to 
use solution 
Cytochalasin B Sigma Aldrich Company Ltd., 
Gillingham, UK 
5 mg/ml 
2-mercaptoethanol (2ME) Sigma Aldrich Company Ltd., 
Gillingham, UK 
Ready to 
use solution 
at 14.3M 
 
Table 2-3: List of other reagents used. 
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2.5. Enzyme Linked Immunosorbent Assay (ELISA) 
 
2.5.1. Human IL-6 ELISA  
Human IL-6 ELISA (DuoSet, R&D Systems, Abingdon, UK) was performed 
according to the manufacturer’s guidelines. Briefly, NUNC Maxisorp 96-well plates 
(Fisher Scientific, Loughborough, UK) were coated with 100 μl of 2 μg/ml capture 
antibody (mouse anti-human IL-6, stock 360 μg/ml) diluted in PBS and incubated 
overnight at room temperature. Wells were washed with 200 μl wash buffer (x 3) and 
blocked with 200 μl of assay diluent (Reagent Diluent, 1% BSA in PBS, R&D Systems, 
Abingdon, UK) for 1 hour at room temperature (RT). The wash step was repeated as 
before prior to adding 100 μl of standard, human BALF or baboon tracheal aspirate 
fluid (TAF), all in duplicate. Top standard of 600 pg/ml was prepared from recombinant 
human IL-6 (35 ng/ml) and a seven point standard curve using 2-fold serial dilution was 
prepared using assay diluent. BALF samples were initially diluted between 1/5 and 
1/10; if values were beyond the range of the curve, then higher dilutions or “neat” 
samples were used as appropriate. Baboon TAF samples were diluted between 1/10 
and 1/200 in the manufacturer’s recommended buffer. Control wells contained assay 
diluent. Following 2 hour incubation at RT, wells were washed as before, 100 μl of 200 
ng/ml of biotinylated detection antibody (goat anti-human IL-6; stock 36 μg/ml) was 
added and incubated at RT for 2 hours. Wash step was repeated and 100 μl 
Streptavidin conjugated horseradish-peroxidase (HRPO) enzyme (1 in 200 dilution from 
stock, R&D Systems, Abingdon, UK) was added for 20 minutes at RT in the dark. 
Following the wash step (x 5), 100 μl of tetramethylbenzidine (TMB, substrate solution, 
eBioscience, Hatfield, UK) was added. Once the standards had developed, 50 μl of 2 N 
sulphuric acid was added to stop the reaction. Optical density of each well was 
determined using a microplate reader (Dynex Corporation, Worthing, UK) at 450 nm 
with wavelength correction at 570 nm. Range of detection was between 9.38 – 600 
pg/ml. 
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2.5.2. Human sIL-6R ELISA  
Human sIL-6R ELISA (DuoSet, R&D Systems, Abingdon, UK) was performed 
according to the manufacturer’s guidelines. Briefly, NUNC Maxisorp 96-well plates 
were coated with 100 μl of 2 μg/ml capture antibody (mouse anti-human IL-6R, stock 
360 μg/ml) diluted in PBS and incubated overnight at room temperature. Wells were 
washed with 200 μl wash buffer (x 3) and blocked with 200 μl of assay diluent (Reagent 
Diluent, 1% BSA in PBS, R&D Systems) for 1 hour at RT. The wash step was repeated as 
before prior to adding 100 μl of standard, human BALF, human plasma or baboon TAF 
in duplicate. Top standard of 1000 pg/ml was prepared from recombinant human sIL-
6R (70 ng/ml) and a seven point standard curve using 2-fold serial dilution was 
prepared using assay diluent. BALF samples were initially diluted between 1/5 and 
1/10; if values were beyond the range of the curve, then higher dilutions were used as 
appropriate. Plasma samples were diluted 1/50 or as appropriate. Baboon TAF samples 
were diluted between 1/10 and 1/200 in the manufacturer’s recommended buffer. 
Control wells contained assay diluent. Following 2 hour incubation at RT, wells were 
washed as before, 100 μl of 100 ng/ml of biotinylated detection antibody (goat anti-
human IL-6R; stock 18 μg/ml) was added and incubated at RT for 2 hours. Wash step 
was repeated and 100 μl Streptavidin conjugated HRPO enzyme (1 in 200 dilution from 
stock, R&D Systems) was added for 20 minutes at RT in the dark. Following the wash 
step (x 5), 100 μl of TMB was added. Once the standards had developed, 50 μl of 2 N 
sulphuric acid was added to stop the reaction. Optical density of each well was 
determined using a microplate reader at 450 nm with wavelength correction at 570 
nm. Range of detection was between 15.6 – 1000 pg/ml. 
 
2.5.3. Human Differentially Spliced (DS) sIL-6R ELISA  
Human DS sIL-6R was measured as described previously (Horiuchi et al., 1998). 
Briefly, NUNC Maxisorp 96-well plates were coated with 100 μl of 3 ug/ml anti-human 
DS-sIL-6R monoclonal antibody (2F3, stock 3 mg/ml) in PBS and incubated overnight at 
4ºC. Wells were washed with 200 μl wash buffer (x 3) and blocked with 200 μl of assay 
diluent (5% BSA w/v in PBS) for 1 hour at RT. The wash step was repeated as before 
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prior to adding 100 μl of standard, BALF or plasma in duplicate. Top standard of 1000 
pg/ml was prepared from recombinant human DS sIL-6R (2 μg/ml) and a seven point 
standard curve using 2-fold serial dilution was prepared using assay diluent. All BALF & 
term cord-blood plasma samples were diluted 1/2 and adult plasma samples were 
diluted 1/5 in assay diluent. Control wells contained assay diluent. Following 2 hour 
incubation at RT, wells were washed as before, 100 μl of 100 ng/ml of biotinylated 
detection antibody (anti-human IL-6R, baf227; stock 100 μg/ml) was added and 
incubated at RT for 2 hours. Wash step was repeated and 100 μl Streptavidin 
conjugated HRPO enzyme (1/200 dilution from stock, R&D Systems) was added for 20 
minutes at RT in the dark. Following the wash step (x 5), 100 μl of TMB was added. 
Once the standards had developed, 50 μl of 2 N sulphuric acid was added to stop the 
reaction. Optical density of each well was determined using a microplate reader at 450 
nm with wavelength correction at 570 nm. Range of detection was between 15.6 – 
1000 pg/ml. 
 
2.5.4. Human sgp130 ELISA  
Human sgp130 ELISA (DuoSet, R&D Systems, Abingdon, UK) was performed 
according to the manufacturer’s guidelines. Briefly, NUNC Maxisorp 96-well plates 
were coated with 100 μl of 2 μg/ml capture antibody (mouse anti-human gp130, stock 
720 μg/ml) diluted in PBS and incubated overnight at room temperature. Wells were 
washed with 200 μl wash buffer (x 3) and blocked with 200 μl of assay diluent (Reagent 
Diluent, 1% BSA in PBS, R&D Systems) for 1 hour at RT. The wash step was repeated as 
before prior to adding 100 μl of standard, human BALF or baboon TAF in duplicate. Top 
standard of 10,000 pg/ml was prepared from recombinant human sgp130 (150 ng/ml) 
and a seven point standard curve using 2-fold serial dilution was prepared using assay 
diluent. BALF samples were initially diluted between 1/10 and 1/20; if values were 
beyond the range of the curve, then higher dilutions were used as appropriate. Baboon 
TAF samples were diluted between 1/10 and 1/200 in the manufacturer’s 
recommended buffer. Control wells contained assay diluent. Following 2 hour 
incubation at RT, wells were washed as before, 100 μl of 400 ng/ml of biotinylated 
detection antibody (goat anti-human gp130; stock 72 μg/ml) diluted in Reagent Diluent 
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with 2% heat inactivated normal goat serum was added and incubated at RT for 2 
hours. Wash step was repeated and 100 μl Streptavidin conjugated HRPO enzyme 
(1/200 dilution from stock, R&D Systems) was added for 20 minutes at RT in the dark. 
Following the wash step (x 5), 100 μl of TMB was added. Once the standards had 
developed, 50 μl of 2 N sulphuric acid was added to stop the reaction. Optical density 
of each well was determined using a microplate reader at 450 nm with wavelength 
correction at 570 nm. Range of detection was between 156 – 10000 pg/ml. 
 
2.5.5. Human IL-8 ELISA  
Total human IL-8 ELISA (BD Biosciences, Oxford, UK) was performed according 
to the manufacturer’s guidelines. Briefly, NUNC Maxisorp 96-well plates were coated 
with 100 μl/well capture antibody diluted 1/250 in coating buffer (0.1 M sodium 
carbonate, pH 9.5: 7.13 g sodium bicarbonate, 1.59 g sodium carbonate; q.s. to 1.0 L; 
pH to 9.5 with 10 N sodium hydroxide) and incubated overnight at 4ºC. Wells were 
washed with 200 μl wash buffer (x 3) and blocked with 200 μl of assay diluent (PBS 
FCS) for 1 hour at RT. The wash step was repeated as before prior to adding 100 μl of 
standard, human BALF, human cell-culture supernatant or baboon TAF in duplicate. 
Human BALF and supernatants were diluted between 1/100 and 1/200, or as 
appropriate. Baboon TAF samples were diluted between 1/10 and 1/200 in the 
manufacturer’s recommended buffer. Top standard of 200 pg/ml was prepared from 
lyophilized recombinant human IL-8 (95 ng/ml, Peprotech EC, London, UK) and a seven 
point standard curve using 2-fold serial dilution was prepared. PBS FCS was used as the 
control. Following a 2 hour incubation and wash step (x 5), 100 μl of the working 
detector (detection antibody and streptavidin-HRPO, each diluted 1/250 in PBS FCS) 
was added to each well. After a 1 hour incubation, the wells were washed (x 7) and 
100 μl of TMB was added. Once the standards had developed, 50 μl of 2 N sulphuric 
acid was added to stop the reaction. Optical density of each well was determined using 
a microplate reader at 450 nm with wavelength correction at 570 nm. Range of 
detection was between 3.125 – 200 pg/ml. 
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2.5.6. Human IL-877 ELISA  
Human IL-877 was detected as described previously (Nashkevich et al., 2002a) 
with modifications. NUNC Maxisorp 96-well plates were coated with 100 μl/well of 5 
μg/ml capture antibody N11 (stock 1.3 mg/ml) and incubated overnight at 4°C. Wells 
were washed with 200 μl wash buffer (x 3) for IL-877 ELISA (PBS + 0.05% Tween-20 + 
300mM NaCl) and blocked with 200 μl of assay diluent (IL-877 wash buffer + 0.5% 
protease-free BSA) for 1 hour at room temperature. The wash step was repeated as 
before prior to adding 100 μl of standard, BALF or cell-culture supernatant in duplicate. 
Top standard of 200 pg/ml was prepared from recombinant human IL-877 (10 μg/ml) 
and a seven point standard curve using 2-fold serial dilution was prepared. Assay 
diluent was used as the control. Following a 2 hour incubation and wash step (x 3), 100 
μl of the working detector (detection antibody from BD OptEIA human IL-8 ELISA kit 
and streptavidin-HRPO, each diluted 1/250 in assay diluent) was added to each well. 
After a 1 hour incubation, the wells were washed (x 5) and 100 μl of TMB was added. 
Once the standards had developed, 50 μl of 2 N sulphuric acid was added to stop the 
reaction. Optical density of each well was determined using a microplate reader at 450 
nm with wavelength correction at 570 nm. Range of detection was between 3.125 – 
200 pg/ml. 
 
2.5.7. Human monocyte chemotactic protein-1 (MCP-1) ELISA  
Human MCP-1 ELISA (Human CCL-2 ELISA Ready-SET-Go! eBioscience, ) was 
performed according to the manufacturer’s guidelines. Briefly, NUNC Maxisorp 96-well 
plates were coated with 100 μl/well capture antibody (purified anti-human CCL2; clone 
5D3-F7) diluted 1/250 in coating buffer (coating buffer powder reconstituted in 1.0 L 
deionised water) and incubated overnight at 4°C. Wells were washed with 250 μl wash 
buffer (x 5) and blocked with 200 μl of assay diluent (supplied as 5 x; diluted to 1 x in 
sterile water) for 1 hour at room temperature. The wash step was repeated as before 
prior to adding 100 μl of standard, human BALF, cell-culture supernatant or baboon 
TAF in duplicate. Human BALF and supernatants were diluted between 1/100 and 
1/200, or as appropriate. Baboon TAF samples were diluted between 1/10 and 1/200 
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in the manufacturer’s recommended buffer. Top standard of 1000 pg/ml was prepared 
from stock recombinant human MCP-1 solution at 1.0 μg/ml and a seven point 
standard curve using 2-fold serial dilution was prepared. Assay Diluent was used a s 
negative control. Following a 2-hour incubation at RT and a wash step, the detection 
antibody (biotin-conjugate anti-human CCL2; clone 2H5) was diluted 1/250 and 100 
μl/well was added and incubated for 1 hour. Wells were washes as before and 100 μl 
of enzyme (Avidin-HRPO) was added for 30 minute incubation at RT. Wash step (x 7) 
was followed by the addition of 100 μl/well of TMB.  Once the standards had 
developed, 50 μl of 2 N sulphuric acid was added to stop the reaction. Optical density 
of each well was determined using a microplate reader (Dynex Corporation) at 450 nm 
with wavelength correction at 570 nm. Range of detection was between 15.625 – 1000 
pg/ml. 
  
 
2.5.8. Human total matrix-metalloprotease-9 (MMP-9) ELISA  
Human MMP-9 ELISA (R&D Systems DuoSet) was performed according to the 
manufacturer’s guidelines. Briefly, NUNC Maxisorp 96-well plates were coated with 
100 μl of 1 μg/ml capture antibody (mouse anti-human MMP-9; stock 180 μg/ml) 
diluted in PBS and incubated overnight at RT. Wells were washed with 200 μl wash 
buffer (x 3) and blocked with 200 μl of assay diluent (Reagent Diluent, 1% BSA in PBS, 
R&D Systems) for 1 hour at RT. The wash step was repeated as before prior to adding 
100 μl of standard or supernatant in duplicate. Top standard of 2000 pg/ml was 
prepared from recombinant human MMP-9 (50 ng/ml) and a seven point standard 
curve using 2-fold serial dilution was prepared using assay diluent. Samples were 
diluted between 1/100 and 1/200. Control wells contained assay diluent. Following 2 
hour incubation at RT, wells were washed as before, 100 μl of 100 ng/ml biotinylated 
detection antibody (goat anti-human MMP-9; stock 36 μg/ml) diluted in Reagent 
Diluent with 2% heat inactivated normal goat serum was added and incubated at RT 
for 2 hours. Wash step was repeated and 100 μl Streptavidin conjugated HRPO enzyme 
(1/200 dilution from stock, R&D Systems) was added for 20 minutes at RT in the dark. 
Following the wash step (x 5), 100 μl of TMB was added. Once the standards had 
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developed, 50 μl of 2 N sulphuric acid was added to stop the reaction. Optical density 
of each well was determined using a microplate reader (Dynex Corporation) at 450 nm 
with wavelength correction at 570 nm. Range of detection was between 31.25 – 2000 
pg/ml. 
2.5.9. Proteinase-3 ELISA 
[Proteinase-3 ELISA was designed by Dr Brad Spiller in the department, using 
commercial reagents. BALF samples from preterm infants were performed and 
analysed by Dr Salima Abdulla] 
 
Mouse monoclonal anti-proteinase 3 antibody (Hycult Biotechnology, 
Netherlands) was immobilised onto 96-well plates prior to blocking with 5% BSA in PBS 
containing 0.5% Tween-20 (blocking buffer).  Samples and standards were diluted in 
blocking buffer and incubated with the coated plates for 1 h.  Purified proteinase-3 
(Athens Research and Technology, GA, USA) was diluted from 0 - 250ng/ml for the 
standard curve.  Unbound protein was washed away with PBS prior to detection with 
rabbit polyclonal anti-proteinase-3 antiserum (Eurogentec, Belgium) and peroxidase-
conjugated donkey anti-rabbit immunoglobulin (Jackson Immuno Research 
Laboratories, Newmarket, UK).  Plates were developed with OPD-EASY (Acros organics, 
Belgium), and the reaction stopped with 2N H2SO4 before reading at 490 nm.  
 
2.6. Primate (baboon) model of CLD 
[All animal procedures were  by Drs JJ Coalson and V Winter in San Antonio, Texas. 
ELISAs were performed by Dr E McGreal on site at San Antonio, Texas. Differential 
counts from digital images of cytospins and data analysis were undertaken in Cardiff by 
me.]   
 
2.6.1. Animal Management 
All animal husbandry, handling and procedures were as previously described 
(Coalson et al., 1999a). These were performed at the Southwest Foundation for 
Biomedical Research (San Antonio, Texas, USA), approved by the Institutional Animal 
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Care and Use Committee and conformed to American Association for Accreditation of 
Laboratory Animal Care Guidelines. Briefly, preterm baboons (Papio cynocephalus) 
were delivered by elective caesarean section under general anaesthesia at 125 ± 2 or 
140 ± 2 days (term: 185 days) from pregnant dams. Antenatal steroids were given 48 
and 24 h before planned delivery. All newborns were intubated at birth, received a 
single bolus (100 mg/kg) of exogenous surfactant (Survanta; donated by Ross 
Laboratories, Columbus, Ohio, USA) prior to ventilation with a pressure-limited, time-
cycled infant ventilator (InfantStar; Infrasonics, San Diego, Calif., USA) for 14 days. 
Ventilation was initiated at a rate of 40 breaths/min with peak inspiratory pressure 
(PIP) sufficient to move the chest, positive end-expiratory pressure (PEEP) at 5 cm H2O 
and fraction of inspired oxygen (FiO2) at 0.4. A volume-sparing ventilatory strategy was 
followed to maintain tidal volumes at 4–6 ml/kg. Briefly, the ventilation rate was 
adjusted as required to regulate PaCO2 between 45 and 55 mm Hg to a maximum rate 
of 60. If a PIP > 40 cm H2O was needed to achieve target tidal volumes and PaCO2, the 
acceptable limit for PaCO2 was increased to 65 mm Hg. Target goals for PaO2 were 55–
70 mm Hg. Oxygenation was primarily manipulated through changes in PEEP and its 
effect on mean airway pressure (Paw) and FiO2. All animals survived to necropsy 
following administration of sodium pentobarbital at day 14 (336 h). None of the study 
animals exhibited any evidence of pneumonia histopathologically or by chest 
radiograph, nor was sepsis evident clinically or microscopically. 
 
2.6.2. Tracheal Aspirate and Lavage Fluids and Cell Counts 
Tracheal aspirate fluid (TAF) was obtained at the indicated time-points (day 1 = 
24 h, day 3, day 6-7, day 10-11 and day 14) from 10 animals undergoing ventilation 
PRN by disconnecting the ventilator and instilling 1 ml sterile saline via the endo-
tracheal tube. The ventilator was reconnected and 4–5 breaths were allowed before 
disconnecting once more and aspirating the fluid. This was repeated once and finally 
the catheter lumen was cleared with 1 ml of sterile saline suctioned into the Luken’s 
trap. In the case of five 125-day and five 140-day gestational control animals, necropsy 
lavage was performed by instilling the lower left lobe with sterile saline via the 
bronchus until the lobe was completely filled; saline was withdrawn and the procedure 
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repeated four more times. Total cell counts were performed on TAF and necropsy 
lavage specimens using a hemocytometer. TAF and lavage specimens were centrifuged 
at 1,500 rpm for 10 min in a refrigerated centrifuge, supernatants were aliquoted and 
stored at –70 ° C.  
 
2.6.3. Differential Cell Counts of Baboon Cytospins 
Digital images of four different fields of Wright-Giemsa stained cytospin slides 
from baboon TAFs were taken. Differential counts were obtained by counting at least 
300 events from each slide (field) manually (total 1200 events from 4 slides) and total 
cell numbers (polymorphonuclear leucocytes, mononuclear cells, epithelial cells & 
others) and percentages calculated from the differential count. 
 
2.6.4. ELISA 
As described before in section 2.5. IL-6, IL-8 and MCP-1 have previously been 
measured in this species using human antibodies (Coalson et al., 1999a, Viscardi et al., 
2006b). Commercial human ELISA kit were used, as described above.  
 
 
2.7. CLD in Preterm Ventilated Infants 
Ethical approval for project was obtained by Prof S Kotecha. Consent and collection of 
BALF was undertaken by Drs PL Davies and Dr N. Maxwell. IL-6, sIL-6R and sgp130 
ELISAs were performed by Dr. Mallinath Chakraborty, with some data also contributed 
by Dr Eamon McGreal 
  
2.7.1. Patient Groups  
Ventilated preterm infants born before 32 weeks gestation were recruited, 
after obtaining written parental consent, from the Regional Neonatal Unit at University 
Hospital of Wales in Cardiff, UK. Ethical approval was obtained from the local Research 
Ethics Committee. Infants with significant hypoxia, known congenital abnormalities, 
abnormal morphology or who were extremely unwell (not expected to survive) were 
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excluded from the study. All infants in the study were categorised as: CLD group who 
required respiratory support or supplemental oxygen at 36 weeks corrected 
gestational age and RDS group who were free of respiratory support at 36 weeks 
corrected gestational age.  
 
2.7.2. BALF Collection and Processing  
Non-bronchoscopic broncho-alveolar lavage (BAL henceforth) was performed 
on ventilated infants (daily in the first week and twice-weekly thereafter) as previously 
described (de Blic et al., 2000). Briefly, infants were disconnected from the ventilator 
and, with their head turned to the left, an appropriate size suction catheter was passed 
down the endo-tracheal tube until resistance was felt. 1 ml/kg of warmed 0.9% saline 
was instilled down the tube and was immediately suctioned out by connecting the 
upper end of the suction tube to a water trap using wall suction pressure of 8-12 kPa. 
This was repeated once more and the total volume of fluid instilled and recovered was 
recorded. The recovered fluid was pooled and placed on ice before being transported 
to the lab. In the lab, a haemocytometer count of total cells was done from the pooled 
fluid before it was centrifuged at 4°C at 1000 g for 10 minutes. The supernatant was 
removed, aliquoted out to smaller volumes (25µl) and frozen at -80ºC until further use. 
The pellet was re-suspended in PBS with 5 mM of EDTA to a density of 0.5 X 106 
cells/ml. 50 μl of suspension was used to prepare cytospins by spinning at 300 rpm for 
3 minutes followed by air-drying and fixing in methanol. Diff-Quik (Medion Diagnostics 
AG, Duedingen, Switzerland) stained cytospins were used to enumerate differential 
cell counts by counting at least 300 cells per sample under direct vision with a high 
powered light microscope.  
 
2.8. B9 cell assay 
 
2.8.1. Introduction 
The B9 cells are an IL-6 dependent mouse B cell hybridoma derived from spleen 
tissue and are lymphoblastoid in morphology. They were developed as a sub-clone of 
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the B13.29 cell-line (Lansdorp et al., 1986), which were chosen for their IL-6 dependent 
proliferation (Aarden et al., 1987b). Since their isolation, these cells have been used as 
an IL-6 bioassay due to their sensitivity to human IL-6 (Nordan et al., 2001b). 
 
2.8.2. B9 cells and initial thawing  
Cells were bought from European Collection of Cell Cultures (ECACC, Health 
Protection Agency, Porton Down, Salisbury, UK). Media used was RPMI 1640 
containing 2 mM L-glutamine (Lonza, Slough, UK) with 5% HI-FCS and 50 μM of 2-ME. 
For cell cultures, 25 pg/ml of rhIL-6 was freshly added to media. All incubations were in 
a humidified incubator at 37°C and 5% CO2.  
A frozen vial was thawed, cells re-suspended in 5 ml of fresh warm media with 
IL-6 and incubated. Condition of cells was monitored by observation under 
microscope. After initial thawing, cells needed 2-3 media changes before they started 
to grow. 
 
2.8.3. Subcultures 
Cells in suspension were poured into a universal container and centrifuged at 
150 g for 5 minutes. The pellet was re-suspended in 1 ml of fresh media (no IL-6) and 
counted for viable cells. 10 μl of the cell suspension was withdrawn and mixed with 10 
μl of 0.4% Trypan blue (Sigma). Cells were counted in a haemocytometer by light 
microscopy at 10X magnification. For subcultures, 3 x 104 viable cells were re-
suspended per ml of fresh media with IL-6 (4.5 x 105 cells/15 ml for a 75 cm2 flask). 
Flasks were incubated for 72-96 hours before cells were harvested for experiments or 
subculture. 
 
2.8.4. Assays  
All assays were performed between passage numbers 10-25 (Nordan et al., 2001a). For 
assays, 5000 cells were seeded per well in 96-well plates with or without rhIL-6 (as 
appropriate) and with other cytokines or BALF and incubated under the same 
conditions as above in a total volume of 100l. All BALF samples were appropriately 
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diluted to an estimated IL-6 concentration of 2 pg/ml (based on the immune values) to 
keep the bioactivity within the range of the assay. A colorimetric assay was used at the 
end of the incubation to estimate the number of viable cells, using a tetrazolium 
compound [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4sulfophenyl)-
2H-tetrazolium, inner salt; MTS] and an electron coupling reagent (phenazine 
methosulfate; PMS). MTS is reduced by dehydrogenases in metabolically active (viable) 
cells to a yellow water-soluble dye, formazan, which is freely soluble in the culture 
medium (Slater et al., 1963). The amount of formazan in solution is directly 
proportional to the number of viable cells, and can be measured by the absorbance at 
490 nm. At 68 hours, 20 l of a solution of MTS was added to each well and 
absorbance was read at 490 nm in a spectrophotometer. Functional activity was 
assessed by comparing with an IL-6 standard curve. For controls, a dose of 8 pg/ml of 
IL-6 was chosen to give a more visible effect in relation to the standard curve. 
For specific trans-signalling assays, cell-surface IL-6R was blocked by using a 
monoclonal anti-mouse IL-6R antibody 2B10 (Greenhill et al., 2011, Lissilaa et al., 2010) 
which was incubated with cells for 30 minutes at 37C and 5% CO2 before stimulation 
with cytokines or BALF. 2B10 antibody was a generous gift from NovImmune SA, 
Geneva, Switzerland. For assays using combinations of cytokines or cytokines with 
specific antibodies, all proteins (or BALF) were premixed at room temperature for at 
least 30 minutes before stimulating cells. 
 
 
2.9. Rheumatoid Arthritis Synovial Fibroblast (RASF) culture and stimulation 
 
Sterile Human Synovial Fibroblasts were isolated from synovial tissue obtained 
after synovectomy from Rheumatoid Arthritis patients at the time of total knee joint 
replacement (Dayer et al., 1976). RASF cells do not express IL-6R on the cell-membrane 
but can respond to IL-6 trans-signalling (via cell-surface gp130) to selectively express 
MCP-1 (Nowell et al., 2003). Thus, a culture of these cells was used as a bioassay to 
test the effects of IL-6 trans-signalling in vitro.  
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RASF, growing in Dulbecco’s Minimum Enrichment Media (DMEM) with 10% 
(v/v) HI-FCS, were obtained from Dr Mari Nowell (Department of Biochemistry, Cardiff 
University). Cells were incubated in a humidified incubator at 37°C and 5% CO2 and 
allowed to grow to confluency. For subcultures, cells were harvested with Trypsin 
EDTA for 10 minutes in the incubator and then neutralised with serum-supplemented 
media. Cell-suspension was centrifuged at 500 g for 6 minutes and the pellet was re-
suspended in 2.0 ml of fresh media. 1 ml was re-suspended in 15 ml of fresh media and 
incubated. 
1 ml of the suspension was re-suspended in 10 ml of fresh media and 400 μl 
was pipetted into each well of a 24-well plate. Cells were allowed to adhere and grow 
to 70-80% confluency. Then media was aspirated and cells were washed x 2 with 500 
μl of 0.9% NaCl per well. 400 μl of fresh DMEM (no FCS) was added to the wells and 
incubated overnight. Cells were washed again as before and then stimulated with 
media only, IL-6 (50 ng/ml), HIL-6 (50 ng/ml) or IL-6 (50 ng/ml) in the presence of sIL-
6R (50, 100 and 500 ng/ml), both with or without 2B10 antibody (2.5 μg/ml) for 18 
hours. All combination of cytokines and antibodies were pre-incubated at room 
temperature for 30 minutes before adding to cells. Supernatants were collected at the 
end of the incubation period and stored at -80°C until further analysis. Supernatants 
were assayed for MCP-1 as described before.  
 
2.10. Cord-blood collection from term infants 
[Ethical approval for project was obtained by Prof S Kotecha.] 
  
2.10.1. Subjects and Consenting 
For in vitro studies on newborn PMNs and monocytes, blood was collected from 
the placental cord after delivery of term infants by elective caesarean section. Mothers 
with any medical complications were excluded from the study. The two most common 
indications for elective section were previous section and breech presentation. For the 
current study, it was considered unethical to collect venous blood from healthy term 
infants. Also, infants delivered by normal labour were considered inappropriate as 
there is evidence of cell activation during the process of labour (Shen et al., 2009). 
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There is increasing evidence that preterm delivery is associated with chorioamnionitis 
and foetal inflammation. Thus, cells from preterm infants were also considered to be 
inappropriate as there is significant possibility of activation.  
Cord blood was collected from term infants delivered by elective caesarean 
section after obtaining written parental consent. Indications for elective caesarean 
section included previous caesarean section or breech presentation. Mothers with any 
medical conditions potentially complicating pregnancy were excluded from the study. 
Prior ethical approval was obtained from the local Research Ethics Committee before 
sample collection.  
 
2.10.2. Cord blood collection and initial processing 
After the baby was delivered and cord clamped & cut, the placenta was slowly 
delivered into a bag. Blood was collected from the vessels in the cord attached to the 
placenta. 17 ml of blood was collected into a syringe containing 3 ml of 3.8% sodium 
citrate and immediately processed. Anti-coagulated blood was centrifuged at 450 g for 
20 minutes to separate cells from the plasma. The plasma was centrifuged at 1300 g 
for 20 minutes to obtain platelet poor plasma (PPP), part of which was aliquoted and 
frozen at -80C for future use. The cell layer was further processed as below.  
 
 
2.11. Peripheral venous blood collection from healthy adult volunteers 
[Ethical approval for project was obtained by Prof S Kotecha] 
 
Control blood was collected from healthy adult volunteers after informed 
consent. Prior ethical approval was obtained from the local Research Ethics Committee 
before sample collection. 18 ml of blood was collected into a syringe containing 2 ml of 
3.8% sodium citrate and immediately processed similar to cord blood above. 
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2.12. Purification of polymorphonuclear leucocytes and mononuclear cells from 
cord and adult blood 
 
2.12.1. Cell purification by discontinuous Percoll gradient 
Purification of cells has been described previously (Haslett et al., 1985). The cell 
layer (from 2.10.2) after separation from plasma was further processed. 3 ml of 6% 
Dextran solution was added per 20 ml of blood and was reconstituted to the original 
volume of blood (20 ml) with warmed 0.9% NaCl. Cells were mixed well with dextran 
by manual rolling and incubated in a water bath at 37C for 30-45 minutes. Two layers 
of cells were visible after this step: an upper leukocyte-rich layer and a lower RBC layer 
with a clear border of separation. The leukocyte layer was carefully aspirated and 
centrifuged at 200 g for 6 minutes; the pellet at the end of this step was re-suspended 
in 2 ml of autologous PPP (as before). 
Two Percoll gradients were prepared as below: 
51% layer – 1.02 ml 90% Percoll + 0.98 ml PPP  
42% layer – 0.84 ml 90% Percoll + 1.16 ml PPP 
The 51% layer was added to the bottom of a 15ml conical tube and carefully overlaid 
with the 42% layer followed by the leukocyte layer, so as to avoid mixing. The 15 ml 
tube with the three separate layers was centrifuged at 350 g for 13 minutes without 
braking. At the end of this step, three layers, two bands and a pellet were visible, as 
detailed in figure 2.1 below. 
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Figure 2-1: Representative layer and bands after purification of leukocytes through a 
discontinuous Percoll gradient. Arrows point to layers from top to bottom as described 
above: blue = top layer of plasma, yellow = band of mononuclear cells (MNC), black = 
42% Percoll layer, green = band of polymorphonuclear leukocytes (PMN), pink = 51% 
Percoll layer, red = RBC pellet at the bottom. 
  
The MNC and PMN bands were carefully and separately aspirated with a 1 ml 
pipette and re-suspended in 10 ml of Hank’s Balanced Salt Solution (HBSS) without 
calcium (Ca), magnesium (Mg) or phenol red. 
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2.12.2. Processing of PMNs 
PMNs were washed twice in 10ml HBSS without Ca and Mg using centrifugation 
at 200 g for 5 minutes.  Cells were counted in a haemocytometer and finally re-
suspended in RPMI 1640 (for cell stimulation experiments) or HBSS with Ca and Mg 
(for degranulation experiments) to a final concentration of 5 x 106 cells per ml. 
 
2.12.3. Processing of MNCs  
MNCs were washed twice in 10ml HBSS without Ca and Mg using centrifugation 
at 200 g for 5 minutes.   Cells were counted in a haemocytometer and finally re-
suspended in RPMI 1640 (for cell stimulation experiments) to a final concentration of 
2.5 x 106 cells per ml. 
 
2.12.4. Preparation of PMN cytospins 
50 μl of cell suspension at a concentration of 5 x 106 cells/ml were pipetted into 
a cytofuge funnel and cytospins prepared using a ‘Cytospin 3’ (Shandon) by 
centrifuging at 300 rpm for 3 minutes onto polysine slides (Thermo Scientific). Slides 
were air-dried and fixed with 100% methanol before staining with Diff-Quick for a 
differential count.    
       
2.13. Stimulation of purified PMNs and MNCs 
PMNs and MNCs were re-suspended in RPMI 1640 with 10% heat inactivated 
(HI) foetal calf serum (FCS, Invitrogen) at a concentration of 5 X 106 cells/ml. 200 μl of 
cell suspension (1 x 106 cells) were pipetted per well into a 24-well plate and 
stimulated overnight with media or LPS (diluted in media) at a concentration of 10 
ng/ml. Supernatants were collected after 18 hours of incubation and frozen at    -80°C 
until further analysis.  
Total IL-8 and IL-877 were measured in supernatants by specific ELISA as 
described before. 
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2.14. Processing of IL-877 
2.14.1. Conversion of IL-877 by BALF  
Equal volumes of recombinant human (rh) IL-877 (10 ng/ml) was incubated 
overnight with TBS-BSA, BALF or BALF with AAT (10 μM), PMSF (10 mM), 1-10 
phenanthroline (10 mM) or ATIII (150 μg/ml). Table 2.4 provides details of all 
experimental conditions. Conditions 1, 2 and 3 were added together in equal volumes 
to create the reaction. BALF was pre-incubated with the protease inhibitors for 30 
minutes at room temperature before adding IL-877. 
 
Condition 1 Condition 2 Condition 3 
Sample time-point 
(hours) 
TBS+BSA TBS+BSA TBS+BSA 0, 18 
TBS+BSA TBS+BSA IL-877 (10 ng/ml) 0, 18 
TBS+BSA AAT (10 μM) IL-877 (10 ng/ml) 18 
TBS+BSA PMSF (10 mM) IL-877 (10 ng/ml) 18 
TBS+BSA 1-10 phenanthroline (10 
mM) 
IL-877 (10 ng/ml) 18 
TBS+BSA ATIII (150 μg/ml) IL-877 (10 ng/ml) 18 
TBS+BSA Ethanol  IL-877 (10 ng/ml) 18 
TBS+BSA Serum (1 in 3) IL-877 (10 ng/ml) 0, 18 
BALF TBS+BSA IL-877 (10 ng/ml) 0, 18 
BALF AAT (10 μM) IL-877 (10 ng/ml) 18 
BALF PMSF (10 mM) IL-877 (10 ng/ml) 18 
BALF 1-10 phenanthroline (10 
mM) 
IL-877 (10 ng/ml) 18 
BALF ATIII (150 μg/ml) IL-877 (10 ng/ml) 18 
Table 2-4: Details of all experimental conditions in conversion of IL-877 by BALF. 
Concentrations (in parenthesis) are all final. Samples were collected at 0 hour & 18 
hours and frozen at -80C until further analysis.  
 
2.14.2. Conversion of IL-877 by purified neutrophil serine proteases  
Purified human neutrophil elastase (HNE), cathepsin-G (CG) & proteinase-3 (Pr-
3) were incubated with rhIL-877 at 37C in TBS BSA buffer. For time-course 
experiments, 300 nM of IL-877 was incubated with buffer or 3 μM of each of the three 
proteases (enzyme:substrate = 10:1). Samples (20 μl) were collected at 0 hour, 1 hour, 
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2 hours, 4 hours, 6 hours, 12 hours and 24 hours and the reaction was stopped by 
adding 280 μl of AAT at 2.14 μM concentration (final concentration of IL-8 = 20 nM, 
protease = 0.2 μM and AAT 2 μM) and then frozen at -80C until further analysis.  
For dose-response experiments, 300 nM of IL-877 was incubated with buffer or 
proteases at a concentration of 3 μM, (enzyme:substrate = 10:1), 1.5 μM, 
(enzyme:substrate = 5:1), 300 nM (enzyme:substrate = 1:1), 60 nM (enzyme:substrate 
= 1:5) and 30 nM (enzyme:substrate = 1:10). Samples (10 μl) were collected at 0 hour 
and 18 hours and the reaction was stopped by adding 10 μl of AAT at 30 μM. Samples 
were frozen at -80C until further analysis.   
 
2.14.3. Neutrophil Degranulation Assay  
PMNs were purified from healthy adult human volunteers as described above. 
Cells were re-suspended in HBSS with C and Mg at a concentration of 5 x 106 cells/ml 
and 200 μl of this suspension (containing 1 x 106 cells) was pipetted into individual test 
tubes. Cells were then exposed to 5 μg/ml of cytochalasin B for 15 minutes at 37°C in a 
water-bath before being stimulated by fMLP (2 μM), rhIL-872 or rhIL-877 controls (100 & 
10 nM each), or samples collected from conversion experiments with purified 
proteases (final estimated IL-8 concentration in samples 10 nM).  After incubation for 
30 mins in a water-bath at 37°C, tubes were centrifuged at 200 g for 2 minutes and 
supernatants stored at -80C until further analysis. Total MMP-9 was measured in 
samples by specific ELISA as described above. 
                                                                    
 
2.15. Airway Epithelial Cell Culture and Stimulation  
All airway epithelial cell cultures were undertaken by Dr Wendy Powell. I have used 
supernatants stored by her at -80°C. 
 
2.15.1. Culture of transformed epithelial cells 
Transformed epithelial cells (table 2.5) were cultured in 75cm2 flasks containing 
media supplemented with L-glutamine and 5% HI-FCS. Cells were grown to 80% 
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confluency in a humidified incubator at 37ºC and 5% CO2. The cells were detached 
with 0.25% (w/v) trypsin-Ethylenediaminetetraacetic (EDTA) solution. The cells were 
subcultured at splitting ratios of 1:3 to 1:6 depending on individual experiments. The 
medium was changed every other day.  
Epithelial cells were seeded at the density appropriate to individual 
experiments, into 25cm2 flasks, 6, 24 or 96 well plates. Cells were left to adhere prior 
to washing in saline and serum starving. Prior to cytokine treatments, cells were 
washed again in saline and fresh serum-free media added. Transformed epithelial cells 
were starved in DMEM media with no HI-FCS or additives. 
 
Epithelial cells Medium required Supplier 
A549 DMEM  Hyclone 
BEAS2B F12-K  Hyclone 
 
Table 2-5: List of transformed airway epithelial cells with culture conditions 
 
2.15.2.  Small airway epithelial cells (SAEC) 
SAEC (Lonza CC-2547) were cultured in T-25cm2 flasks in SAEC basal media 
containing growth supplements (Clonetics SAGM BulletKit CC-3118). The vials 
contained 5 x 106 cells/ml. Cells were seeded at an appropriate density specific to 
individual experiments. The recommended seeding density is 2,500 cells/cm2. An 
appropriate volume of media at 1ml/5cm2 was added to the flasks and allowed to 
equilibrate at 37ºC, 5% CO2 humidified incubator for 30 minutes. The cryo vial was 
wiped with ethanol. The cap was loosened to relieve pressure and was retightened, 
before rapidly thawing the cryo vial in a 37ºC water bath. The vial was removed once 
the cells had thawed. The cells were resuspended and added directly to the flasks 
containing the warmed up media. The flask was gently rocked to ensure an even 
distribution of cells. The flask containing the cells was returned to the 37ºC, 5% CO2 
incubator. 
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 The cells were subcultured when they had reached 60-80% confluency. For a 
25cm2 flask, 2ml of Trypsin/EDTA , 7-10ml of HEPES buffered saline solution (HEPES-
BSS) 4ml Trypsin Neutralising Solution (TNS) and growth media were brought to room 
temperature. New culture flasks were prepared with 4ml growth media and placed in 
the incubator for 30 minutes. The media in each flask of cells was aspirated and 
discarded. The cells were rinsed with 5ml of room temperature HEPES-BSS. After 
aspirating the HEPES-BSS, the cells were covered in Trypsin/EDTA solution. The cell 
layer was examined microscopically. Trypsinization takes 2-6 minutes and was allowed 
to continue until 90% of the cells were of a rounded appearance. The flask was given a 
firm tap to remove the remainder of the cells from the flask surface. If the cells did not 
detach, the flask was returned to the incubator for 30 seconds before firmly tapping 
the flask again. Once the cells had released, the Trypsin was neutralised with 4ml of 
room temperature TNS. The detached cells were transferred to a sterile 15 ml tube. 
The flask was rinsed with 2ml HEPES-BSS to collect residual cells and added to the 15ml 
tube. The cells were centrifuged at 220 x g for 5 minutes to obtain a pellet. The 
supernatant was removed, leaving 100-200μl around the pellet. The tube was flicked 
to resuspend the cells. The cells were diluted in 2-3ml growth medium and counted. 
The cells were re-suspended and the appropriate density of cells were added to the 
new flasks containing the warmed up media. To each flask, 1ml of growth media was 
added for every 5cm2 surface area of the flask. The new flasks were returned to the 
incubator. 
The growth media was changed the day after seeding and then every other day. 
More media was added as the cells became more confluent. At 25% confluency, the 
cells were given 1ml/5cm2. When confluency reached 25-45%, 1.5ml per 5cm2 was 
added. When the cells were more than 45% confluent, the cells received 2ml/5cm2 of 
growth media. Fresh media was warmed in a sterile container in the incubator. The 
medium was removed from the cells and replaced with the warmed, fresh medium. 
The flask was returned to the incubator. 
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2.15.3. Airway Epithelial cell stimulations 
Epithelial cells were seeded into 6-well plates at a density of 3 x 105 cells/ml and 
allowed to adhere for more than 12 hours prior to washing with saline and further 
culture in serum-free media (A549 and BEAS-2B) for six hours (SAECs were grown in 
defined serum-free medium). Cells were washed again in saline prior to stimulation 
with IL-1β (5 ng/ml for A549 and BEAS-2B cells and 1 ng/ml for SAEC)   for 18 hours at 
37ºC and 5% CO2. Supernatants were collected after incubation were and immediately 
frozen at -80C until further analysis. Total IL-8 and IL-877 were measured in 
supernatants by ELISA as described before. 
 
 
2.16. Thrombin functional assay 
Thrombin functional assay was performed by Mr John Hogwood and supervised by Dr 
Elaine Gray from the National Institute of Biological Standards and Controls, as per 
established methods using commercial reagents. 
 
Thrombin activity was measured by a single point estimation against a 
calibration curve using the 2nd International Standard for Thrombin (01/580, NIBSC, 
South Mimms, UK) in a microtitre plate, with colour developed from a thrombin 
substrate, S2238 (Instrumentation Laboratories, Warrington, UK). To exclude the 
activity of any additional material present in the samples that could cleave the 
substrate, a highly specific inhibitor hirudin (Refludan, Pharmion, UK) to thrombin was 
used to provide a background level of activity. Thrombin levels were calculated with 
this background activity excluded.  
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2.17. Statistical analysis 
 
All statistical analysis was performed using GraphPad Prism v 5.03 (GraphPad 
Software Incorporated, La Jolla, USA).  
 
2.17.1. Primate (baboon) model of CLD 
Data are reported as medians with interquartile ranges (IQR). Comparisons 
between individual days were made using a one-way ANOVA for repeated measures 
(Friedman’s test) with Dunn’s multiple comparison post-test (comparing all pairs of 
columns). Comparisons between groups were made using one-way ANOVA for non-
parametric data (Kruskal-Wallis test) with Dunn’s multiple comparison post-test. 
Correlations were assessed using Spearman’s rank correlation test for non-parametric 
data. Significance was set at p < 0.05. 
 
2.17.2. CLD in ventilated preterm infants 
Data is reported as medians of peak-values from each infant in the first week of 
life. I chose to analyse peak-values because of incomplete serial data. Numerical data 
was compared using Mann-Whitney U test and categorical data by using Fisher’s exact 
test. Correlation was tested by calculating Spearman correlation coefficient. 
Significance was set at p<0.05. 
 
2.17.3. B9 cell assay for IL-6 
Data from BALF experiments are expressed as a fold change in proliferation of 
cells compared to rhIL-6 at 2 pg/ml (as all BALF samples were diluted to an estimated 
concentration of 2 pg/ml to maintain cell proliferation within the range of the assay). 
Data is reported as mean with standard error (SEM). Data between the groups was 
compared by using two-tailed Student’s unpaired t-test. Correlation was tested by 
calculating Spearman correlation coefficient. Significance was set at p<0.05. 
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2.17.4. Processing of IL-877 
Observational data from clinical samples are reported as medians; data from all 
other experiments are reported as means with standard errors (SEM). Data from time-
course experiments with IL-877 and purified proteases were normalised to starting 
values and expressed as fold change from 0 hour. Data from dose-response 
experiments are expressed as percentage of IL-877 remaining after incubation. 
Comparison of data between two groups was done by Mann-Whitney U test 
(observational data from clinical groups) or two-tailed unpaired Student’s t-test (all 
other experimental data). Data between multiple groups was compared by one-way 
ANOVA with post-hoc multiple-comparison tests as appropriate (details mentioned in 
figure legends). Data from time-course and dose-response experiments were 
compared by two-way ANOVA with Bonferroni post test. Categorical data was 
compared by using Fisher’s exact test. Correlations were assessed by using Spearman’s 
rank correlation test. Significance was set at p < 0.05. 
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3. Expression of IL-6, sIL-6R and sgp130 in the 
preterm lung 
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3.1. Overview 
 
Interleukin-6 (IL-6) is a key pro-inflammatory cytokine which has been detected 
at increased concentration in the preterm lung in infants who develop CLD (Kotecha et 
al., 1996b). However, in several animal models, IL-6 has been found to have an anti-
inflammatory and protective effect. This could be explained by the effects of IL-6 trans-
signalling which can have a profound influence on the resolution of the neutrophilic 
phase of acute inflammation (Hurst et al., 2001). Functional activity of IL-6 trans-
signalling is modulated by the soluble form of its two receptor subunits, sIL-6R and 
sgp130. Although expression of IL-6 is well described in preterm infants, little is known 
about expression of sIL-6R or sgp130.  
The primate model of CLD in preterm baboons (Coalson et al., 1999a) has been 
an invaluable tool to further our understanding of the disease. These animals, who 
receive similar clinical care as human preterm infants, have been studied in several 
trials, both observational and intervention. However, expression of the members of 
the IL-6 trans-signalling family the preterm baboon lung has not been looked at. As a 
first step towards my hypothesis, I collected tracheal aspirate fluid from preterm 
baboons and looked at the expression of IL-6, sIL-6R &sgp130, their interrelationships 
and their association with cellular influx into the lungs.  
 
 
3.2. Aims of the Project (Expression in the Preterm Baboon Lung) 
 
 To determine the expression of the IL-6, sIL-6R, sgp130, IL-8 and MCP-1 in 
broncho-alveolar lavage fluid (BALF) from ventilated preterm baboons. To 
determine the concurrent pattern of influx of inflammatory cells in BALF from 
preterm ventilated baboons.  
 To analyse possible correlations between expression of the IL-6 trans-signalling 
molecules, the related chemokines and influx of inflammatory cells into the 
lungs.  
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3.3. Effect of Ventilation on Lung Inflammation in Preterm Baboons 
 
This model is designed to replicate ventilation conditions currently practiced on 
human preterm neonates (“gentle ventilation”). Total cells counts were significantly 
increased in animals that were born at 125 days and ventilated in this manner (as 
described before) for 14 days (125d + 14d pro re nata [PRN]) compared to gestational 
controls (GC) born at 125 days (125d GC vs 125d + 14d PRN p < 0.01) or at 140 days 
(140d GC vs 125d + 14d PRN p < 0.05, figure 3.1). This suggests that even gentle 
ventilation, after receiving prenatal steroids and postnatal surfactant replacement, 
results in significant pulmonary inflammation in the lungs of premature baboons.   
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Figure 3-1: Pulmonary inflammation due to gentle ventilation. Total cell counts in 
necropsy lavage of animals born at 125 days gestation (125d GC; n=5), 140 days 
gestation (140d GC; n=5) and animals born at 125 days gestation and ventilated for 14 
days before being euthanised (125d + 14d PRN; n=10). Groups are represented on the 
x-axis while cell counts in millions/ml is represented on the y-axis. Each datapoint 
represents an individual animal and solid bars at each timepoint represent medians. (** 
= p < 0.01, * = p < 0.05). 
3.4. Expression of IL-6, sIL-6R and sgp130 
 
A total of 50 tracheal aspirate fluid (TAF) samples (10 animals at 5 time-points) 
and 20 necropsy lavage samples (five 125 day gestational controls, five 140 day 
gestational controls and ten 14 day post ventilation samples) were analysed. IL-6 was 
detected from 49 TAF samples (98%) but from only 2 necropsy lavage samples (10%); 
sIL-6R and sgp130 were detected in all samples. 
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The concentration of IL-6 (figure 3.2a and table 3.1) significantly increased from 
day 3 to day 6-7 (p < 0.001) before reaching its peak at day 10-11 (p < 0.01 compared 
to day 3); this rise decreased to levels comparable to day 1 and day 3 by day 14 (p < 
0.05 compared to day 6-7). In contrast, expression of sIL-6R (figure 3.2b and table 3.1) 
did not change significantly between the time-points in the study period. Expression of 
sgp130 (figure 3.2c and table 3.1) increased significantly from day 1 to day 6-7 (p < 
0.01) to reach a peak at day 10-11 (p < 0.05 compared to day1). There was a trend 
towards decreasing concentration at day 14, although this was not statistically 
significant from earlier time-points.   
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Figure 3-2: Expression of trans-signalling molecules. Concentrations of (a) IL-6, (b) sIL-
6R and (c) sgp130 in the ventilated baboon lung. Individual time-points (days) are 
represented on the x-axis while concentrations (pg/ml) are on the y-axis. Each 
datapoint represents an individual animal and solid bars at each timepoint represent 
medians. (*** = p < 0.001, ** = p < 0.01, * = p < 0.05). 
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3.5. Ratios of trans-signalling molecules 
 
For trans-signalling, an excess of sIL-6R is needed to form complexes with IL-6 
(sIL-6R/IL-6) which dimerises membrane gp130 and initiates intra-cellular signalling; an 
excess of sgp130 binds to this complex and inhibits its interaction with membrane 
gp130. Thus, a potential for trans-signalling is better represented by ratios of these 
molecules to show relative excess. To represent pro trans-signalling complexes, I 
calculated the molar (human equivalent) ratio of sIL-6R/IL-6 and for anti trans-
signalling complexes, the molar ratio of sgp130/sIL-6R. 
In this cohort of 10 animals, concentrations of IL-6 were almost always in 
excess of sIL-6R (except in two animals on day 14); concentrations of sgp130 were 
always in excess of both IL-6 and sIL-6R. IL-6 was below the range of detection in one 
sample; for the purposes of statistical analysis of sIL-6R/IL-6 ratio using a rank test, the 
IL-6 concentration was transposed to the detection limit of the ELISA (9.375 pg/ml). 
The ratio of sIL-6R/IL-6 (figure 3.3a and table 3.1) decreased significantly from day 3 to 
its nadir on day 6-7 (p < 0.01) which was sustained until day 10-11 (p < 0.01 compared 
to day 3). There was a trend towards recovery of this ratio on day 14 but this was not 
statistically significant. In contrast, the ratio of sgp130/sIL-6R (figure 3.3b and table 
3.1) reached a peak on day 6-7 (p < 0.05 compared to day1).  
Comparison of the two ratios on individual days shows that the anti trans-
signalling ratio (sgp130/sIL-6R) was always in excess of the pro trans-signalling ratio 
(sIL-6R/IL-6) (table 3.1).  
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Figure 3-3: Molar ratio of trans-signalling molecules. Ratios of (a) sIL-6R:IL-6 and (b) 
sgp130:sIL-6R in the ventilated baboon lung.  Individual time-points (days) are 
represented on the x-axis while the molar ratios are represented on the y-axis (log 
scale). Molar ratios are calculated as human equivalents. Each datapoint represents an 
individual animal and solid bars at each timepoint represent medians. (** = p < 0.01, * = 
p < 0.05). 
 Day 1 Day 3 Day 6 -7 Day 10 -11 Day 14 
IL-6  1107 
(392.3 – 
1421.0) 
440.5 
(261.4 – 
756.5) 
2613 
(1238.0 – 
4036.0) 
2787 
(1635.0 – 
3628.0) 
881 
(370.8 – 
1732.0) 
sIL-6R 273.1 
(217.2 – 
312.9) 
227.8 
(167.0 – 
359.5) 
326.7 
(250.3 – 
471.4) 
284.3 
(251.6 – 
516.9) 
234.8 
(175.1 – 
347.7) 
sgp130 13175 
(6793 – 
23341) 
14373 
(6194 – 
23840) 
22133 
(17710 – 
61597) 
24945 
(12795 – 
47603) 
16481 
(11897 – 
43297) 
sIL-6R/IL-6 0.125 
(0.0975 – 
0.5425) 
0.295 
(0.175 – 
0.57) 
0.07 
(0.05 – 
0.125) 
0.07 
(0.0475 – 
0.1125) 
0.14 
(0.09 – 
0.6525) 
sgp130/sIL-
6R 
23.05 
(16.96 – 
42.19) 
25.64 
(20.72 – 
45.78) 
45.27 
(33.84 – 
64.28) 
28.78 
(23.88 – 
85.53) 
35.33 
(20.18 – 
89.57) 
 
Table 3-1: Concentrations of IL-6, sIL-6R & sgp130 in pg/ml and the molar ratios 
(human equivalents) of sIL-6R/IL-6 & sgp130/sIL-6R represented as medians (IQR) at 
each time-point. 
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3.6. Cell counts 
 
To study the effect of ventilation on influx of inflammatory cells, I analysed 
total and differential cell counts in TAF. Total cell counts in the lungs of ventilated 
animals (figure 3.4a and table 3.2) were not significantly different between time-points 
during the length of the study. Differential cell counts could not be calculated for two 
animals on two days (one on day 3 and the other on day 14) due to poor quality of the 
slides; these were excluded from the analysis. Similar to total cells, the number of 
PMNs (figure 3.4b and table 3.2) and mononuclear cells (figure 3.4c and table 3.2) did 
not significantly differ between the days. To understand the pattern of shift of the 
predominant inflammatory cell population, I calculated the ratio of PMN/MNCs. 
Analysis of this ratio (figure 3.4d and table 3.2) showed a gradual shift of inflammatory 
cell influx from a 1.8-fold excess of PMNs on day 1 to a 1.5-fold excess of MNCs on day 
14 (day 1 vs day 14 p < 0.01). 
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Figure 3-4: Cell counts in TAF. Numbers of (a) total cells, (b) PMNs and (c) MNCs 
recovered in TAF from ventilated preterm baboons. Individual time-points (days) are 
represented on the x-axis while cell numbers in millions/ml are represented on the y-
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axis. (d) Ratio of numbers of PMN/MNC. Each datapoint represents an individual 
animal and solid bars at each timepoint represent medians. (** = p < 0.01).  
 
 Day 1 Day 3 Day 6-7 Day 10-11 Day 14 
Total cells 1.225 
(.8313 – 
1.813) 
0.9813 
(0.5625 – 
2.05) 
1.731 
(1.013 – 
2.112) 
0.7813 
(0.5531 – 
1.475) 
0.8563 
(0.5031 – 
1.081) 
PMNs 0.4306 
(0.1763 – 
0.6251) 
0.2870 
(0.1502 – 
0.6385) 
0.5228 
(0.4323 – 
0.6971) 
0.1692 
(0.1239 – 
0.2927) 
0.1977 
(0.05108 – 
0.3502) 
MNCs 0.1502 
(0.09748 - 
0.3983) 
0.2297 
(0.134 – 
0.5633) 
0.368 
(0.3263 – 
0.5335) 
0.2199 
(0.1376 – 
0.2895) 
0.2987 
(0.2066 – 
0.4775) 
PMN/MNC 1.783 
(1.425 – 
2.824) 
1.183 
(1.001 – 
1.442) 
1.211 
(0.8461 – 
1.984) 
0.8926 
(0.7577 – 
1.188) 
0.6625 
(0.3884 – 
1.021) 
 
Table 3-2: Cell counts (millions/ml) and ratios of PMN/MNC in TAF represented as 
medians (IQR) at each timepoint. 
 
3.7. Expression of Chemokines 
 
As IL-6 trans-signalling has been shown to have a profound effect on cell 
trafficking in an acute inflammatory model by switching the expression of key 
chemokines from a pro-inflammatory to pro-resolution phenotype, I analysed the 
concentrations of IL-8 and MCP-1 in TAF from ventilated preterm baboons. IL-8 (figure 
3.5a) concentration significantly increased on day 6-7 (day 1 vs day 6-7 p < 0.01, day 3 
vs day 6-7 p < 0.05) and persisted until day 10-11 (day 1 vs day 10-11 p < 0.001, day 3 
vs day 10-11 p < 0.05) before slowly resolving at day 14 (not statistically significant 
compared to previous time-points). The pattern of expression of MCP-1 (figure 3.5b) 
was similar with a significant rise on day 6-7 (day 1 vs day 6-7 p < 0.001, day 3 vs day 6-
7 p < 0.01) which persisted until day 10-11 (day 1 vs day 10-11 p < 0.01) before 
showing a trend towards resolution at day 14. 
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Figure 3-5: Expression of chemokines. Concentrations of (a) IL-8 and (b) MCP-1 in the 
ventilated baboon lung. Individual time-points (days) are represented on the x-axis 
while concentrations (pg/ml) are on the y-axis. Each datapoint represents an individual 
animal and solid bars at each timepoint represent medians. (*** = p < 0.001, ** = p < 
0.01, * = p < 0.05). 
 
3.8. Summary of results in preterm ventilated baboons 
 
My results in the preterm baboons confirm that IL-6 and its two soluble 
receptors are expressed in the lung, and that they exhibit dynamic changes during the 
course of ventilation. Gentle ventilation used in this model, and reflective of current 
clinical practice (Coalson et al., 1999b), results in significant inflammation in the lung, 
as measured by the soluble mediators but not reflected in the numbers of the cellular 
infiltrate. However, there was a change in the pattern of cellular infiltrate over the 
course of the study period from predominantly PMNs to MNCs. Analysis of the pro (sIL-
6R/IL-6) and anti (sgp130/sIL-6R) trans-signalling potential suggested a gradual shift in 
expression of these cytokines towards the former at the end of the study period, and 
this was reflected in a change in the influx of inflammatory cells resembling a pro-
resolution phenotype. 
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3.9. Expression in Human Preterm Infants: Aims of the Project 
 
 To determine the expression of the IL-6, sIL-6R, sgp130, IL-8 and MCP-1 in 
broncho-alveolar lavage fluid (BALF) from ventilated preterm human infants. To 
determine the concurrent pattern of influx of inflammatory cells in BALF from 
preterm ventilated human infants.  
 To determine the proportion of the dsIL-6R isoform in the lungs of preterm 
infants and compare it between the two groups of infants, CLD and No CLD. 
 To analyse possible correlations between expression of the IL-6 trans-signalling 
molecules, the related chemokines and influx of inflammatory cells into the 
lungs.  
 To compare expression of all of the molecules and cells between the two 
groups of infants, CLD and no CLD. 
 To analyse the inter-relationships in the expression of IL-6, sIL-6R and sgp130 
by calculating functionally relevant ratios and compare them between the two 
groups, CLD and no CLD. 
 
 
3.10. Clinical Subjects 
 
A total of 32 preterm infants were studied, 17 CLD and 15 No CLD. Two infants 
in the CLD group were excluded from the analysis as they had major congenital 
abnormalities (sacro-coccygeal teratoma). Thus, a total of 30 infants were included in 
the final analysis. 104 BALF samples were collected in the first week of life from these 
infants for analysis (73 CLD and 31 no CLD). The median gestation and birth-weight of 
CLD infants was lower than No CLD infants, although no significant difference was 
noted (table 3.3). The duration of ventilation (days) was significantly greater in the CLD 
infants (p <0.01). 
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Table 3-3: Clinical characteristics of the study population. Numerical values are 
expressed as medians (inter-quartile range). Categorical values are expressed as 
numbers of infants (percentages). 
 
3.11. Inflammatory Markers  
 
To determine if there is a difference in the markers of inflammation in the two 
groups of patients, I analysed the numbers of infiltrating PMNs and MNCs into the 
lungs and also the key chemokines IL-8 and MCP-1. The peak number of PMNs (p=0.03, 
figure 3.6a) and MNCs (p=0.04, figure 3.6b) recovered from BALF were significantly 
higher in the CLD group compared to the no CLD group (table 3.4). Peak concentrations 
of IL-8 (p<0.01, figure 3.6c) and MCP-1 (p=0.02, figure 3.6d) were also significantly 
higher in the CLD group (table 3.4). Thus, infants developing CLD had higher 
concentrations of the two key chemokines, reflected by an increased cellular infiltrate. 
Clinical Characteristic  No CLD CLD p 
Total infants 15 15  
Gestational age in weeks (IQR) 28+3 (27 – 29+4) 27+5 (25+4 – 
29+2) 
0.21 
Birth weight (g) 1120 (960 – 
1260) 
850 (717.3 – 
1120) 
0.11 
Prolonged rupture of 
membranes (>24 hours) 
1 (6.7) 4 (27.7) 0.33 
Antenatal steroids (≥24 hours) 12 (80.0) 11 (73.3) 1.00 
Caesarean delivery 10 (66.7) 8 (53.3) 0.71 
Exogenous surfactant 
replacement 
15 (100) 15 (100)  
Mechanical ventilation (days) 1.5 (1.0 – 2.5) 7.0 (5.0 – 18.0) <0.01 
Patent ductus arteriosus 6 (46.2) 10 (66.7) 0.45 
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Figure 3-6: Inflammatory markers in the preterm lung. Peak numbers (cells/ml) of (a) 
PMNs and (b) MNCs and peak concentration (pg/ml) of (c) IL-8 and (d) MCP-1 in the 
lungs of ventilated preterm infants. The clinical groups are represented on the x-axis 
while the cells numbers (and a and b) or concentration (in c and d) is represented on 
the y-axis. Each datapoint represents an individual infant and solid bars are at 
medians. (** = p < 0.01, * = p < 0.05)  
 
 No CLD CLD p 
PMNs 0.94 (0.36 – 1.68) 1.85 (1.21 – 3.29) 0.03 
MNCs 0.21 (0.07 – 0.57) 0.83 (0.23 – 2.05) 0.04 
IL-8 3401 (1587 – 19080) 133600 (19310 – 209700) < 0.01 
MCP-1 3434 (1821 – 16545) 25080 (11180 – 60670) 0.02 
 
Table 3-4: Inflammatory markers in the lung. Medians (IQR) of peak values of 
infiltrating PMNs and MNCs (millions/ml) and peak concentration of IL-8 and MCP-1 
(pg/ml) in the lungs of ventilated preterm infants. 
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3.12. Expression of IL-6, sIL-6R and sgp130 
 
I next analysed the concentration of IL-6, sIL-6R and sgp130 in these infants. 
Although there was a trend towards increased concentrations in the CLD group, both 
peak IL-6 (p=0.13, figure 3.7a and table 3.5) and peak sIL-6R (p=0.21, figure 3.7b and 
table 3.5) expression were not statistically different between the two groups. In 
contrast, peak sgp130 was significantly higher in the CLD group compared to the no 
CLD infants (p=0.03, figure 3.7c and table 3.5). 
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Figure 3-7: Expression of IL-6 trans-signalling molecules. Peak concentration (pg/ml) of 
(a) IL-6, (b) sIL-6R and (c) sgp130 in the lungs of preterm ventilated infants. The clinical 
groups are represented on the x-axis while the concentration is represented on the y-
axis. Each data-point represents an individual infant and solid bars are at medians. (* = 
p < 0.05) 
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3.13. Molar ratios of IL-6 trans-signalling molecules 
 
As sIL-6R is a key agonist of IL-6 activity whilst sgp130 acts as an antagonist of 
sIL-6R/IL-6 complexes, to represent relative abundance of pro- and anti- trans-
signalling potential, I calculated the molar ratios sIL-6R/IL-6 and sgp130/sIL-6R 
respectively. There was a trend towards increased peak molar ratio in BALF of sIL-
6R/IL-6 in the CLD infants compared to the No CLD infants but this was not statistically 
significant (p=0.06, figure 3.8a). However, the peak molar ratio of sgp130/sIL-6R was 
significantly higher in the CLD infants compared to the No CLD infants (p=0.02, figure 
3.8b, table 3.5). 
sgp130 concentration was in excess of sIL-6R concentration in all infants and 
the median values of the antagonistic ratio (sgp130/sIL-6R) were between six- to ten-
fold higher than the agonistic ratio (sIL-6R/IL-6) within each group. Thus, the specific 
inhibitor of trans-signalling, sgp130, and the ratio sgp130/sIL-6R was significantly 
higher in the CLD group.  
My initial hypothesis was that impaired IL-6 trans-signalling in the lungs of 
infants developing CLD could lead to delayed resolution of inflammation and 
contribute to the pathogenesis of the condition. To test this hypothesis, I looked for 
any correlation between the anti trans-signalling ratio (sgp130/sIL-6R) in the CLD 
infants and corresponding IL-8 expression or influx of PMNs into the lungs, and the pro 
trans-signalling ratio (sIL-6R/IL-6) in No CLD infants and the corresponding expression 
of MCP-1 or the influx of MNCs into the lungs. No significant correlations were 
observed between any of the ratios and the corresponding chemokines or cells in 
either of the groups. When all preterm infants were combined, there was a weak but 
statistically significant correlation between the ratio sIL-6R/IL-6 (pro trans-signalling) 
and influx of MNCs into the lungs (r=0.24, p=0.04); no significant correlation was found 
for the ratio sgp130/sIL-6R (anti trans-signalling) and the corresponding IL-8 expression 
or PMN influx. 
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Figure 3-8: Molar ratio of trans-signalling molecules. Peak ratio of (a) sIL-6R:IL-6 and 
(b) sgp130:sIL-6R in preterm ventilated infants. The clinical groups are represented on 
the x-axis while the ratio is represented on the y-axis. Each datapoint represents an 
individual infant and solid bars are at medians. (* = p < 0.05) 
 
 
Table 3-5: Expression of IL-6 trans-signalling molecules and their ratios. Medians (IQR) 
of concentrations of IL-6 trans-signalling molecules (pg/ml) and their molar ratios in 
the lungs of preterm ventilated infants. 
 
  
3.14. Expression of DS sIL-6R  
 
Two inducible isoforms of sIL-6R can mediate these trans-signalling responses; 
one produced at sites of inflammation by proteolytic cleavage (PC sIL-6R) (Mullberg et 
al., 1993b) and a second differential (or alternative) mRNA spliced isoform, DS sIL-6R 
(Horiuchi et al., 1994b). Both lack the membrane-proximal regions of the cognate 
 No CLD CLD p 
IL-6 2096 (637.1 – 6977) 7900 (1383 – 16440) 0.13 
sIL-6R 1244 (750.7 – 3155) 2852 (1195 – 7636) 0.21 
sgp130 20788 (7680 – 37440) 65290 (20280 – 94590) 0.03 
sIL-6R:IL-6 1.01 (0.21 – 2.09) 2.03 (0.72 – 3.86) 0.06 
sgp130:sIL-6R 7.80 (3.13 – 11.92) 12.97 (10.45 – 30.59) 0.02 
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receptor but the two isoforms are differentiated  by the presence of 10 extra amino 
acids (a.a.) at the COOH terminal of DS sIL-6R (Jones et al., 2001). Levels of DS sIL-6R 
seem to be regulated by age (Jones et al., 2001); however, expression of this isoform in 
the neonatal population has not previously been described. To determine the 
expression of sIL-6R generated by alternative splicing mechanism, an additional 21 CLD 
and 11 no CLD samples were tested by ELISA for DS sIL-6R.  Due to the limited 
availability of specimens from the main study population, these samples were from a 
separate but matched (table 3.6) population collected within one year of the main 
study population and from the same neonatal unit. 
 
 
Table 3-6: Clinical characteristics of the study population used for measuring DS sIL-6R. 
Numerical values are expressed as medians (inter-quartile range). Categorical values 
are expressed as numbers of infants 
 
Both total sIL-6R (p=0.53, fig 3.9a) and DS sIL-6R (p=0.12, fig 3.9a) were 
comparable between the two groups. However, the majority of the sIL-6R in BALF 
 No CLD CLD p 
Total infants 4 3  
Gestational age in weeks (IQR) 27+2 (25+6 – 
28+3) 
28+3 (27+1 – 29+3) 0.4 
Birth weight (g) 975 (857.5 – 
1243) 
1080 (1020 – 
1230) 
0.63 
Prolonged rupture of membranes (>24 
hours) 
1 (25.0) 0 (0.0) 1.0 
Antenatal steroids (≥24 hours) 4 (100) 3 (100)  
Caesarean delivery 2 (50.0) 3 (100) 0.43 
Exogenous surfactant replacement 4 (100) 3 (100)  
Mechanical ventilation (days) 12.5 (6.8 – 
15.3) 
36.0 (12.0 – 
44.0) 
0.28 
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seemed to be the proteolytically cleaved isoform (figure 3.9b). Expression of DS sIL-6R 
in preterm BALF was significantly correlated to the total sIL-6R detected (r=0.82, 
p<0.0001, figure 3.10).   
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Figure 3-9: Expression of total and DS sIL-6R in preterm BALF. (a) Concentration 
(pg/ml) of total sIL-6R (orange circles) and DS sIL-6R (orange squares) in RDS and total 
sIL-6R (green circles) and DS sIL-6R (green squares) in CLD. Interrupted line represents 
the limit of detection of the ELISA. (b) Proportion (expressed as a percentage) of total 
sIL-6R expressed as DS sIL-6R in RDS (orange circles) and CLD (green squares).   
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Figure 3-10: Correlation between the expressions of DS sIL-6R (y-axis) with total sIL-6R 
(x-axis) in preterm BALF. Each datapoint represents a preterm infant and continuous 
line represents “line of best fit”, drawn by linear regression analysis.   
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It has been previously suggested that the expression of DS sIL-6R in circulation 
is related to age, with younger subjects expressing higher proportion of total sIL-6R as 
the DS isoform. To test this hypothesis, I measured total and DS sIL-6R in plasma from 
newborn infants. As matched plasma was not available from preterm infants, 
concentration of DS sIL-6R in circulation was measured in samples of cord blood from 
term infants delivered by elective caesarean section (n=18) and from healthy adult 
controls (n=14). Plasma levels of total sIL-6R (p 0.051, fig 3.11a) and DS sIL-6R (p 0.052, 
fig 3.11a) were lower in cord blood compared to adult plasma and the difference 
approached statistical significance. The proportion of total sIL-6R expressed as DS sIL-
6R in plasma was also lower in cord blood (p 0.14, fig 3.11b), but this was not 
statistically significant. Unlike BALF, there was no significant correlation between the 
expression of total sIL-6R and DS sIL-6R in newborn plasma (fig 3.12). Thus, DS sIL-6R 
was expressed as a small proportion of total sIL-6R in both preterm neonatal BALF and 
in term neonatal circulation. 
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Figure 3-11: Expression of total and DS sIL-6R in newborn circulation. (a) Concentration 
(pg/ml) of total sIL-6R (blue triangles) and DS sIL-6R (blue inverted triangles) in RDS 
and total sIL-6R (pink triangles) and DS sIL-6R (pink inverted triangles) in CLD. (b) 
Proportion (expressed as a percentage) of total sIL-6R expressed as DS sIL-6R in RDS 
(blue triangles) and CLD (pink inverted triangles). 
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Figure 3-12: Correlation between the expressions of DS sIL-6R (y-axis) with total sIL-6R 
(x-axis) in term newborn infant circulation. Each datapoint represents a term infant 
and continuous line represents “line of best fit”, drawn by linear regression analysis. 
 
 
3.15. Discussion 
 
3.15.1. Summary 
I have reported expression of IL-6 and its soluble receptors, sIL-6R and sgp130, 
along with other markers of inflammation, in the lungs of both preterm baboons and 
human infants.  
My analysis in the preterm baboons confirm that IL-6 and its two soluble 
receptors are expressed in the lung, and that they exhibit dynamic changes during the 
course of ventilation. Even gentle ventilation used in this model, and reflective of 
current clinical practice (Coalson et al., 1999b), results in significant inflammation in 
the lung which shows a change in the pattern of cellular infiltrate over the course of 
the study period. 
In human infants, peak concentrations of the chemokines IL-8 and MCP-1 as 
well as peak numbers of PMNs and MNCs were all significantly higher in infants who 
developed CLD. The specific inhibitor of trans-signalling, sgp130 was significantly 
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higher in infants developing CLD later. More importantly, an excess of sgp130 was 
noted in all infants from both groups, suggesting an abrogation of the IL-6 trans-
signalling pathway in the preterm lung. I have also described, for the first time, 
expression of DS sIL-6R in preterm lung and term newborn circulation. 
 
3.15.2. Expression of cytokines and chemokines in the preterm baboon lung 
All the cytokines and chemokines measured in our cohort of 10 animals, except 
sIL-6R, exhibited a similar pattern of expression showing significant increase in 
concentration at around day 6-7, persisting till day 10-11 and a trend towards 
resolution on day 14. Expression of sIL-6R and sgp130 has not been described in this 
model before. IL-8 concentration previously described during development of this 
model (Coalson et al., 1999b), showed a similar pattern of rise after day 6 which 
persisted till day 10, and a trend towards resolution after day 10. However, for IL-6, 
only concentrations on day 10 were significantly higher compared to other time-points 
(Coalson et al., 1999a). In an interventional trial with high-frequency ventilation in this 
model, preterm baboons randomised to conventional ventilation (n=12) showed a rise 
in IL-8 concentrations after day 6 which reached a peak at day 10 before resolving 
around day 14 (Yoder et al., 2000a). IL-6 concentrations in this cohort did not 
demonstrate the dynamic changes I have observed. In an extension of this model to 
include antenatal colonization with Ureaplasma, there was no variability of IL-6 
concentrations (n=5) in the lungs of control (not exposed to antenatal Ureaplasma) 
animals (Yoder et al., 2003a). IL-8 (n=8) showed a rise on day 3 which persisted until 
day 5 before resolving at around day 10 but increased again to reach a peak 
concentration on day 14. An important difference in this study was that antenatal 
corticosteroids were not used in any of the animals. In another interventional study on 
ductus arteriosus ligation in preterm baboons, both IL-6 and IL-8 in the cohort of 
control animals (n=13) did not show the pattern of variability that I have observed 
(McCurnin et al., 2005b). Thus, significant variability in the expression of IL-6 have 
been noted in these animals, which could partly be explained by differences in 
interventions used or modes of injury. On the other hand, IL-8 has been consistently 
shown to increase in concentration after a few days, even with gentle ventilation. 
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In previous reports from this baboon model, absolute concentrations of IL-6 and 
IL-8 (pg/ml) were lower than that detected in our cohort. One reason for this could be 
difference in estimation methods; previously, for IL-6 measurement, a 
radioimmunoassay (RIA) was used with specific antiserum to human IL-6 and IL-8 was 
measured by an enzyme immunoassay. Thus, although the pattern of expression of IL-
8 in our cohort is in agreement with previous reports, the dynamic changes I have 
observed in IL-6 concentration in the lung are not. Moreover, I have measured higher 
absolute values for both IL-6 and IL-8 in our cohort of ventilated animals, possibly due 
to differences in laboratory methods and sensitivity of ELISA compared to RIA. 
In summary, all three members of the IL-6 trans-signalling family of molecules 
were detected in the lungs of preterm baboons after gentle ventilation for 14 days. 
Dynamic changes were noted in the expression of IL-6 and sgp130, but not sIL-6R. The 
chemokines IL-8 and MCP-1 also showed dynamic changes similar to IL-6 and sgp130.  
 
 
3.15.3. Cellular infiltrate in the lungs of preterm ventilated baboons 
In our cohort of 10 ventilated baboons, I have not observed significant 
differences in the numbers of PMNs or MNCs infiltrating into the lung. This agrees with 
the first report on this model (Coalson et al., 1999a), where no significant differences 
were noted in the differential cell counts. However, Coalson and colleagues found 
mononuclear cells to be always in excess of PMNs in tracheal aspirates. In the trial on 
high-frequency ventilation (Yoder et al., 2000a), PMN numbers increased at around 
day 9-10 and were higher than MNCs in control animals (standard ventilation, 
comparable to our cohort). Overall, the authors reported an excess of MNCs at other 
time-points (no statistics were reported for any variation between the days). I have 
observed a gradual shift in the population of cells infiltrating into the lungs from PMNs 
at early time-points to MNCs later on (PMN/MNC); values were significantly different 
between day 1 and day 14. Thus, my observations are different from previous reports 
in this model. 
A large body of existing literature suggests that CLD in human infants is a 
disease associated with prolonged PMN and ill-sustained MNC infiltration into the 
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lungs of infants. The first description of this observation was in the 1980s (Ogden et al., 
1983, Merritt et al., 1983, Ogden et al., 1984b) when prenatal steroids and postnatal 
exogenous surfactant replacement were still experimental. In the ‘90s, with the advent 
of both of these interventions, the association of persistent neutrophilia in the lungs 
with CLD was maintained (Arnon et al., 1993, Groneck et al., 1994, Watterberg et al., 
1994, Kotecha et al., 1995, Munshi et al., 1997). However, surfactant use seemed to be 
associated with an increase in MNC numbers (Arnon et al., 1993). More recent studies 
in the last decade have confirmed the association between prolonged infiltration of 
PMNs and CLD (Kotecha et al., 2003). My results of increased influx of PMNs into the 
lungs of CLD infants is in keeping with previous reports. Increased MNCs in the CLD 
infants, although previously reported once (Arnon et al., 1993), probably reflects 
higher intensity and/or duration of inflammation in this group of infants. 
 
3.15.4. Expression of the chemokines IL-8 and MCP-1 in preterm ventilated 
human infants 
Attraction of innate immune cells to sites of inflammation is achieved by 
induction of a chemotactic gradient. Key chemokines involved in formation of such a 
gradient are IL-8 for PMNs (Remick, 2005) and MCP-1 for monocytes and mononuclear 
cells (Yadav et al., 2010). In observational studies, IL-8 has been consistently found to 
be significantly increased in the lungs of infants developing CLD (Ryan et al., 2008, 
Bose et al., 2008) compared to infants with No CLD. Almost all cells in the body can 
secrete IL-8 (Remick, 2005) and it is one of the early chemokines expressed in the 
preterm lungs which precedes the influx of PMNs (Munshi et al., 1997). Increased 
concentrations of MCP-1 have also been associated with the development of CLD 
(Baier et al., 2001, Baier et al., 2004). Thus, my results of increased concentration of 
both IL-8 and MCP-1 in their lungs of preterm ventilated infants who developed CLD 
later, is in agreement with previous reports. However, the dynamic pattern of 
expression of the chemokines IL-8 and MCP-1 in the preterm baboons was not 
reflected in the cellular infiltrate recovered from the lungs.  
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I have specifically looked at the expression of IL-8 and MCP-1 as they have been 
previously shown to be modulated by IL-6 trans-signalling (Hurst et al., 2001). The 
effect of IL-6 trans-signalling on the above chemokines has not been studied in the 
baboon model or in humans. Evidence on the differential control of neutrophil 
activating chemokines by IL-6 trans-signalling was provided by a rodent model of 
inflammation (McLoughlin et al., 2004). In a peritoneal inflammatory model in 
knockout mice, the authors demonstrated up-regulation of keratinocyte-derived 
chemoattractant (KC, murine homologue of human GRO-α) and MIP-2 (murine 
homologue of human IL-8) in IL-6-/- mice resulting in an increased influx of PMNs, 
possibly due to a lack of IL-6 trans-signalling (as this pattern was reversed on 
reconstitution of IL-6 trans-signalling). However, a down-regulation of another 
neutrophil attracting chemokine, LPS-induced CXC chemokine (LIX, murine homologue 
of human GCP-2) was noted in the same knockout mice. Thus the overall effect of IL-6 
trans-signalling on chemokines is complex. 
Control of expression of chemokines at sites of inflammation and subsequent 
influx of immune cells is complex and regulated at several different steps. Both IL-8 
and MCP-1 are produced by a variety of cells and in response to a wide ranging array 
of stimuli (Remick, 2005, Yadav et al., 2010). Apart from IL-8, infiltration of PMNs into 
an inflammatory site is regulated by several other chemokines including growth-
related protein-α (GRO-α), GRO-β, GRO-γ, epithelial cell-derived neutrophil activating 
peptide-78 (ENA-78) and granulocyte chemotactic peptide-2 (GCP-2) (Rollins, 1997). 
Similarly,  several chemokines, apart from MCP-1, are involved in attracting 
mononuclear cells to a site of inflammation including MCP-2, MCP-3, MCP-4, 
macrophage inflammatory protein-1α (MIP-1α), MIP-1β (Rollins, 1997).  
IL-8 and MCP-1 are the best studied in the preterm lung; however, whether 
they are the most relevant chemokines involved in cell trafficking in the preterm 
neonatal lung is unknown. Their increased expression in CLD infants may not represent 
a “cause and effect” relationship but rather be a sign of increased intensity and 
duration of inflammation in these infants, probably due to persistent injurious stimuli. 
Thus, all of the mediators of inflammation (cells and chemokines) I have measured 
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have complex control mechanisms, and the overall effect is most likely due to a 
combination of factors rather than due to any one in isolation.     
 
3.15.5. Expression of IL-6, sIL-6R and sgp130 in preterm ventilated human 
infants 
 
Expression of IL-6 in the preterm ventilated lung in human infants has been 
extensively studied since the first description of increased concentration in the lungs of 
infants with prolonged rupture of membranes (PROM) (Grigg et al., 1992). In one of 
the early studies, IL-6 was found to be significantly higher on day 10 in the lungs of 
infants developing CLD compared to those who did not (Kotecha et al., 1996b). 
Significant differences in IL-6 concentration were found earlier in the course of 
ventilation on days 3 and 5 (Munshi et al., 1997) and days 2 and 3 (Jonsson et al., 
1997a). Although elevated IL-6 concentrations in the lungs of preterm infants at birth 
has been associated with subsequent CLD, (Choi et al., 2006a), this more likely 
represents intra-uterine inflammation. However, this has not been a consistent finding 
across other studies where comparable concentrations were recovered from infants 
who did and did not develop CLD (Kazzi et al., 2001, von Bismarck et al., 2008b). CLD 
was defined differently in studies as oxygen requirement at 28 days of age (Kotecha et 
al., 1996b, Jonsson et al., 1997a, von Bismarck et al., 2008b) or at 36 weeks corrected 
gestational age (Munshi et al., 1997, Kazzi et al., 2001) predictably resulting in 
variability in the incidence of CLD. There was variation in the clinical characteristics and 
the care provided to infants in the different studies as well. Overall, IL-6 has been 
associated with the development of CLD which is in agreement with this cytokine being 
an important mediator during inflammation, However, similar to the chemokines, 
raised concentrations of IL-6 by itself is unlikely to be a direct cause of CLD but more 
likely represents increased duration of inflammation. I have defined CLD as oxygen 
requirement at 36 weeks corrected gestational. My analysis shows a trend towards 
higher peak IL-6 concentrations in the lungs of CLD infants which was not statistically 
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significant. I am not sure whether including more infants in the groups would have 
made this trend statistically significant. 
While there is an extensive literature on IL-6, only one study (which was 
published as this study was commencing) has reported concentrations of the soluble 
receptors sIL-6R and sgp130 in the preterm human lung (von Bismarck et al., 2008b). 
The authors collected two samples of tracheal aspirate fluid (TAF) from ventilated 
preterm infants ≤ 32 weeks gestation, the first on day 1 and the second between days 
4-7. No significant differences in the concentration of mean sIL-6R or mean sgp130 
were reported between CLD (defined as oxygen requirement at 28 days of age) and No 
CLD infants at either of the time-points included in the study (day 1 and day 4-7). 
However, in the CLD infants, there was a significant increase in both mean sIL-6R and 
mean sgp130 concentrations from day 1 to day 4-7. The increase in concentration of 
sgp130 is similar to what I have observed in the cohort of preterm baboons. However, 
they have reported an increase in sIL-6R concentration in preterm TAF for the first 
time , although the authors do not report an accompanying increase in innate immune 
cells. Apart from more number of days on ventilation, the CLD infants were of 
significantly lower gestation compared to the No CLD infants.  
I have noted a trend towards increased peak sIL-6R concentrations in the CLD 
infants; however, peak sgp130 concentrations were significantly higher in these infants 
in my cohort (fig 3.7c). Differences in sampling methods (we have collected daily BALF 
samples from all infants in the first week), group stratification (I defined CLD as oxygen 
requirement at 36 weeks corrected gestational age) and statistical methods (I have 
reported medians while von Bismarck and colleagues reported means ± SEM) could be 
potential explanations for the above observations. However, the significantly higher 
concentration of sgp130 is an important finding being reported for the first time in 
preterm infants. 
Our current knowledge about the mechanism of production of sIL-6R includes 
proteolysis (Mullberg et al., 1993c) and also differential mRNA splicing (Horiuchi et al., 
1994b). Since the cell-surface expression of IL-6R is limited to hepatocytes and 
circulating immune cells, these are probably the main sources of sIL-6R. Although 
innate immune cells seem to be the main source of circulating sIL-6R (McFarland-
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Mancini et al., 2010), PMNs seem to be the main source of localised sIL-6R during 
acute inflammation (Hurst et al., 2001, Chalaris et al., 2007). Apoptosis of PMNs at 
sites of inflammation has been suggested to be a natural stimulant for the release of 
sIL-6R from the cell surface, and neutrophil depletion resulted in reduction of sIL-6R 
concentration (Chalaris et al., 2007). However, MNCs can also contribute to the 
production of sIL-6R (McLoughlin et al., 2004).  
In our cohort of 10 preterm baboons, there were no significant differences in 
the concentration of sIL-6R between the different time-points. A possible explanation 
for this could be a lack of variation in the numbers of PMNs or MNCs recovered at the 
various time-points, which are the cellular sources of this cytokine. In contrast, in the 
preterm human infants, peak numbers of both PMNs and MNCs were higher in the CLD 
group (3.6a and 3.6b), although this was not reflected in a significant increase of sIL-6R 
concentration. Apoptosis of PMNs at sites of inflammation has been suggested to be 
natural stimulant for the release of sIL-6R from the cell surface (Chalaris et al., 2007). 
As PMNs in the lungs of CLD infants have been reported to have lower rates of 
apoptosis (Kotecha et al., 2003, Oei et al., 2003), this could be a possible explanation 
for the lack of significantly higher sIL-6R concentration in the CLD lungs, in spite of 
having higher cell counts. Rates of apoptosis of PMNs in the preterm baboon lung are 
not known.  
Expression of membrane gp130 on cells is described to be ubiquitous, and 
homozygous deletion of gp130 is lethal (Yoshida et al., 1996), suggesting its vital role 
during foetal development. Several mechanisms have been described which regulate 
expression of cell-surface gp130 (Geisterfer et al., 1995, Bhat et al., 1999, Sharkey et 
al., 1995, Deb et al., 1999, Vallieres and Rivest, 1997, Geisterfer and Gauldie, 1996, 
Blanchard et al., 2001). At least two isoforms of sgp130 have been detected in human 
serum (Narazaki et al., 1993) due to alternative splicing of mRNA (Diamant et al., 1997, 
Tanaka et al., 2000) and limited proteolytic cleavage of cell-surface gp130 (Mullberg et 
al., 1993a, Montero-Julian et al., 1997). PMNs exhibit time dependent expression of 
sgp130 when cultured in vitro without stimulation (Jablonska and Jablonski, 2002) and 
inflammatory stimuli have also been shown to upregulate sgp130 expression 
(Jablonskaca et al., 2003) from PMNs. MNCs have also been proposed as a source if 
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sgp130 (Memoli et al., 2005). Considering the high levels of sgp130 (390 ± 72 ng/ml) 
normally detected in human serum (Narazaki et al., 1993), it is not yet clear what the 
regulatory mechanism involved in its expression are, both normally and during 
inflammation. Cellular sources of sgp130 have also not been elucidated, although 
potentially all cells expressing gp130 could be a source.  
There is evidence supporting modulation of sgp130 expression in non-
inflammatory conditions (Walshe et al., 2010) and during the normal menstrual cycle 
(Sherwin et al., 2002). Compared to healthy controls, serum levels of sgp130 were 
found to be significantly higher and cerebrospinal fluid (CSF) levels to be significantly 
lower in patients with multiple sclerosis (Padberg et al., 1999). Endometrial biopsies 
from idiopathic infertile women secreted significantly less sgp130 compared to fertile 
women (Sherwin et al., 2002). The authors of this study (Sherwin et al., 2002) also 
suggested that proteolytic cleavage of membrane gp130 was the main mechanism of 
production of sgp130 from the endometrial biopsies as none of the primers encoding 
the known splice variants of sgp130 had a product after polymerase chain reaction 
(PCR). This finding has been reported previously from multiple myeloma cell lines 
(Montero-Julian et al., 1997). Patients with acute ischaemic stroke had significantly 
lower serum sgp130 levels in the first week compared to healthy controls (Acalovschi 
et al., 2003). Modulation of sgp130 expression has also been described in aqueous 
humour from patients with uveitis (Simon et al., 2008), in plasma from patients with 
metabolic syndrome (Zuliani et al., 2010) and women with pre-eclampsia (Wang et al., 
2011), all compared to matched healthy controls. Together, this data provides ample 
evidence of modulation of expression of sgp130, both in health and disease, although 
the mechanism involved in such regulation have not been proposed.   
Similar to IL-6, sgp130 concentrations increased significantly on day 6-7 in the 
preterm baboon, which persisted till day 10-11 before resolving on day 14. In the 
preterm human infants, significantly higher concentration of sgp130 was found in the 
lungs of CLD infants compared to those without CLD. Taken together, this data 
suggests the existence of mechanisms modulating sgp130 expression in the preterm 
lung during inflammation. It is widely accepted that sgp130 is a specific inhibitor of IL-6 
trans-signalling and acts to regulate effects of trans-signalling in vivo (Narazaki et al., 
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1993, Jostock et al., 2001b). However, the role of the different isoforms, if any, is yet to 
be elucidated. As our knowledge regarding expression and regulation of sgp130 is 
incomplete, the possible mechanisms of its dynamic expression are unclear. 
Considering the high concentrations detected in the lungs of preterm baboons and 
human CLD infants, I hypothesise that sgp130 could have a profound regulatory effect 
on IL-6 trans-signalling; however, a firm conclusion cannot be drawn from 
observational data and further functional studies are needed to clarify the impact of 
sgp130 in these specimens.  
 
3.15.6. Ratio of IL-6 trans-signalling molecules in preterm ventilated human 
infants 
 
The effect of IL-6 trans-signalling is dependent on the relative presence of IL-6 
and its two soluble receptor subunits. Thus, a complex of sIL-6R/IL-6 acts as an agonist 
on cells lacking the membrane IL-6R. This “cytokine” is specifically inhibited by sgp130, 
which competes with membrane gp130 to bind the complex. Detailed in vitro binding 
assays (Gaillard et al., 1999) showed that: 
In the absence of sgp130, the proportion of free (unbound to any of the soluble 
receptors) and bound (as part of the sIL-6R/IL-6 complex) IL-6 are constant over a wide 
range of IL-6 concentrations, free IL-6 being about 30% of the total (free + bound) IL-6. 
The proportion of free IL-6 is decreased by increasing concentrations of sIL-6R, which is 
accompanied by a corresponding increase in the sIL-6R/IL-6 complex. The proportion 
of free IL-6 remains unaltered in the presence of sgp130. However, the proportion of 
(detectable) sIL-6R/IL-6 complex (bound IL-6) decreases in the presence of sgp130, 
presumably due to formation of the ternary complex IL-6/sIL-6R/sgp130. 
In summary, interaction of these molecules can be predicted by the 
mathematical model proposed by the authors. They demonstrated that the 
concentration of the sIL-6R/IL-6 complex is directly proportional to the concentration 
of sIL-6R (not IL-6) and inversely proportional to the concentration of sgp130. Thus, 
although IL-6 is the bioactive molecule, trans-signalling by the complex is controlled by 
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the soluble receptor components. The soluble IL-6R seems to be the key molecule, as 
the complexes of sIL-6R/IL-6 and IL-6/sIL-6R/sgp130 would not form in its absence. To 
have an impact on concentration, both of the soluble receptors were required in 
excess of IL-6 concentration. 
IL-6 trans-signalling has been implicated in several diseases, involving both 
systemic and localised inflammation. The best characterised among them is arthritis 
where an excess of sIL-6R, compared to IL-6, is present in synovial fluid of the inflamed 
joint. Localised synovial sIL-6R/IL-6 (mass) ratio in osteoarthritis was found to be 
around 50 (Kotake et al., 1996), 320 (Uson et al., 1997) and 10 (Desgeorges et al., 
1997) in different studies. For rheumatoid arthritis, the (mass) ratio ranged from 14 
(Kotake et al., 1996), 19 (Uson et al., 1997) and 1 (Desgeorges et al., 1997). An excess 
of sIL-6R was also found in the synovial fluid of the majority of patients with juvenile 
idiopathic arthritis (Peake et al., 2006). Unfortunately, the corresponding 
concentration of local sgp130 in the joint was not reported in these studies. Blockade 
of arthritis by specifically targeting this complex (sIL-6R/IL-6) with sgp130 in an animal 
model (Nowell et al., 2003) confirmed the role of IL-6 trans-signalling in the 
pathogenesis of this disease.  
 Compared to IL-6, a large excess of sIL-6R was found in serum of patients with 
inflammatory bowel disease (Mitsuyama et al., 1995). Circulating sIL-6R levels were 
increased, in excess of IL-6, in active Crohn’s disease compared to patients who were 
in remission; more interestingly, expression of sgp130 was decreased in patients with 
active disease compared to patients in remission or healthy controls (Gustot et al., 
2005). The authors also found a significant decrease of sgp130 concentrations in 
patients with active ulcerative colitis. Taken together, these results suggest an 
alteration of the balance of the IL-6 system towards a pro trans-signalling phenotype in 
inflammatory bowel disease. Delayed apoptosis of T-cells in Crohn’s disease was 
reversed by sgp130, confirming the role of IL-6 trans-signalling in the pathogenesis of 
this disease (Atreya et al., 2000).  
 In the lungs, IL-6 trans-signalling has been reported in the context of asthma. 
An imbalance in the T-helper 1 (Th1) and Th2 subtypes of CD4+ T-cells has been 
implicated in the pathogenesis of bronchial asthma (Neurath et al., 2002) and IL-6 
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seems to shift the balance towards Th2 polarisation of naïve CD4+ T-cells (Diehl and 
Rincon, 2002). Serum levels of sIL-6R was increased in asymptomatic patients with 
asthma and even more so during an acute attack, although corresponding IL-6 or 
sgp130 levels were not reported in this study (Yokoyama et al., 1997). Localised 
concentration of sIL-6R from BALF samples was significantly higher in asthmatic 
subjects compared to normal controls at baseline and after allergic challenge (Doganci 
et al., 2005), although corresponding IL-6 or sgp130 concentrations were not reported 
by the authors. Historical data of BALF IL-6 levels (measured functionally in a cell-based 
assay) from a separate study (Broide et al., 1992) would suggest a moderate excess of 
sIL-6R as measured by Doganci and colleagues (Doganci et al., 2005). However, using a 
murine model of asthma, the latter authors (Doganci et al., 2005) demonstrated that 
specific blockade of IL-6 trans-signalling by using sgp130 resulted in down-regulation of 
Th2 type cytokines (IL-4, IL-5 and IL-13) and up-regulation of Th1 phenotype. In an ex 
vivo culture system, IL-6 trans-signalling was found to have a profound impact on the 
airway remodelling phenotype by smooth muscle cells, another long-term 
consequence of atopic asthma (Ammit et al., 2007).  
 The other player in this trio, sgp130, was significantly higher in the CLD group 
of human infants. As noted earlier, few studies have reported concurrent 
concentrations of all three molecules in a localised site of inflammation. The normal 
serum level of sgp130 has been reported to be around 390 ng/ml (Narazaki et al., 
1993) while that of sIL-6R has been reported around 30 ng/ml (Horiuchi et al., 1998, 
Keul et al., 1998). This suggest a >10-fold (mass) excess of sgp130 normally exists in 
human serum. Whether similar values are present during systemic or localised 
inflammation is not yet clear. In Crohn’s disease, where IL-6 trans-signalling has been 
implicated in disease pathogenesis, the (mass) ratio of sgp130/sIL-6R increased from 
5.7 in patients in remission to 9.6 in patients active disease, due to both a decrease in 
sIL-6R and an increase in sgp130 concentrations.  
In summary of the previous data, IL-6 trans-signalling has been implicated in 
several localised diseases (with or without systemic involvement), although concurrent 
measurement of all the three molecules has not been routinely reported. An excess of 
sIL-6R seems to be necessary for driving the balance towards trans-signalling, as 
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demonstrated in the joints of arthritis patients. IL-6 trans-signalling is effectively 
inhibited by an excess of sgp130.  
In our cohort of 10 preterm baboons, I have observed a significant decrease in 
the agonistic ratio (sIL-6R/IL-6) at day 6-7 which persisted until day 10-11 before 
increasing again at day 14. This would suggest a decrease in trans-signalling potential. 
During the same time period, the antagonistic ratio (sgp130/sIL-6R) reached a peak on 
day 6-7, again suggesting a decrease in trans-signalling potential. Indeed, a significant 
increase in IL-8 concentration was observed between day 6-7 and day 10-11, which 
could be due to a lack of IL-6 trans-signalling effects. However, a firm conclusion 
cannot be drawn as the regulation of chemokines by IL-6 trans-signalling is complex, as 
also many other factors can regulate IL-8 expression. In my cohort of preterm human 
infants, there were no significant differences noted in the peak IL-6 or sIL-6R levels in 
BALF between CLD and No CLD infants, although a trend towards higher values in CLD 
was observed. Analysis of the peak molar ratio of sIL-6R/IL-6 showed an modest excess 
of sIL-6R compared to IL-6 in CLD infants (median ratio 2.489) but not in No CLD infants 
(median ratio 1.014). 
As the potential for IL-6 trans-signalling is determined by the relative 
expression of the two molecules, I compared the expression of the agonistic ratio (sIL-
6R/IL-6) to that of the antagonistic ratio (sgp130/sIL-6R). The medians of the 
antagonistic ratio in the preterm baboons was in excess of the agonistic ratio at all the 
measured time-points (184.4 fold on day 1, 86.9 fold on day 3, 646.7 fold on day 6-7, 
411.1 fold on day 10-11 and 252.4 fold on day 14), largely due to the excess of sgp130 
in the lungs. The ratio of sgp130/sIL-6R in the preterm human infants was about 8-fold 
more in the No CLD group and 13-fold more in the CLD group. In the study by von 
Bismarck (von Bismarck et al., 2008b), although sIL-6R was in modest excess of IL-6, 
there was a 20-fold excess in the relative concentration of sgp130 (sgp130/sIL-6R) in 
both group of infants at both time-points (these were calculated from reported mean 
values of individual cytokines). Inferring from the current knowledge, this would seem 
to be inadequate to favour IL-6 trans-signalling in the preterm infant lung.  
Since a large excess of sgp130 can completely abrogate the effects of the sIL-
6R/IL-6 complex (Gaillard et al., 1999), this supports my hypothesis that there is 
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potentially a lack of functional IL-6  trans-signalling in the preterm ventilated lungs. 
The strategy of using a large excess of sgp130 to block IL-6 trans-signalling has been 
successful in several disease models (Nowell et al., 2003, Doganci et al., 2005, Atreya 
et al., 2000). Recently this approach has been found to be useful in a model of lung 
inflammation by Chlamydophila pneumoniae as well (Rodriguez et al., 2010), although 
the recovery of sgp130 from the lungs was not reported.  
In summary, the relative excess of sgp130 in the preterm ventilated lung could 
have a profound effect on IL-6 trans-signalling activity. This excess was evident in both 
the preterm baboons & human infants, and appropriate functional activity assays 
would be needed to confirm this hypothesis.  
 
 
3.15.7. Expression of DS sIL-6R 
Two different cDNAs for IL-6R have been generated from cell-lines expressing 
membrane IL-6R by PCR (Lust et al., 1992, Oh et al., 1996). This finding was confirmed 
when the protein was detected in cell-culture supernatants (Horiuchi et al., 1994b). A 
monoclonal antibody was raised to detect the 10 unique amino acids in DS sIL-6R and 
an ELISA to specifically detect this isoform was described (Horiuchi et al., 1998). The 
authors also found an inverse relationship of DS sIL-6R and age, with the highest 
concentrations found in younger age groups. On an average, about 15% of the total 
sIL-6R in circulation in healthy individuals was found to be the DS isoform. Based on 
this observation, it has been suggested that the concentration of DS sIL-6R in the 
neonatal population could be higher that that in adults (Prof Simon Jones, personal 
communication). Also, the concentration of DS sIL-6R in a localised site of 
inflammation has not been studied before. Data from my cohort demonstrates that 
only a minor proportion of the sIL-6R present in the preterm lung was the splice 
variant, with the majority represented by the proteolytic cleaved form. Also, the splice 
variant seemed to be a minor proportion of the total sIL-6R in the term newborn 
circulation. Interestingly, the total sIL-6R in term newborn cord-blood was comparable 
to levels in the adult control population. 
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3.16. Summary of Chapter 
I have described in detail the expression of IL-6, sIL-6R and sgp130, in the 
preterm lungs, both in a controlled primate model of preterm ventilation and in 
preterm human infants, with relation to some key inflammatory markers. The primary 
finding from this part of the study is the high levels of sgp130 noted in the preterm 
ventilated lung, and its excess in relation to IL-6 or sIL-6R. This makes me speculate 
that sgp130 could have a profound influence on IL-6 trans-signalling in the preterm 
lung and leads me on to the next part of my project involving functional activity of IL-6 
in the preterm lung.   
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4. Functional Activity of IL-6 in the Preterm 
Ventilated Lungs 
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4.1. Overview 
 
So far, I have analysed the concentration of IL-6 and its soluble receptor 
isoforms, sIL-6R and sgp130 in the preterm lungs in an animal models and in human 
infants. My analysis suggested that the concentration of sgp130 in significantly raised 
during ventilation of the preterm lungs. Since sgp130 is a specific inhibitor of IL-6 
trans-signalling, raised concentrations of this molecule can have a profound impact on 
the functional activity of IL-6 in the preterm lung. As antigenic concentration cannot 
predict functional activity, I proceeded to measure functional activity in a cell based 
bioassay. 
B9 cells are a mouse pre-B cell hybridoma which are IL-6 dependent for 
proliferation (Aarden et al., 1987a). They have been used by several investigators as a 
sensitive bioassay for IL-6 (Nordan et al., 2001a). Previously, these cells have been 
reported to be insensitive to several other cytokines (Helle et al., 1988b) apart from IL-
6. The concentration of IL-6 needed to stimulate these cells to proliferate is in the low 
pg/ml range (Peters et al., 1996, Helle et al., 1988b). This makes the B9 cells an ideal 
cell-line to measure IL-6 bioactivity from clinical samples. The other major cell-based 
functional assay for IL-6 trans-signalling is the BAF/3 cells which require 100 – 1000 
fold more concentration of cytokines for proliferation, making this an unsuitable 
model for use with clinical samples, particularly low-volume samples like preterm BALF 
which precludes any possible concentration steps. 
To model IL-6 trans-signalling in the B9 cells, a synthetic protein, consisting of 
covalently linked human IL-6 with sIL-6R, was used (Fischer et al., 1997). This protein, 
called hyper IL-6 (HIL-6), is able to efficiently engage with cell-membrane gp130 and 
initiate intra-cellular signalling. Importantly, the IL-6R binding site of IL-6 is already 
occupied in this molecule, making it unable to initiate cis signalling (through the 
membrane-bound IL-6 receptor). This is also a stable molecule and not subject to 
dissociation as the natural complex is, making it an ideal choice for modelling trans-
signalling. Thus, HIL-6 was chosen to be used as a positive control of a specific agonist 
of IL-6 trans-signalling. 
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4.2. Overall hypothesis and aims of the project 
 
In the previous section, I have described observational data on the expression 
of IL-6 trans-signalling molecules in lung fluid collected from preterm ventilated 
baboons and human infants. My analysis shows a significant increase in the 
concentration of sgp130, a specific inhibitor of IL-6 trans-signalling, in the lungs of 
preterm baboons and human infants who later develop CLD. This observation leads to 
the hypothesis that there is possible abrogation of the IL-6 trans-signalling pathway in 
the lungs of these infants, this in turn providing a possible explanation for the poorly-
resolved neutrophil-driven inflammation noted in the lungs of these infants.  
The specific aims of this part of the project were: 
 To establish a sensitive and specific bioassay for IL-6 (using the B9 cells-line). 
 To modify the assay appropriately for measuring IL-6 trans-signalling activity. 
 To measure total IL-6 activity and IL-6 trans-signalling activity in BALF samples 
from ventilated preterm infants. 
 To compare differences in activity between the two groups of infants, CLD and 
No CLD. 
 
 
4.3. Sensitivity of B9 cells to IL-6 cis-signalling 
 
As reported previously (Nordan et al., 2001a), the B9 cells were highly sensitive 
to rhIL-6 and started to proliferate at concentrations of 0.1 pg/ml of IL-6 (figure 4.1). 
Half-maximal proliferation was noted at around 2-4 pg/ml and maximal proliferation at 
around 10-12 pg/ml.  
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Figure 4-1: Representative dose response curve of B9 cells to rhIL-6. Concentration of 
IL-6 (pg/ml) is represented on the x-axis while B9 cell proliferation (absorbance at 490 
nm) is represented on the y-axis. Points plotted are means (± SEM) of at least three 
independent experiments. 
 
All of this proliferative activity was completely inhibited in the presence of anti 
human IL-6 monoclonal antibody (figure 4.2). For all future experiments, a 
concentration of 10 ng/ml of the antibody was used to ensure complete inhibition of 
all IL-6 activity. 
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Figure 4-2: Inhibition of B9 cell proliferation in the presence of anti human IL-6 
monoclonal antibody. Conditions (with respective concentrations) are represented on 
the x-axis while B9 cell proliferation (optical density at 490 nm) in represented on the 
y-axis. Bars represent means (±SEM) of three independent experiments. Significance 
was tested by one-way ANOVA with Dunnets post-test (comparing with control column 
– “no IL-6”. (MAb = monoclonal antibody, *** = p < 0.0001). 
 
    
4.4. Specificity of B9 cells to IL-6 
 
B9 cells are reported to be unresponsive to a variety of human cytokines, either 
alone or in combination with human IL-6 (Helle et al., 1988b). In order to confirm this 
observation, I stimulated the B9 cells with cytokines (IL-1β, TNF-α, IL-4) and phlogistic 
stimuli of microbial origin (LPS), molecules which are expected to be present at sites of 
inflammation. Apart from IL-6 (at 5 pg/ml), none of the molecules resulted in any 
increase in proliferation of cells compared to background (cells without IL-6, fig 4.3).  
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Figure 4-3: Specificity of B-9 cells. Proliferation of B9 cells (represented as absorbance 
readings on the y-axis) in response to different cytokines and infective agents (with 
doses, represented on the x-axis). Bars represent means (±SEM) of three independent 
experiments. Significance was tested by one-way ANOVA with Dunnets post-test 
(comparing with control column – “no IL-6”). (*** = p < 0.0001). 
 
 
4.5. Sensitivity of B9 cells to IL-6 trans-signalling 
 
While the response of B9 cells to IL-6 is well characterised (cis-signalling), their 
response to IL-6 trans-signalling is not known. To test this, I used the synthetic 
molecule hyper IL-6 (Fischer et al., 1997) which is a covalently linked compound of IL-6 
and sIL-6R. This molecule is only capable of intra-cellular signalling through the gp130 
receptor-subunit. As the IL-6R binding site on HIL-6 is taken up by the sIL-6R molecule, 
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hyper IL-6 shows no activity towards the membrane-bound IL-6 receptor, thus lacking 
any IL-6 cis-signalling activity.  
Stimulation of B9 cells with HIL-6 resulted in significant increase in proliferation 
of cells in a dose-dependent manner (fig 4.4). Maximum proliferation was observed at 
a concentration of 4 – 8 pg/ml with half-maximal proliferation at a concentration of 
around 0.5 – 1.0 pg/ml. Thus, the B9 cells were equally sensitive to IL-6 trans-
signalling. 
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Figure 4-4: Sensitivity of B9 cells to IL-6 trans-signalling. Concentration of HIL-6 (pg/ml) 
is represented on the x-axis (log-scale) while proliferation of cells is represented on the 
y-axis. Interrupted line represents background proliferation of cells (no HIL-6). Points 
plotted are means (±SEM) of three independent experiments.  
 
 
4.6. Modifications of the assay to measure IL-6 trans-signalling 
 
To measure specific trans-signalling activity in clinical samples, I chose a 
strategy to selectively inhibit cis-signalling. This was achieved by blocking the mouse IL-
6R present on B9 cells with monoclonal antibodies. As shown in the schematic below 
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(fig 4.5), effective blocking of the IL-6R with an appropriate monoclonal antibody (blue) 
would abrogate intra-cellular responses (marked as red crosses) due to IL-6 cis-
signalling; however, the gp130 molecule would be free to attach with a complex of sIL-
6R/IL-6 to initiate IL-6 trans-signalling.  
(a)       (b) 
              
Figure 4-5: Schematic representation of modification of the B9 cell assay to measure 
IL-6 trans-signalling in clinical samples. (a) Anti-mouse monoclonal IL-6R antibody is 
represented in blue (MAb) which results in blocking of membrane-bound IL-6R, 
resulting in inhibition of IL-6 cis-signalling. (b) The gp130 molecule remains free for IL-6 
trans-signalling. A complex of sIL-6R/IL-6 can bind to gp130 and initiate intra-cellular 
signalling. (Modified from Jones SA et al, J Interferon Cytokine Res, 2005 
May;25(5):241-53) 
 
Initially, a commercial anti-mouse IL-6R monoclonal antibody clone 15A7 
(Coulie et al., 1990) was used for the purpose (Biolegend). As shown in fig 4.6 a and b, 
suppression of cell proliferation by the 15A7 antibody, in the presence of IL-6 at a 
concentration of 5 pg/ml, started at concentration of antibody above 40 ng/ml and 
complete suppression (to background levels, “no IL-6”) was achieved at a 
concentration around 2.5 μg/ml. Thus, by using this strategy, I could specifically block 
all cis-signalling in the B9 cells while leaving the gp130 sub-unit free for trans-
signalling. 
 
MAb 
Human IL-6 Human sIL-6R 
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Figure 4-6: (a) Dose-response of 15A7 antibody. Concentration of antibody (pg/ml) is 
represented on the x-axis (log scale) while proliferation of cells, expressed as a fold 
change from IL-6 at a concentration of 5 pg/ml, is represented on the y-axis. The upper 
dotted line represents proliferation of cells in the presence of IL-6 at a concentration of 
5 pg/ml (no antibody) and the lower dotted line represents cell-proliferation in the 
absence of IL-6. Points plotted are means (±SEM) of three independent experiments. 
(b) Inhibition of B9 cell proliferation in the presence of 15A7 antibody. Conditions (with 
respective concentrations) are represented on the x-axis while B9 cell proliferation, 
expressed as a fold change from IL-6 at a concentration of 5 pg/ml, is represented on 
the y-axis. Bars represent means (±SEM) of three independent experiments. 
Significance was tested by one-way ANOVA with Dunnets post-test (comparing with 
control column – “no IL-6”). (*** = p < 0.0001). 
 
The possibility of anti-mouse sIL-6R antibody binding to and inhibiting the 
human sIL-6R in the clinical samples of BALF, leading to spurious results was 
considered. Before proceeding to measure trans-signalling, I conducted experiments to 
confirm that the anti-mouse IL-6R antibody would not cross-react with human sIL-6R. 
To test this, a direct ELISA was designed whereby human and mouse sIL-6R were 
plated onto 96-well plates and tested for binding with the 15A7 antibody. As shown in 
figure 4.7, 15A7 antibody did not bind to rhIL-6; however, there was significant binding 
to both mouse and human sIL-6R (p < 0.0001 compared to no antigen). Indeed, the 
15A7 antibody seemed to bind to recombinant human sIL-6R more avidly than to 
recombinant mouse sIL-6R (p < 0.05) when the two were compared. These results 
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suggested to me that there could be significant cross-reactivity between the 15A7 
antibody and human sIL-6R (in the BALF samples) which could result in inhibition of IL-
6 trans-signalling in the B9 assay. 
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Figure 4-7: Cross-reaction of 15A7 antibody with human sIL-6R. Antigens (recombinant 
mouse sIL-6R in green, recombinant human sIL-6R in red, recombinant human IL-6 in 
blue and negative control in yellow) are depicted on the x-axis while absorbance values 
at 450 – 570 nm are represented on the y-axis. Bars are means (± SEM) of two 
independent experiments. Significance was tested by one-way ANOVA with Dunnets 
post-test (comparing with control column – “no antigen”. (*** = p < 0.0001; # = p < 
0.05). 
 
I next searched for another appropriate anti-mouse IL-6R monoclonal antibody 
in order to avoid inter-species cross-reaction, but none were available commercially. A 
personal enquiry from Dr Simon Jones at Cardiff University identified another clone of 
anti-mouse IL-6R monoclonal antibody called 2B10 (Greenhill et al., 2011, Lissilaa et al., 
2010) which did not cross-react with the human molecule. I obtained sufficient 
quantities of this antibody as a generous gift from NovImmune (Geneva, Switzerland), 
the company who had developed this antibody (not commercially available).  
The 2B10 antibody resulted in dose-dependent inhibition of B9 cell 
proliferation. Similar to the 15A7 clone, inhibition started at a concentration of 40 
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ng/ml and above (fig 4.8). Complete inhibition (down to background levels – “no IL-6”) 
was achieved at around 1.25 μg/ml, which was lower than that required for the 15A7 
clone. To ensure complete inhibition of B9 cell proliferation, the 2B10 antibody was 
used at a concentration of 2.5 μg/ml in all future experiments. 
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Figure 4-8: (a) Dose-response of 2B10 antibody. Concentration of antibody (pg/ml) is 
represented on the x-axis (log scale) while proliferation of cells, expressed as a fold 
change from IL-6 at a concentration of 5 pg/ml, is represented on the y-axis. The upper 
dotted line represents proliferation of cells in the presence of IL-6 at a concentration of 
5 pg/ml (no antibody) and the lower dotted line represents cell-proliferation in the 
absence of IL-6. Points plotted are means (±SEM) of three independent experiments. 
(b) Inhibition of B9 cell proliferation in the presence of 2B10 antibody. Conditions (with 
respective concentrations) are represented on the x-axis while B9 cell proliferation, 
expressed as a fold change from IL-6 at a concentration of 5 pg/ml, is represented on 
the y-axis. Bars represent means (±SEM) of three independent experiments. 
Significance was tested by one-way ANOVA with Dunnets post-test (comparing with 
control column – “no IL-6”). (*** = p < 0.0001; * = p < 0.05). 
 
I next considered the possibility of cross-reaction of the 2B10 antibody with the 
human sIL-6R (in the BALF samples). This was initially tested in the same direct ELISA as 
for the 15A7 antibody previously. The 2B10 antibody demonstrated significant binding 
with the recombinant mouse sIL-6R (fig 4.9). The absorbance values for a 
concentration of rm sIL-6R of 500 ng/ml was beyond the upper limit of detection, and 
only at concentrations of below 31.25 ng/ml was this within the range of detection; 
this was significantly higher than the negative control (p < 0.0001 compared to “no 
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antigen). When tested against rh sIL-6R coated at 500 ng/ml, 2B10 did not exhibit 
statistically significant binding, although the signal was higher compared to rh IL-6 or 
no antigen. This may reflect the 10-fold increased concentration of rh sIL-6R compared 
to rh IL-6. There was also a significant difference in binding of the 2B10 antibody with 
recombinant mouse (rm) sIL-6R and rh sIL-6R (p < 0.05).  
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Figure 4-9: Testing cross-reaction of 2B10 antibody with human sIL-6R. Antigens 
(recombinant mouse sIL-6R in green, recombinant human sIL-6R in red, recombinant 
human IL-6 in blue and negative control in yellow) are depicted on the x-axis while 
absorbance values at 450 – 570 nm are represented on the y-axis. Bars are means (± 
SEM) of two independent experiments. Significance was tested by one-way ANOVA 
with Dunnets post-test (comparing with control column – “no antigen”. (*** = p < 
0.0001; # = p < 0.05). 
 
I next tested this further in an activity assay using synovial fibroblast cells from 
rheumatoid arthritis patients. These cells do not express IL-6R on the cell-membrane 
but can respond to IL-6 trans-signalling (via cell-surface gp130) to selectively express 
MCP-1 (Nowell et al., 2003). Cells were a generous donation from Dr Mari Nowell at 
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Cardiff University. As expected, the cells did not respond to rh IL-6 but a combination 
of rh IL-6 with rh sIL-6R (complexed by pre-mixing at room temperature for 30 
minutes) resulted in a dose-dependent increase in expression of MCP-1. Hyper IL-6, a 
specific agonist of trans-signalling, also resulted in a significant increase of expression 
of MCP-1. More importantly, this effect was preserved in the presence of the 2B10 
antibody, suggesting that there was no significant binding or inhibition of the human 
sIL-6R by the antibody. No significant differences were observed in the expression of 
MCP-1 under different conditions of stimulation either in the presence or absence of 
the 2B10 antibody.  
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Figure 4-10: Testing cross-reaction of 2B10 antibody with human sIL-6R in RASF cells. 
Stimulations (presence = +, absence = -) are represented on the x-axis (with doses 
when appropriate) below each bar and expression of MCP-1 in the supernatant (pg/ml) 
is represented on the y-axis. Negative controls are depicted by yellow bars, complex of 
sIL-6R/IL-6 in the absence of 2B10 antibody is depicted by red bars and by green bars 
in the presence of 2B10 antibody. Stimulation with HIL-6 is depicted by the blue bars. 
Bars represent means (± SEM) of three independent experiments. Significance was 
tested by one-way ANOVA with Dunnets post-test (comparing with control column – 
“media”. (*** = p < 0.001;** = p < 0.01; * = p < 0.05). 
To show that the 2B10 antibody does not affect trans-signalling in the B9 cell 
assay, the proliferation of cells in response to HIL-6 was tested, both in the presence 
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and absence of 2B10 antibody. As shown in figure 4.11, no significant difference in 
proliferation of cells to HIL-6 was observed when cell surface mIL-6R was blocked with 
the 2B10 antibody. Thus, proliferation of cells in the presence of 2B10 antibody was 
considered to be due to IL-6 trans-signalling. 
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 Figure 4-11: IL-6 trans-signalling in the presence of 2B10 antibody. 
Concentration of HIL-6 (pg/ml) is represented on the x-axis (log-scale) while 
proliferation of cells (absorbance at 490 nm) is represented on the y-axis. Red circles 
and green squares depict proliferation in the absence or presence of 2B10 antibody 
respectively. Points plotted are means (± SEM) of three independent experiments.   
 
To confirm that the response to HIL-6 is indeed due to trans-signalling 
responses, I observed the proliferation of cells with HIL-6 in the presence of sgp130, a 
specific inhibitor of IL-6 trans-signalling. For these experiments, a chimeric protein of 
sgp130 linked to the Fc portion of IgG (Jostock et al., 2001b) was used as a specific 
inhibitor. These experiments were conducted in the presence of 2B10 antibody at a 
concentration of 2.5 μg/ml. As shown in figure 4.12, sgp130Fc inhibited B9 cell 
proliferation (in response to HIL-6 at a concentration of 4 pg/ml) in a dose-dependent 
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manner. Inhibition started at a concentration above 40 pg/ml of sgp130Fc (sgp130Fc: 
HIL-6 = 10:1) and complete inhibition was observed at around 4000 pg/ml of sgp130Fc 
(sgp130Fc: HIL-6 = 1000:1). These results confirmed that the proliferation of B9 cells in 
response to HIL-6 was indeed due to IL-6 trans-signalling as it could be completely 
inhibited by the specific inhibitor sgp130Fc.  
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Figure 4-12: Dose-response of sgp130Fc. Concentration of sgp130Fc (pg/ml) is 
represented on the x-axis (log scale) while proliferation of cells, expressed as a fold 
change from HIL-6 at a concentration of 4 pg/ml, is represented on the y-axis. The 
upper dotted line represents proliferation of cells in the presence of HIL-6 at a 
concentration of 4 pg/ml (no sgp130Fc) and the lower dotted line represents cell-
proliferation in the absence of HIL-6. All cells were exposed to 2.5 μg/ml of 2B10 
antibody for 30 minutes at 37°C before stimulation. HIL-6 and sgp130Fc were pre-
incubated together for 30 minutes at room temperature before adding to cells. Points 
plotted are means (±SEM) of three independent experiments. 
4.7. IL-6 functional activity in preterm BALF 
 
So far, I have shown that the B9 cells can be used as a sensitive and specific 
assay for IL-6 functional activity. I have also modified the assay in order to be able to 
measure specific trans-signalling activity. I next proceeded to measure IL-6 activity in 
preterm BALF. 
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During initial experiments with BALF, I observed that the functional activity of 
IL-6, as measured in the assay, was consistently greater that the estimated 
concentration of IL-6 in the BALF sample. As the active range of the assay (in terms of 
IL-6 concentration) was narrow, all future experiments were conducted after diluting 
the BALF samples to an estimated IL-6 concentration of 2 pg/ml (based on ELISA 
values) to keep the activity in the range of the assay. By using a constant concentration 
of IL-6 in all the BALF samples, similar proliferation of B9 cells would be expected; thus, 
any changes in proliferation could be attributed to differences in concentration of the 
trans-signalling molecules. Consequently, all activity is expressed as a fold-change in 
proliferation of B9 cells as compared to rh IL-6 at a concentration of 2 pg/ml. 24 
random samples of BALF from each group (CLD and RDS) were chosen to measure 
functional activity. 
Figure 4.13 shows a panel of controls which were run alongside each 
experiment. There was a predictable dose response in proliferation of B9 cells to 
increasing doses of IL-6 up to a concentration of 8 pg/ml. As shown in figure 4.1, the 
limit of the assay (maximal B9 cell proliferation) was reached at a concentration of 10 
pg/ml; thus for these experiments, I chose to use IL-6 at a maximum concentration 8 
pg/ml to stay within the range of the assay. IL-6 at a concentration of 8 pg/ml was used 
as a positive control for cis- and trans-signalling, to demonstrate that at this 
concentration, both anti-IL-6 antibody at a concentration of 10 ng/ml and 2B10 
antibody (anti cis-signalling) at a concentration of 2.5 μg/ml inhibits proliferation of 
cells to background levels (“no IL-6”). No significant differences were noted in the 
proliferation of cells in the absence of IL-6 (first green bar in figure 4.13), in the 
presence of IL-6 at 8 pg/ml and anti human IL-6 monoclonal antibody (second red bar 
in figure 4.13), or in the presence of IL-6 at 8 pg/ml and 2B10 antibody (second yellow 
bar in figure 4.13). Similarly, no significant differences were observed in the 
proliferation of cells in the presence of IL-6 at a concentration of 8 pg/ml on its own 
and in the presence of the two isotype controls for the anti IL-6 and 2B10 antibodies. 
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 Figure 4-13: Panel of controls. Different conditions are represented on the x-
axis while proliferation of B9 cells (expressed as a fold change) is represented on the y-
axis. The green bars represent proliferation of B9 cells with or without IL-6 at different 
concentrations, red bars represent proliferation in the presence of anti human IL-6 
antibody and its isotype control, yellow bars represent proliferation in the presence of 
2B10 antibody and its isotype control, and the brown bar represents proliferation in 
the presence of HIL-6 at a concentration of 2 pg/ml and 2B10 antibody. Bars represent 
means (± SEM) of results of 4-5 independent experiments. Significance was tested by 
one-way ANOVA with Dunnets post-test (comparing with control column – IL-6 at 2 
pg/ml). (*** = p < 0.0001, * = p < 0.05) 
   
 
As shown in figure 4.14, total IL-6 activity was found to be about 2-fold greater 
than estimated from the ELISA concentrations. This increase in activity was observed 
equally in both groups and there was no significant difference in activity between the 
RDS or CLD groups. All of this functional activity was IL-6 dependent as it was inhibited 
140 
 
to background levels (“no IL-6”) in the presence of an anti-human IL-6 monoclonal 
antibody, again equally in both groups. When BALF was added to cells which had been 
exposed to 2B10 antibody (to block IL-6 cis-signalling), no increase in proliferation of 
cells was noted above background levels. Thus no specific IL-6 trans-signalling activity 
was noted in any of the BALF samples from the No CLD and CLD groups of ventilated 
preterm infants.  
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Figure 4-14: IL-6 functional activity in preterm BALF. Orange bars represent a panel of 
controls (as in fig 4.14), blue bars represent activity in No CLD infants and green bars 
represent activity in CLD infants. Stimulations (and co-stimulations) are noted on the x-
axis while proliferation of B9 cells (expressed as a fold change) is represented on the y-
axis. Control bars represent means (± SEM) of at least 4 independent experiments and 
BALF bars (No CLD and CLD) represent means (± SEM) of two experiments with 24 
samples in each group, each sample analysed in triplicate in an experiment. 
Significance was tested by one-way ANOVA with Dunnets post-test (comparing with 
control column – IL-6 at 2 pg/ml). (*** = p < 0.0001)   
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4.8. IL-6 trans-signalling in B9 cells using recombinant molecules 
 
Although the B9 cells seemed to be competent to IL-6 trans-signalling, no 
specific trans-signalling activity was noted in the presence of preterm BALF samples. 
One of the reasons for this observation could be the insensitivity of the cells to the 
natural complex (HIL-6 is a synthetic and stable complex and is more potent than the 
natural complex in vitro). To test whether the B9 cells do indeed respond to the 
natural complex, rh IL-6 at 5 pg/ml and rh sIL-6R at increasing concentrations, were 
premixed at room temperature for the natural complex to form before they were 
added to the B9 cells, both in the absence and presence of 2B10 antibody. As shown in 
figure 4.15, no increase in proliferation of cells were noted on addition of sIL-6R, even 
up to a 1000-fold excess compared to IL-6. These results suggested that, although the 
B9 cells are IL-6 trans-signalling competent, they did not seem to respond to the 
natural complex of sIL-6R/IL-6 at the concentrations used (within the range of the 
assay), although the biological activity of these molecules was validated in experiments 
described in RASF cells (figure 4.10), admittedly at significantly higher concentrations.  
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Figure 4-15: IL-6 trans-signalling with recombinant molecules. Effect of IL-6 (5 pg/ml) 
and different concentrations of sIL-6R in the absence (green bars) and presence (blue 
bars) of 2B10 antibody. Panel of controls with IL-6 (orange bars), HIL-6 and sIL-6R 
(yellow bars) are shown on the left. Bars are at means (± SEM) of at least 3 
independent experiments. Significance was tested by one-way ANOVA with Dunnets 
post-test comparing proliferation against IL-6 standard at 5 pg/ml. (*** = p < 0.001). 
Y13 is the isotype control for the 2B10 antibody.  
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4.9. Discussion 
  
4.9.1. Summary of Chapter 
In this part of my work, I have confirmed the sensitivity and specificity of the B9 
cell-line as an IL-6 bioassay. By modifying the assay to block IL-6 cis-signalling, I have 
also established that it is a sensitive assay for IL-6 trans-signalling. Stimulation of the 
cell with preterm ventilated BALF samples showed an increase in total IL-6 activity 
which was entirely IL-6 dependent. However, no specific trans-signalling activity was 
observed. Although the cells are trans-signalling competent, they were unresponsive 
to a complex of recombinant human IL-6 and sIL-6R (at the concentrations used). 
Further modifications of the assay would be necessary to measure IL-6 trans-signalling 
by the natural complex in clinical samples. 
 
4.9.2. The B9 cells as an IL-6 bioassay 
     B9 cells, a sub-clone of the B13.29 cell-line (Lansdorp et al., 1986), were chosen 
for their sensitivity to proliferation in the presence of IL-6 (Aarden et al., 1987b). Since 
their isolation, these cells have been used as an IL-6 bioassay due to their sensitivity to 
human IL-6 (Nordan et al., 2001b). These cells were found to be unresponsive to a 
wide variety of human cytokines (expected to be present at sites of inflammation), 
either alone or in combination with human IL-6 (Helle et al., 1988a) including IL-1, IL-
1, IL-2, IL-3, IL-4, GM-CSF and TNF-. The authors found that with the exception of 
murine IL-4, these cells responded only to IL-6. However, several reports since then 
have shown interference with this assay, some of which is conflicting. A synergistic 
effect of IL-2 and IL-6, but not IL-2 on its own, on the proliferation of these cells has 
been reported (Chirmule et al., 1991). The authors noted expression of IL-2R on the 
cell-surface in the presence of IL-6, which is normally not present. This was proposed 
as the most likely mechanism of the synergistic effect noted. However, the source 
species of the cytokines, or the actual concentrations used in the assay were not 
stated. This result was disputed by other authors (Morrissey et al., 1992) who used 
murine antigens in defined concentrations. Using rigorous methods, the authors did 
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not find increased expression of IL-2 receptors on the B9 cells and speculated that non-
specific staining of receptors by Chirmule et al may have contributed to this finding. 
Another report showed the interference of metals on this assay (Orupabo et al., 1992). 
Lead and cadmium were found to inhibit proliferation of the B9 cells which was 
reversible by increased concentration of IL-6. However, inhibition of proliferation by 
copper, cobalt and mercury were found to be irreversible. LPS from E. coli increased 
proliferation of the B9 cells in a dose-dependent manner, both on its own (> 40 ng/ml) 
and in the presence of IL-6 (Pedersen et al., 1995). The additive effect was noted at 
low concentration of IL-6 and disappeared at the higher concentrations, which 
presumably achieved maximal proliferation by itself. Similar results were reported by 
another group of researchers who showed proliferation of the B9 cells to “μg/ml” 
quantities of LPS obtained from Salmonella abortus. However, in an earlier report, LPS 
was not found to interfere with the B9 cell assay up to concentrations of 10 μg/ml 
(Soliman and Twigg, 1992). Purity of LPS may be a factor which could explain this 
discrepancy. I have not measured concentration of these factors in preterm BALF, 
which could possibly influence the assay, although notably all responses here were IL-6 
dependent. 
Among members of the IL-6 family, IL-11 (Burger and Gramatzki, 1993) and 
Oncostatin-M (Barton et al., 1994) stimulated proliferation of the B9 cells. However, 
the cells were reportedly 1000-fold less sensitive to both of these cytokines compared 
to IL-6 (Schwabe et al., 1996). Proliferation of B9 cells in the presence of other 
members of the IL-6 family has not been reported in the literature. 
Human TNF- and TGF- have been reported to have an inhibitory effect on B9 
cell proliferation, which could not be overcome by increasing concentrations of IL-6 
(Schwabe et al., 1996). I did not have matched TNF- or TGF- concentrations in my 
BALF samples; however, TNF- has been reported in low “pg/ml” concentrations in the 
lungs of ventilated preterm infants (Kazzi et al., 2008, Viscardi et al., 1997). Reported 
concentrations of TGF- in the preterm lung have been in the “ng/ml” range (Kotecha 
et al., 1996a). My BALF samples were diluted >100 fold to keep IL-6 concentrations 
within the range of the bioassay. Although an inhibitory effect of either of these 
cytokines cannot be ruled out, all BALF samples resulted in proliferation of B9 cells 
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suggesting the lack of any significant effect of the inhibitory cytokines in my assay. 
Other cytokines and infectious agents tested in my assay did not seen to affect the 
cells at the concentrations used. A sub-clone of the B9 cell-line, B9-11, has also been 
cultured which is very sensitive to IL-11 (Lu et al., 1994). Thus, other sub-clones may 
exist in the population of B9 cells which may be sensitive to a specific cytokine 
resulting in a proliferative response; this may be a possible explanation for the 
increase in functional activity noted in all my samples. The synergistic effect of two or 
more cytokines in a clinical sample also cannot be ruled out, although combinations of 
cytokines have not yet been shown to have such an effect on these cells (Helle et al., 
1988a, Schwabe et al., 1996). 
   
4.9.3. Modifications for trans-signalling 
In cells where both the cognate IL-6R and gp130 are expressed, as in the B9 
cells, both IL-6 cis- and trans-signalling are supported. In order to assess these affects, I 
used IL-6 on its own for the cis-signalling effect. To test ability for trans-signalling, I 
used a covalent complex of IL-6 with IL-6R called hyper IL-6 (Fischer et al., 1997). The 
receptor binding site of IL-6 in this complex is already occupied by the covalently linked 
sIL-6R, thus precluding any effect on the cell-surface IL-6R. My experiments 
demonstrated that the B9 cells are IL-6  trans-signalling competent. Cells proliferated 
in the presence of low concentrations of hyper IL-6 with half-maximal proliferation 
occurring at concentrations of 0.5 – 1.0 pg/ml (figure 4.4). That this was due to IL-6 
trans-signalling was demonstrated by inhibition of proliferation of the B9 cells when 
sgp130 Fc , a specific inhibitor of IL-6 trans-signalling, was premixed with H IL-6 (figure 
4.12).  
The exquisite sensitivity of the B9 cells to both IL-6 cis- and trans-signalling 
made this an ideal candidate assay to measure functional activity in clinical samples, 
where concentration of cytokines are low. If a complex clinical sample like preterm 
BALF, which contains free IL-6 as well as the complex of sIL-6R/IL-6, is used to 
stimulate these cells, then the resultant proliferation would be due to “total” IL-6 
functional activity. In order to understand the relative effects of cis- and trans-
signalling, I needed to block the effects of one of the pathways. My chosen strategy 
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was to inhibit the effects of IL-6 cis-signalling by blocking the cognate mouse IL-6R on 
the cells, but not affecting the function of human sIL-6R in the clinical samples. 
Although I chose monoclonal anti-mouse IL-6R antibodies, my first choice (clone 15A7) 
showed cross inhibition of the human sIL-6R as well (figure 4.7), making it an 
inappropriate molecule for my experimental system. The anti-mouse IL-6R monoclonal 
antibody 2B10 was generated by immunising Wistar rats with mouse IL-6R expressing 
CHO cells (Lissilaa et al., 2010, Greenhill et al., 2011). Using this molecule as a 
concentration of 1.25 μg/ml resulted in complete inhibition of B9 cell proliferation in 
response to IL-6 (blocks cis-signalling). The lack of cross-inhibition was demonstrated 
by two different experiments (figures 4.9 and 4.10). The 2B10 antibody did not 
interfere with the effects of IL-6 trans-signalling by H IL-6 (figure 4.11).  
 
4.9.4. IL-6 bio-activity in BALF 
Once I established the cis- and trans-signalling competence of the B9 cells, I 
proceeded to measure IL-6 functional activity in human preterm BALF. Observational 
work with the BALF samples showed me that, while the peak concentration of both IL-
6 and sIL-6R were comparable in both groups of infants, sgp130 was significantly 
higher in the CLD infants. My main aim was to measure total IL-6 functional activity in 
both groups of infants and then detect any effect in modification of functional activity 
due to the presence of the soluble receptors, mainly sgp130. In order to be able to 
assess this, I equalised the estimated concentration of IL-6 in all samples from both 
groups to 2 pg/ml, based on the ELISA concentration. The 2 pg/ml concentration was 
chosen to produce a sub-maximal proliferation of the cells, so that any enhancement 
or inhibition of proliferation would be detectable within the range of the assay. Thus, 
all functional activity in BALF was expressed as a fold-change in proliferation compared 
to an IL-6 standard of 2 pg/ml. Also, I hypothesised that since the concentration of IL-6 
was equivalent in both group of infants, any difference in proliferation between the 
groups could be attributed to a differences in concentration of the soluble receptors, 
mainly sgp130. 
A panel of controls used with each experiment confirmed previous results 
noted during the set-up stage of the assay. It also confirmed the modifications used to 
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model IL-6 trans-signalling in this cell-line. On stimulation with preterm BALF, a two-
fold increase in proliferation of cells was noted in both groups of infants; there were 
no statistically significant difference between the two groups. Complete inhibition of 
proliferation in the presence of anti-human IL-6 monoclonal antibody demonstrated 
that this proliferation was indeed IL-6 dependent. However, no significant proliferation 
of B9 cell was noted in the presence of the 2B10 antibody, suggesting a lack of any IL-6 
trans-signalling activity in the samples. When modelled with recombinant cytokines, a 
similar lack of proliferation of cells was noted to IL-6 trans-signalling.  
A two-fold increase in functional activity, compared to the expected, was noted 
in both groups of infants. Possible reasons could be proliferation of the cells in 
response to other members of the IL-6 cytokine family, such as IL-11 (Burger and 
Gramatzki, 1993) and oncostatin-M (Barton et al., 1994), although that seems unlikely 
as the B9 cells are a thousand-fold less sensitive to these cytokines compared to IL-6 
(Schwabe et al., 1996). A sub-clone of the B9 cell-line, B9-11, has also been cultured 
which is very sensitive to IL-11 (Lu et al., 1994). More sensitive sub-clones of the B9 
cells, if present, may be a possible explanation for the increase in functional activity 
noted in my samples. The synergistic effect of two or more cytokines in a clinical 
sample also cannot be ruled out, though combinations of cytokines have not yet been 
shown to have such an effect on these cells (Helle et al., 1988a, Schwabe et al., 1996). 
Overall, my data suggests that I have measured specific IL-6 bioactivity in BALF samples 
from preterm infants in a sensitive bioassay.  
Lack of IL-6 trans-signalling activity could be explained by several potential 
theories. Concentrations of IL-6 and sIL-6R were comparable in both groups of infants, 
while concentration of sgp130 was significantly higher in the CLD group of infants. 
However, within each group, concentration of sgp130 was in excess of sIL-6R 
concentration in all samples. Thus, it is possible that sgp130 may have bound to any 
sIL-6R/IL-6 complex formed in the sample, leading to lack of any significant activity. 
Also, after dilution of BALF for use in the assay, the concentration of both IL-6 and sIL-
6R were low in all samples. This may have prevented formation of any active complex, 
which has previously been shown to require much higher concentration of cytokines as 
well as an excess of sIL-6R in vitro (as discussed below).  
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The only other study looking at IL-6 functional activity in lung fluid from 
preterm ventilated infants was by Bagchi and colleagues. The authors reported higher 
IL-6 activity (6.6 fold) in CLD infants compared to RDS infants on the first day of life 
(Bagchi et al., 1994). There is a fundamental difference between their study and ours. 
While the study by Bagchi et al was to look at total IL-6 activity (modulation of IL-6 
activity by the soluble receptors was not known at that time), my study was designed 
to primarily determine modulation of IL-6 activity by the soluble receptors. Thus, IL-6 
concentration in my samples were all diluted to an estimated concentration of 2 
pg/ml. Apart from this, other significant differences also exist between the study by 
Bagchi et al  and ours. Their cohort of patients were recruited in the early 90s when 
surfactant replacement therapy was not as widespread as in my cohort. Indeed, only 
27% of patients in the RDS and 74% in the CLD groups received exogenous surfactant 
replacement (cf 100% of infants in my cohort received exogenous surfactant 
replacement). Differences also existed in clinical characteristics of infants in the two 
groups (incidence of preterm labour, route of delivery and incidence of PDA). The cell-
line used by the authors was also different from my cell-line. The difference in results 
could potentially be explained by a combination of these factors as mentioned above 
or this may simply reflect differences in the population under study, as it is well 
recognised that the pattern and severity of disease in this population has changed 
significantly over the past 10-20 years (Jobe, 1999). 
  
  
4.9.5. Other IL-6 trans-signalling assays 
The B9 cell assay for IL-6 functional activity is the most common one used 
(Nordan et al., 2001a). However, as this cell-line expresses membrane-bound IL-6R, it 
is unsuitable for measuring specific IL-6 trans-signalling activity without modification; 
my study has implemented appropriate modifications on these cells to achieve that. 
There is another cell-line which has been used by investigators as a model for specific 
IL-6 trans-signalling, called BAF-B03 cells. These are IL-3 dependent mouse pre-B cells, 
and only one of a few cell-types which does not express membrane-bound sgp130 
(Hibi et al., 1990). The cells are made IL-6 trans-signalling competent by stably 
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transfecting them with human gp130 cDNA and called BAF130-9 (Hibi et al., 1990, 
Gearing et al., 1994). The ability of these transfected cells to respond to IL-6 trans-
signalling was demonstrated in 1990 when they proliferated in the presence of a 
combination of IL-6 and sIL-6R (Hibi et al., 1990). However, it is notable that the 
concentration of IL-6 (2 – 200 ng/ml) and sIL-6R (5 μg/ml) used were supra-physiologic. 
A similarly strategy using transfected BAF-B03 cells were used to demonstrate 
proliferative response of these cells to other members of the IL-6 family (Gearing et al., 
1994). However, the most extensive use of this cell-line as a model for IL-6 trans-
signalling was by the German group led by Professor Stefan Rose-John (referred to as 
Ba/F3 cells by this group). In their report of the first description of hyper IL-6 (Fischer 
et al., 1997), they used the cells transfected with gp130 (Ba/F3-gp130) to demonstrate 
that HIL-6 was a functionally active complex capable of IL-6 trans-signalling. However, 
a difference in concentration of cytokines needed to have a proliferative effect was 
noted. While HIL-6, which is a stable complex of sIL-6R/IL-6, could achieve maximal 
proliferation of cells at a concentration of 1 ng/ml, a much higher concentration of IL-6 
(100 ng/ml) and sIL-6R (100 – 1000 ng/ml) was required to achieve comparable 
proliferation of the cells. This has been a consistent finding of the group in several 
subsequent papers exploring different aspects of the IL-6 trans-signalling pathway 
(Horsten et al., 1997, Muller-Newen et al., 1998, Garbers et al., 2011).  
The effect of IL-6 trans-signalling depends on the formation of the sIL-6R/IL-6 
complex. In clinical specimens containing a mixture of the cytokines IL-6, sIL-6R and 
sgp130, complex formation depends on the relative presence of the individual 
molecules. In in vitro binding experiments, investigators have explored the formation 
of the sIL-6R/IL-6 complex and free IL-6 concentration in mixtures of cytokines with 
varying relative concentrations (Muller-Newen et al., 1998, Gaillard et al., 1999). Based 
on various starting concentration of the cytokines and their equilibrium constants, the 
authors demonstrated that availability of free IL-6 is affected by sIL-6R concentrations 
only; availability of sIL-6R/IL-6 complex increases with sIL-6R concentration and 
decreases with sgp130 concentration. 
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Measured starting values (ng/ml) Calculated percentages (%) 
IL-6 sIL-6R sgp130 Free IL-6 sIL-6R/IL-6 
complex 10 100 0 34 66 
1 100 0 33 67 
0.1 100 0 32 68 
0.01 100 0 32 68 
     
10 100 400 32 30 
1 100 400 29 30 
0.1 100 400 29 30 
0.01 100 400 29 30 
     
10 200 400 18 42 
1 200 400 17 42 
0.1 200 400 17 42 
0.01 200 400 17 42 
     
10 1000 400 4.3 76 
1 1000 400 4.2 76 
0.1 1000 400 4.2 77 
0.01 1000 400 4.2 77 
     
10 100 4000 30 4.0 
1 100 4000 28 4.0 
0.1 100 4000 28 3.3 
0.01 100 4000 28 3.3 
     
10 1000 4000 3.7 9 
1 1000 4000 3.6 9 
0.1 1000 4000 3.6 9 
0.01 1000 4000 3.6 9 
  
Table 4-1: Availability of free IL-6 and sIL-6R/IL-6 complex in a mixture of cytokines 
[modified from (Gaillard et al., 1999)]  
 
In my cohort of infants, the peak mass concentration of IL-6 and sIL-6R was 
comparable in most samples. This meant that the molar concentration of sIL-6R was 
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lower or equivalent to that of IL-6 (figure 3.8a). Thus, based on the above table, we can 
predict that the majority of IL-6 in preterm BALF would be present as free IL-6 and the 
percentage of sIL-6/IL-6 would be minor. This could explain my observation in the 
functional assay where total IL-6 activity was observed in all samples but no IL-6 trans-
signalling activity was detected.  
The effect of sgp130 is complex, as measured by a functional assay. In my 
cohort, there was a molar excess of sgp130, compared to sIL-6R in all infants, 
regardless of the group they belonged to (figure 3.8b). Thus, any sIL-6R/IL-6 complex 
would be effectively bound to sgp130, precluding any functional trans-signalling 
activity. Recently, sgp130 has been shown to affect IL-6 classical signalling (Garbers et 
al., 2011); an excess of sIL-6R decreases free IL-6 and increases the sIL-6R/IL-6 complex 
which is bound by excess sgp130. However, free IL-6 is only affected by the 
concentration of sIL-6R, especially when it is in a significant excess. Thus, although 
sgp130 was significantly higher in the CLD infants, this did not have any effect on the 
functional assay as the proportion of the sIL-6R/IL-6 complexes in BALF was equivalent 
but minor in both groups, thus insufficient to have any effect at all. A sensitive and 
specific IL-6 trans-signalling assay (like B9 cells with membrane IL-6R expression 
knocked out) would be a more appropriate bioassay  to measure IL-6 trans-signalling in 
this situation.       
The reported effect of IL-6 trans-signalling by recombinant molecules in in vitro 
assays has been variable. A difference in potency between HIL-6 and IL-6/sIL-6R was 
noted by several investigators (Fischer et al., 1997, Garbers et al., 2011). Thus, HIL-6 
has been noted to have a much higher potency compared to the natural complex. A 
possible explanation for that could be the fact that HIL-6 is a stable molecule where IL-
6 is covalently bound to sIL-6R, whereas the natural complex of sIL-6R/IL-6 is dynamic. 
My experience with the B9-cell assay is similar, where low concentrations of HIL-6 was 
able to evoke proliferative responses but comparable doses of IL-6 (which can evoke 
cis-signalling responses) with large excesses of sIL-6R failed to do the same. Increasing 
the dose of IL-6 in the mixture resulted in “breakthrough” signalling, even in the 
presence of 2B10 antibody. Thus, the sensitivity of the assay to IL-6, which is an 
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attraction for clinical studies, also proved to be a drawback when attempting to elicit 
trans-signalling responses. 
 
 
4.10. Summary  
I have tested an existing sensitive and specific bio-assay for IL-6 and modified it 
to measure specific IL-6 trans-signalling activity by blocking the IL-6R with a 
monoclonal antibody. Using the assay, I demonstrated equivalent total IL-6 activity in 
BALF from CLD and no-CLD infants. However, no specific IL-6 trans-signalling activity 
could be elicited, probably due to the minor proportion of sIL-6R/IL-6 complexes in the 
samples. Using recombinant molecules, no IL-6 trans-signalling activity could be 
elicited, even in the presence of a large excess of sIL-6R, suggesting the lack of 
formation of a stable complex at the concentration of cytokines used. Further 
modifications of the assay, by using a strategy to knock-out IL-6R expression, may be 
beneficial in the future for measuring specific IL-6 trans-signalling activity in clinical 
samples.    
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5. Regulation of Interleukin-877 Expression and 
Function in the Lungs of Preterm Ventilated Infants 
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5.1. Overview and background  
 
Interleukin-8, a member of the CXC family of chemokines (CXCL8), is expressed 
in humans by a wide variety of cells (Remick, 2005). Due to variations in the number of 
amino acids (a.a.) at the amino-terminal end, several isoforms of IL-8 are expressed, of 
which the 72 a.a. isoform (IL-872), secreted mainly by immune cells, is the best 
characterised molecule. IL-877 is the major isoform expressed by non-immune cells. 
Functionally, IL-872 and other shorter isoforms are more potent than IL-877 in vitro and 
in vivo (Nourshargh et al., 1992, Mortier et al., 2011a).  
Recently, expression of IL-877 has been described in circulation in extremely 
premature infants, which was the predominant isoform at early gestational ages 
(Maheshwari et al., 2009). Although total IL-8 is significantly increased in concentration 
in the lungs of infants developing CLD, the concentration of IL-877 in the preterm lung 
or its proportion of the total IL-8 concentration is not known. As significant 
inflammation is detected in the lungs of preterm infants developing CLD, I 
hypothesised that the more potent shorter isoforms of IL-8 would predominate in the 
preterm lung. Understanding the expression of IL-877 and its processing in the preterm 
lung could lead to novel approaches in modulating lung inflammation in the preterm 
infants.  
 
5.2. Aims of the project 
 
 To determine the expression of total IL-8 and IL-877 in BALF from preterm 
ventilated infants. 
 To compare the expression of total IL-8 and IL-877 in infants who develop CLD 
with those who do not.   
 To determine the functional potential of BALF to convert IL-877 to shorter 
isoforms and identify possible proteases involved in the mechanisms of 
conversion.  
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 To determine the effect of proteases, potentially involved in the above 
conversion, on IL-877 in-vitro and determine the functional relevance of this 
conversion on PMNs.   
 
 
5.3. Modification and Validation of the IL-877 ELISA  
 
The IL-877 ELISA has been described before using a specific pair of capture (N11) 
and detection (H6) monoclonal antibodies (Nashkevich et al., 2002b). Using the same 
pair of antibodies, I first validated the ELISA in my laboratory. As shown in figure 5.1, 
the N11 monoclonal antibody, when used for capture, was specific for IL-877 and did 
not capture the shorter isoform IL-872.  
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Figure 5-1: Validation of the IL-877 ELISA. Plates were coated with N11 antibody and 
antigen was detected by H6 antibody. Concentration of the antigens IL-877 (green 
circles) and IL-872 (red squares) are represented on the x-axis (pg/ml) while absorbance 
at 450 nm (corrected at 570 nm) is represented on the y-axis. Points represent means 
(± SEM) of three independent experiments. Values were compared by two-way ANOVA 
with Boferroni's post-test. (*** = p < 0.001, * = p < 0.05) 
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To demonstrate that the commercial ELISA (BD OptEIA human IL-8 ELISA) 
captured both the antibodies (detects "total" IL-8), both IL-877 and IL-872 were 
individually tested in this assay. As shown in figure 5.2, the pair of capture and 
detection antibodies from the commercial kit detected both antigens equally at all 
concentrations in the range tested. The range of concentration was kept the same as 
for the previous experiment for easy comparison.  
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 Figure 5-2: Validation of the commercial ELISA. Plates were coated with BD 
capture antibody and detected with BD detection antibody. Concentration of the 
antigens IL-877 (green circles) and IL-872 (red squares) are represented on the x-axis 
(pg/ml) while absorbance at 450 nm (corrected at 570 nm) is represented on the y-
axis. Points represent means (± SEM) of three independent experiments. Values were 
compared by two-way ANOVA with Boferroni's post-test. 
 
Although the two ELISAs with their own pairs of antibodies performed as 
expected, the original IL-877 ELISA (with the N11 and H6 pair of antibodies) was found 
to be insensitive (low optical density values, "high" limit of sensitivity at 80 pg/ml). In 
an attempt to improve on this assay, an ELISA was designed with the two capture 
antibodies (N11 and BD capture), the BD detection antibody, and both the antigens 
were again tested. The N11 antibody specifically captured IL-877 which was detected by 
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the BD detection antibody (figure 5.3a). This also improved sensitivity as better optical 
density values were obtained and the limit of sensitivity was lower at 3.125 pg/ml (as 
with the commercial kit for total IL-8). The BD ELISA capture antibody detected IL-8 
isoforms with equal sensitivity in the assay (figure 5.3b). For all future IL-877 ELISAs, the 
pair of  N11 capture antibody and BD detection antibody was used.  
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Figure 5-3 : Modification of IL-877 ELISA. Antigens IL-877 (green circles) and IL-872 (red 
squares) were captured by (a) N11 and (b) BD capture antibody. Both were detected 
by the BD detection antibody. Concentration of the antigens are represented on the x-
axis (pg/ml) while absorbance at 450 nm (corrected at 570 nm) is represented on the 
y-axis. Points represent means (± SEM) of three independent experiments. Values 
were compared by two-way ANOVA with Boferroni's post-test. (*** = p < 0.001) 
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5.4.  Clinical characteristics of the patient cohort 
 
A total of 38 samples from 22 infants (11 No CLD and 11 CLD) were analysed for 
the study. Clinical characteristics of the two groups are shown in table 5.1. Apart from 
the number of ventilation-days, which was significantly higher in the CLD infants (p < 
0.01), the two groups were well matched for other clinical characteristics. 
 
 
Table 5-1: Patient and clinical characteristics. Values are medians with inter-quartile 
range (*) or  numbers of infants and percentage of total in group(^). 
 
 
 
 No CLD CLD p 
Total infants 11 11  
Total samples 13 25  
Gestational age (weeks)* 28+3 (27 – 29+4) 27+5 (25+4 – 29+2) 0.45 
Birth weight (g)* 1120 (960 – 1250) 905 (798.8 – 1120) 0.14 
Prolonged rupture of 
membranes (>24 hours)^ 
1 (10) 2 (22) 1.0 
Antenatal steroids (≥24 
hours)^ 
9 (82) 9 (82) 1.0 
Caesarean delivery^ 5 (45) 6 (55) 1.0 
Exogenous surfactant 
replacement^ 
11 (100) 11 (100) 1.0 
Mechanical ventilation-days* 1.0 (1.0 – 1.75) 6.5 (5.0 – 15.5) 0.004 
Patent ductus arteriosus^ 5 (45) 8 (73) 0.39 
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5.5. Expression of IL-877 in the preterm lung 
 
 IL-8 was detected in all 38 samples analysed but IL-877 was below the limit of 
detection in five samples (three CLD and two No CLD infants). Peak concentration of 
total IL-8 (table 5.2 and figure 5.4a, also figure 3.6c) was significantly higher in the CLD 
group compared to No CLD (p = 0.01), as has been consistently reported in the 
literature. Concentration of IL-877 (corresponding to the peak concentration of total IL-
8) was also significantly higher in the CLD group (table 5.2 and figure 5.4b; p = 0.03).  
 
 No CLD CLD 
Total IL-8 (pg/ml) 3401 (1587 - 19080) 175600 (7064 - 202700) 
IL-877 (pg/ml) 144.3 (83.6 - 552.6) 2353 (140.1 - 5668) 
IL-877 (percentage of total IL-
8) 
2.9 (1.28 - 5.27) 2.29 (1.49 - 3.02) 
 
Table 5-2: Expression of IL-8 and IL-877. Medians (IQR) of peak concentrations of total 
IL-8 (pg/ml) and corresponding IL-877 and percentage of total IL-8 expressed as IL-877 in 
preterm BALF from infants in the No CLD and CLD groups.   
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 Figure 5-4: Expression of IL-8 and IL-877 in preterm BALF. Concentration of (a) 
peak total IL-8 and (b) corresponding IL-877 in preterm BALF from infants in the No CLD 
group (red circles) and CLD group (green squares). Groups are represented on the x-
axis while concentration of protein (pg/ml) is represented on the y-axis (log scale). 
Each point represents peak value from a single infant and bars are at medians. (* = p < 
0.05)  
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 However, IL-877 was a minor proportion of the total IL-8 in the samples and 
there was no significant difference between the two groups (figure 5.5a, table 5.2). 
This was reflected by a significant correlation between the concentrations of total IL-8 
and IL-877 (r = 0.94, p < 0.0001, figure 5.5b).  
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 Figure 5-5: Proportion of IL-877. (a) Concentration of IL-877, expressed as a 
percentage of total IL-8 on the y-axis, in No CLD (red circles) and CLD (green squares) 
groups. Groups are represented on the x-axis while proportion of protein (percentage) 
is represented on the y-axis. Each point represents peak value from a single infant and 
bars are at medians. (b) Concentration of peak IL-8 (pg/ml) and corresponding 
concentration of IL-877 (pg/ml) are plotted on the x- and y-axis respectively. Each point 
represents a single infant and correlation was tested by calculating Spearman’s 
coefficient.  
 
 
The majority of IL-8 in preterm circulation is composed of IL-877, in contrast to 
term  or adult circulation and with maturity of the foetus, the expression of IL-8 
isoforms in circulation changes (Maheshwari et al., 2009). However, in preterm BALF, 
no significant correlation was observed between concentration of IL-877 (figure 5.6a) or 
the proportion of IL-8 expressed as IL-877 (figure 5.6b) in the preterm lungs with the 
birth-gestation of infants. For this analysis, only day 1 samples were chosen to reflect 
in-utero concentrations as closely as possible; 13 such samples were available for 
analysis.  
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 Figure 5-6: Gestation and IL-877 expression. Correlation of gestation at birth 
with (a) concentration of IL-877 and (b) percentage of IL-8 expressed as IL-877. Birth 
gestation of infants (weeks) is plotted on the x-axis while first day IL-877 concentration 
(pg/ml) or proportion of total IL-8 (percentage) in the preterm lung is plotted on the y-
axis. Each point represents a single infant and correlation was tested by calculating 
Spearman’s coefficient.  
 
 Thus, I have shown that IL-877 was expressed as a minor proportion of total IL-8 
in preterm BALF. Expression of IL-877 was significantly correlated to total IL-8 
concentration in the lung but not with the birth gestation. 
 
 
5.6. Expression of IL-877 from specific cell-types 
 
5.6.1. Expression in lung epithelial cells 
The majority of IL-8 in preterm BALF seemed to be the more potent shorter 
isoforms, as I had hypothesised on analysing the inflammatory profile. Two possible 
explanations for this observation could be: the low proportion of IL-877 could be due to 
a lack of expression in the lungs, or conversion into the shorter isoforms. Since non 
immune cells, including epithelial cells (Standiford et al., 1990, Arnold et al., 1994a, 
Leverence et al., 2011), are known to express IL-8 under experimental conditions, I first 
looked at the expression of the IL-877 isoform in lung epithelial cells.  
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Due to the difficulty in obtaining neonatal lung explants, I looked at expression 
of IL-877 in two adult lung cell-lines A549 (type II alveolar epithelial cells from 
adenocarcinoma) & BEAS-2B (bronchial epithelial cells), and also in primary adult 
small-airway epithelial cells (SAEC). Although unstimulated A549 cells expressed 
negligible IL-8, this increased 29-fold on stimulation, with 58% of it being IL-877 (figure 
5.7a and b, table 5.3). Unstimulated BEAS-2B cells expressed all of their IL-8 as IL-877; 
on stimulation, there was an 89-fold increase in expression of total IL-8, of which 
around 66% was IL-877. SAECs expressed 25% of their IL-8 as IL-877 in the absence of 
any stimulation; this increased to 56% on stimulation which also resulted in a 10-fold 
increase in expression of total IL-8. Thus, all lung epithelial cells tested expressed 
significant proportion of IL-8 as IL-877 in vitro under experimental conditions. 
A      B 
0
2000
4000
6000
8000
Total IL-8
IL-877
 U      S            U     S            U     S
A549         BEAS2b        SAEC
p
g
/m
l
A549 BEAS-2B SAEC
0
50
100
150
Unstimulated
Stimulated
IL
-8
7
7
p
e
rc
e
n
ta
g
e
(o
f 
to
ta
l 
IL
-8
)
 
Figure 5-7: Expression of IL-877 from airway epithelial cells. (a) Concentration (pg/ml) of 
total IL-8 (red bars) and IL-877 (green bars) from airway epithelial cells both 
unstimulated (U) and when stimulated (S) with IL-1. Cell-lines and incubation 
conditions are represented on the x-axis while concentration (pg/ml) is on the y-axis. 
(b) Proportion of total IL-8 (percentage) expressed as IL-877 from un-stimulated (grey 
bars) and stimulated (with IL-1) airway epithelial cells. Cells-lines with different 
conditions are represented on the x-axis while percentage of IL-877 is represented on 
the y-axis. All bars are means (± SEM) of three independent experiments.  
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Airway Epithelial 
Cells 
Un-stimulated Stimulated 
Total IL-8 (SEM) IL-877 (SEM) Total IL-8 (SEM) IL-877 (SEM) 
A549 19.0 (11.0) 15.6 (9.3) 548.1 (105.7) 319.3 (56.0) 
BEAS-2B 35.3 (7.5) 35.7 (3.0) 3138.0 (424.0) 2084.0 (162.0) 
SAEC 596.3 (267.8) 147.1 (44.2) 6037.0 (1399.0) 3358.0 (900.3)  
 
Table 5-3: Expression of IL-8 from airway epithelial cells. Concentration (pg/ml) of total 
IL-8 and IL-877 by airway epithelial cells, both un-stimulated and when stimulated with 
IL-1. Values are means (SEM) of at least three independent experiments.     
 
5.6.2. Expression in neonatal PMN and MNC 
Expression of IL-877 in adult monocytes (Lindley et al., 1988a, Yoshimura et al., 
1989a) and neutrophils (Bazzoni et al., 1991, Arnold et al., 1994b, Padrines et al., 
1994a) in varying proportions have been described previously. However, the 
proportion of IL-877 expressed by neonatal immune cells is not known. Since these cells 
are a major source of IL-8 and they are found in large numbers in BALF from preterm 
ventilated infants, I next looked at expression of IL-877 from neonatal PMNs and MNCs. 
To do so, cord blood from term infants born by elective Caesarean section for maternal 
non-medical causes (repeat section for previous section, breech presentation) was 
collected and experiments conducted on purified cell populations. Blood from preterm 
infants was considered inappropriate because of the possibility of activation of cells by 
prevailing systemic inflammation. Blood from healthy adult controls was also collected 
and stimulated similarly to act as controls.  
Term cord-blood PMNs expressed 34% of their IL-8 as IL-877 in the un-
stimulated and stimulated state (figure 5.8a and table 5.4); there was a 14-fold 
increase in expression of total IL-8 on stimulation with LPS (figure 5.9a). Adult 
peripheral blood PMNs expressed 27% of their IL-8 as IL-877 in the un-stimulated state, 
which increased to 30% when stimulated with LPS (figure 5.8b and table 5.4); this 
represented a 18-fold increase in expression of total IL-8 on stimulation (figure 5.9b). 
Unstimulated cord monocytes expressed 33% of IL-8 as IL-877 which changed to 53% 
on stimulation (figure 5.8a and table 5.4); there was a 32-fold increase in expression of 
165 
 
total IL-8 on stimulation (figure 5.9c). Matched adult monocytes produced 37% of their 
IL-8 as IL-877 in the un-stimulated state, which changed to 23% when stimulated with 
LPS (figure 5.8b and table 5.4); there was a 6-fold increase in expression of total IL-8 
(figure 5.9d). Taken together, this data shows that more than a third of the total IL-8 
expressed by term neonatal PMNs and MNCs under experimental conditions is the 
long isoform. The proportion of IL-877 from immune cells was also higher than that 
recovered from BALF of preterm ventilated infants (< 5%; figure 5.5a). Thus I have 
demonstrated the potential of resident and infiltrating lung cells to express significant 
proportion of their IL-8 as IL-877.     
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Figure 5-8: Expression of IL-877 from immune cells. Proportion of total IL-8 expressed 
as IL-877 from un-stimulated (grey bars) and stimulated (blue bars) (a) cord-blood and 
(b) adult peripheral-blood PMNs and Monocytes. Cells with different conditions are 
represented on the x-axis while percentage of IL-877 is represented on the y-axis. Bars 
are means (± SEM) of at least three independent experiments. 
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 Figure 5-9: Expression of IL-8 and IL-877 from immune cells. Concentration of 
total IL-8 (pg/ml, red bars) and IL-877 (pg/ml, green bars) from unstimulated and LPS 
stimulated (a) cord-blood PMNs, (b) adult peripheral-blood PMNs, (c) cord-blood 
monocytes and (d) adult peripheral-blood monocytes. Cells with different conditions 
are represented on the x-axis while concentration of protein (pg/ml) is represented on 
the y-axis. Bars are means (± SEM) of at least three independent experiments. 
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Immune 
Cells 
Un-stimulated Stimulated 
Total IL-8 (SEM) IL-877 (SEM) Total IL-8 (SEM) IL-877 (SEM) 
Cord PMN 105.5 (14.5) 36.0 (4.1) 1435.0 (255.0) 567.0 (167.5) 
Adult PMN 89.7 (37.6) 24.5 (7.9) 1639.0 (475.8) 488.8 (145.8) 
Cord MNC 
2814.0 (673.4) 1433.0 (488.8) 
90434.0 
(19794.0) 
42336.0 
(13920.0) 
Adult MNC 11442.0 
(8358.0) 
4203.0 (3149.0) 
72078.0 
(12994.0) 
16542.0 
(2766.0) 
 
  Table 5-4: Expression of IL-8 from innate immune cells. Concentration (pg/ml) of total 
IL-8 and IL-877 by PMNs and MNCs, both un-stimulated and when stimulated with LPS. 
Values are means (± SEM) of at least three independent experiments.     
 
 
5.7. Convertase Activity of BALF 
 
So far, I have shown that a minor proportion of the IL-8 in preterm BALF was 
expressed as IL-877, although lung epithelial cells (adult) and innate immune cells (term 
newborn infant cord blood) expresses significant proportions of their IL-8 as IL-877 
under experimental conditions. This, together with reports of dominant IL-877 
expression in preterm neonatal circulation (Maheshwari et al., 2009) suggested the 
possibility of conversion of IL-877 in the preterm ventilated lung. As several proteases 
have previously been shown to convert IL-877 to shorter isoforms (Van den Steen et al., 
Padrines et al., 1994b, Hebert et al., 1990b, Nakagawa et al., 1991a), I next looked for 
the presence of activity of such factors in preterm BALF.  
Figure 5.10 shows a panel of controls where IL-877 (10 ng/ml = 1.1 nM) was 
incubated overnight (18 hours) in buffer only (tris buffered saline with 0.5% BSA), or in 
the presence of the protease inhibitors AAT (for neutrophil serine proteases; 
concentration 10 μM), PMSF (for various serine proteases; concentration 10 mM), 1-10 
phenanthroline (for metallo-proteases; concentration 10 mM) and ATIII (for thrombin; 
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concentration 150 μg/ml). No significant loss of IL-877 was observed on ELISA after 
incubating with buffer for 18 hours (mean ± SEM: 9498 ± 720 pg/ml)  compared with 
concentration at 0 hours (9768 ± 356 pg/ml). Comparable concentration of IL-877 was 
detected after incubation with protease inhibitors for 18 hours (AAT: 10342 ± 556 
pg/ml; PMSF: 9764 ± 432 pg/ml; 1-10 phenanthroline: 9835 ± 536 pg/ml; ATIII: 10786 ± 
407 pg/ml). Ethanol was used as a negative control for PMSF and 1-10 phenanthroline 
as these stock solutions were diluted in ethanol; no significant differences were 
observed in concentration of IL-877 was detected after incubation with ethanol as 
compared to buffer control (ethanol: 9647 ± 611 pg/ml).  
0
5000
10000
15000
***
Buffer (hr)   0    18  18   18   18  18  18    -     -
BALF (hr)   -       -     -      -     -      -      -     0    18
Ethanol (1 in 6.67)   -       -     +     -     -      -      -      -     -
AAT (10 M)   -       -     -      +    -      -      -      -     -
PMSF (10 mM)   -       -     -      -     +     -      -      -     -
1-10 P'throline (10 mM)   -       -     -      -      -     +     -      -     -
ATIII (150 g/ml)   -       -     -      -      -      -     +     -     -
IL
-8
7
7
(p
g
/m
l)
 Figure 5-10: Panel of controls. Concentration of IL-877 detected by ELISA at 0 
hours and after incubation in different conditions for 18 hours. Conditions are detailed 
on the x-axis and concentration of IL-877 (pg/ml) on the y-axis. Red bars represent 
buffer controls and green bars represent BALF samples (n = 18) at 0 hour and after 18 
hours. All bars are at means ± SEM. Conditions were compared by one-way ANOVA 
with Dunnets post-hoc test comparing against a control column (BALF at 0 hour). (*** 
= p < 0.001)   
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On incubating BALF with known concentrations (10 ng/ml = 1.1nM) of 
exogenously added rhIL-877, recovery of this isoform after an 18 hour incubation was 
significantly decreased by 29% compared to starting concentration at 0 hour (71% 
recovery, p < 0.001; fig 5.11). (Green bars representing BALF at 0 and 18 hours in fig 
5.10 and fig 5.11 are identical). To explore the mechanism of this conversion, IL-877 
was incubated with BALF and AAT, PMSF, 1-10 phenanthroline and ATIII. While both 
AAT (88% recovery, p <0.01) and PMSF (95% recovery, p < 0.001) resulted in significant 
inhibition of conversion of IL-877 by preterm BALF, no similar protection was observed 
with 1-10 phenanthroline (68% recovery, p > 0.05), suggesting neutrophil serine 
proteases, and not metallo-proteases, are the more important group of convertases 
present in preterm BALF. Interestingly, inhibition of convertase activity by ATIII (88% 
recovery, p < 0.01) suggested significant activity of thrombin in the preterm lung.  
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Figure 5-11: Convertase activity of preterm BALF. Concentration of IL-877 detected by 
ELISA at 0 hours and after incubation in different conditions for 18 hours. Conditions 
are detailed on the x-axis and concentration of IL-877 (expressed as fold change in 
concentration compared to BALF at 0-hour) on the y-axis. All bars are at means (± 
SEM). Conditions were compared by repeated measures ANOVA with Dunnets post-
hoc test comparing against a control column (BALF at 18 hour). (*** = p < 0.001, ** = p 
< 0.01; n = 18) 
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There was significantly increased convertase activity in CLD infants (leading to 
decreased recovery of IL-877) compared to No CLD (p = 0.03, fig 5.12). Thus preterm 
BALF retains significant convertase activity towards IL-877, which was mainly due to the 
activity of neutrophil and coagulation-cascade serine proteases but not due to metallo-
proteases.   
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Figure 5-12: Convertase activity in No CLD and CLD infants. Concentration of IL-877 
detected by ELISA at 18 hours in No CLD (red bar) and CLD (green bar) infants. Infant 
groups are detailed on the x-axis and concentration of IL-877 (expressed as fold change 
in concentration compared to BALF at 0-hour) on the y-axis. All bars are at means (± 
SEM). (* = p < 0.05, n = 9 in each group)  
 
5.8. Conversion of IL-877 by purified neutrophil proteases 
  
My data suggested that active neutrophil and coagulation cascade serine 
proteases in BALF can significantly convert exogenously added IL-877. The role of 
thrombin and plasmin has been studied previously (Hebert et al., 1990b, Nakagawa et 
al., 1991a). I next proceeded to look at the pattern of this conversion by the three 
neutrophil serine proteases elastase, cathepsin G and proteinase-3 individually.  
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5.8.1. Conversion of IL-877 by purified neutrophil proteases at different 
concentrations 
I first looked at the effect of different concentrations of neutrophil proteases on 
the conversion of rhIL-877. Keeping the molar concentration of IL-877 constant (300 
nM), a variable concentration of proteases was added so that the enzyme: substrate 
ratio ranged between 10:1 (protease concentration 3 μM) to 1:10 (protease 
concentration 30 nM; a 100-fold change in concentration of proteases). Conversion of 
IL-877 by the neutrophil serine proteases was found to be protease dose-dependent, 
with significantly decreased concentration of IL-877 recovered at the higher 
concentration of proteases after 18 hours of incubation (fig 5.13a-c).  
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Figure 5-13: Protease dose-response. Conversion of IL-877 by purified (a) elastase, (b) 
cathepsin-G and (c) proteinase 3 at varying concentration. Ratio of enzyme: substrate 
is represented on the x-axis while the fold-change (compared to concentrating at 0-
hour) of total IL-8 (red circles) and IL-877 (green squares) is represented on the y-axis. 
Points plotted are means (± SEM) of three independent experiments. Concentration of 
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IL-877 is compared to corresponding concentration of total IL-8 by two-way ANOVA 
with Bonferroni’s post-test. (* = p < 0.05, ** = p < 0.01, *** = p < 0.001) 
 
There were no significant differences in concentration of recovered IL-877 
between the three proteases after 18 hours of incubation, at which point they were 
measured (fig 5.14a). Interestingly, there was a gradual loss of total IL-8 observed at 
the higher concentrations of protease used (fig 5.14b). This loss was significant for 
proteinase 3 at an enzyme:substrate concentration of 5:1 when compared to elastase. 
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 Figure 5-14: Dose-response of conversion of IL-877 by purified proteases. (a) 
Fold change in concentration of IL-877 and (b) total IL-8 by purified proteases at varying 
concentration. Ratio of enzyme: substrate is represented on the x-axis while the fold-
change in concentration (compared to concentrating at 0-hour) is represented on the 
y-axis. Points plotted are means (± SEM) of three independent experiments. Inter-
protease differences in concentration was compared by two-way ANOVA with 
Bonferroni’s post-test. (** = p < 0.01) 
 
5.8.2.  Conversion of IL-877 by purified neutrophil proteases over time 
 I next explored the conversion of rhIL-877 by purified proteases over time. An 
excess of protease was used in these experiments (enzyme: substrate = 10:1) over a 
24-hour time period. All three purified proteases showed significant convertase activity 
over time when incubated with rhIL-877, when compared with buffer control at same 
the time-point (p < 0.001 for all proteases at all time points beyond 0-hour; fig 5.15a). 
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The majority of this conversion took place by 6 hours (17% of IL-877 remaining with 
elastase, 2% with Cathepsin G and 6% with proteinase-3). Among the three serine 
proteases, cathepsin G seemed to have the highest activity towards IL-877; percentage 
of remaining IL-877 was significantly lower when compared with elastase after 2 hours 
(p <0.05) & 4 hours (p < 0.05) of incubation and also on comparison with proteinase-3 
after 1 hour (p < 0.01) and 2 hours (p < 0.001) of incubation. The percentage of 
remaining IL-877 was not significantly different between elastase and proteinase-3 at 
any time-point. IL-877 was converted to shorter isoforms of IL-8 which was detectable 
by immunoassay for total IL-8 (fig 5.14 b). However, after incubation with proteases for 
 12 hours, there was a trend towards further degradation of IL-8 to peptides which 
were not detected by ELISA. This was most evident with proteinase-3 where total IL-8 
detected was significantly lower when compared with buffer control at 24 hours (p < 
0.01). Such an effect has been reported previously with an excess of elastase (Leavell 
et al., 1997) resulting in loss of functional activity. Data is presented as fold-change in 
concentration compared to corresponding concentration at 0-hour. 
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 Figure 5-15: Time-course of conversion of IL-877 by purified proteases. (a) Fold 
change in concentration of IL-877 and (b) total IL-8 by purified proteases at different 
time-points. Time (hours) is represented on the x-axis while the fold-change in 
concentration (compared to concentrating at 0-hour) is represented on the y-axis. 
Points plotted are means (± SEM) of three independent experiments. Differences in 
concentration was compared by two-way ANOVA with Bonferroni’s post-test. (** = p < 
0.01) 
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5.9. Functional activity of IL-8 after incubation with proteases  
 
I have shown that all the three neutrophil serine proteases efficiently convert 
IL-877 to shorter isoforms over time. Next, I proceeded to test functional activity of the 
converted products.  
 
5.9.1. Establishing the neutrophil degranulation assay 
I set up a neutrophil degranulation assay, measuring expression of matrix 
metalloprotease-9 (MMP-9), to test for differences in functional activity between the 
isoforms of IL-8. Cytochalasin B (a mycotoxin which inhibits cytoplasmic division by 
inhibiting network formation by actin filaments) (Theodoropoulos et al., 1994) and 
fMLP was used as a positive control in these experiments; cytochalasin B has been 
shown to enhance fMLP-induced neutrophil responses, including degranulation 
(Honeycutt and Niedel, 1986). The estimated concentration of total IL-8 in the 
conversion experiments (section 5.8.2) at different time-points was 300 nM (3 X 10-7 
M). I compared the amount of MMP-9 produced after degranulation of neutrophils by 
different concentration (10-7 M and 10-8 M) of the two standard isoforms of IL-8, rhIL-
872 and rhIL-877, in the presence of cytochalasin B. All data was normalised to the 
MMP-9 expression in the presence of the positive control (cytochalasin B with fMLP) 
and expressed as a fold-change. As shown in figure 5.16, significant increase in MMP-9 
production was observed with the positive control fMLP (p < 0.001) and in the 
presence of either of the IL-8 isoforms at a concentration of 10-7 M (p < 0.001 for 
both), compared to expression of MMP-9 in the presence of cytochalasin B only 
(negative control). No significant differences were noted between the two IL-8 
isoforms at this concentration. At a concentration of 10-8 M, significant increase in the 
expression of MMP-9 was noted from the neutrophils by both rhIL-872 (p < 0.001) and 
rhIL-877 (p < 0.05) compared to negative control. However, expression of MMP-9 was 
significantly higher when neutrophils were degranulated in the presence of rhIL-872 
compared to rhIL-877 (p < 0.001). Thus, at a concentration of 10-8 M, the shorter 
isoform of IL-8 was functionally more potent than IL-877 in this assay. In all future 
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experiments, IL-8 from all conversion experiments were diluted to a final 
concentration of 10-8 M estimated concentration for degranulation of neutrophils. 
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 Figure 5-16: Establishing the neutrophil degranulation assay. MMP-9 expressed 
from neutrophils after degranulation by control conditions (red bars), rhIL-872 (green 
bars) and rhIL-877 (blue bars). Details of conditions are represented on the x-axis while 
expression of MMP-9 is represented on the y-axis (expressed as a fold change 
compared to the positive control). Bars are at means (± SEM) of three independent 
experiments. Difference in means was compared by one-way ANOVA with Tukey’s 
post-test (comparing all pairs of columns). (*/*** = significant compared to negative 
control cytochalasin B only; ### = significant compared to rhIL-872 at a concentration of 
10-8 M. (* = p < 0.05, *** = p < 0.001, ### = p < 0.001) 
 
 
5.9.2. Functional activity of IL-8 isoforms after processing by proteases 
I then proceeded to test the functional activity of IL-8 isoforms after processing 
of rhIL-877 by purified neutrophil serine proteases over 24 hours. For these 
experiments, all samples were diluted to an equivalent total IL-8 starting concentration 
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of 10-8 M (as explained above), the hypothesis being any difference (or change) in 
functional activity would be due to differences in functional activity between the long 
and shorter isoforms. 
Although elastase and cathepsin G efficiently converted IL-877 (fig 5.15), this was 
not reflected in a change of functional activity (fig 5.17 b-c); no significant differences 
were observed between functional activity of products from elastase or cathepsin G 
and buffer at any time-point. In contrast, there was a significant increase in potency in 
the products after incubation with proteinase-3 after 1 & 2 hours (p < 0.01 compared 
to buffer control) and 3 & 4 hours (p < 0.05 compared to buffer control, fig 5.17 d). 
Similar differences were noted in the functional potency of products on comparing 
proteinase-3 with elastase (p < 0.001 at 1 hour and p < 0.05 at 2 hours) or cathepsin G 
(p < 0.05 at 1 hour and 4 hours). This suggests that although all the three serine 
proteases can convert IL-877, conversion by proteinase-3 results in a functionally 
relevant isoform with increased potency, suggesting a key regulatory role for this 
enzyme for processing IL-8 in the preterm lung.     
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 Figure 5-17: Functional activity of IL-8 isoforms. Summary of processing of rhIL-
877 by (a) buffer, (b) purified elastase, (c) purified cathepsin G and (d) purified 
proteinase-3 showing recovery of total IL-8 (yellow squares), IL-877 (red circles) and 
MMP-9 from degranulation of neutrophils (green upright triangles) by the products of 
conversion. Time (hours) is represented on the x-axis while IL-8/MMP-9 (fold change 
from 0-hour values) is represented on the y-axis. Points plotted are means (± SEM) of 
three independent experiments. Statistical differences in concentration compared to 
buffer-control at each time-point was tested by 2-way ANOVA with Bonferroni’s post-
test. (* = p < 0.05, ** = p < 0.01, *** = p < 0.001).                  
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5.10. Processing of rhIL-872 by proteinase-3 
 
 So far, I have shown that processing of rhIL-877 by proteinase-3 results in 
significant reduction of recovery of total IL-8 at 24-hours. To see if this happens with 
the shorter isoforms of IL-8, I tested rhIL-872 in the same experiments as above. As 
shown in figure 5.18a, on incubating rhIL-872 with proteinase-3, there was a 20% loss of 
protein (as detected by IL-8 ELISA) at 4 hours (p < 0.001 compared to buffer control at 
same time-point) and 80% loss at 24 hours (p < 0.001 compared to buffer control at 
same time-point). On functional analysis, there was a trend towards increased activity 
at 4 hours but this was not statistically significant (fig 5.18b).     
A       B 
0 10 20 30
0.0
0.5
1.0
1.5
Buffer
Proteinase-3
***
***
Time (hrs)
T
o
ta
l 
IL
-8
(f
o
ld
 c
h
a
n
g
e
 f
ro
m
 0
 h
o
u
r)
            
0 10 20 30
0
1
2
3
Buffer + IL-872
Pr-3 + IL-872
Time (hrs)
M
M
P
-9
 f
ro
m
 P
M
N
s
(f
o
ld
 c
h
a
n
g
e
 f
ro
m
 0
 h
o
u
r)
 
 Figure 5-18: Processing of rhIL-872 by purified proteinase-3. (a) Recovery of 
total IL-8  (expressed as a fold change from 0-hour) on incubation with buffer (red 
circles) and proteinase-3 (green squares) over 24 hours. (b) Expression of MMP-9 from 
degranulated PMNs (expressed as a fold change from 0-hour) by rhIL-872 which was 
incubated in the presence of buffer (red circles) or proteinase-3 (green squares) over 
24 hours. Time (hours) is represented on the x-axis while fold-change in protein (total 
IL-8 or MMP-9) is represented on the y-axis. Points plotted are means (± SEM) of three 
independent experiments. Differences in the expression of protein was tested by two-
way ANOVA with Bonferroni’s post-test. (*** = p < 0.001) 
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5.11. Expression of proteinase-3 in preterm ventilated infant BALF 
 
My previous data shows that proteinase-3 processes rhIL-877 resulting in 
increased functional activity. I have also shown that convertase activity is higher in 
BALF from CLD infants compared to RDS infants. This prompted me to look at the 
expression of proteinase-3 in BALF from the preterm infants in my cohort. Proteinase-3 
in BALF was measured by a newly developed sandwich ELISA in-house. As shown in 
figure 5.19, peak expression of total proteinase-3 was significantly higher in BALF from 
CLD infants (median 234.4 nM, IQR 102.8 – 384.4 nM) compared to No CLD infants 
(median 26.5 nM, IQR 5.1 – 196.9 nM; p = 0.03). 
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 Figure 5-19: Expression of proteinase-3 in preterm BALF. Peak proteinase-3 
expression (nM) in BALF from No CLD (red circles) and CLD (green squares) infants. 
Points plotted represent individual infants and bars are at medians. (* = p < 0.05) 
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5.12.    Activity of thrombin in preterm ventilated infant BALF 
 
I have already shown that thrombin may have a significant convertase activity 
in preterm BALF towards rhIL-877 (figure 5.10). In order to clarify this further, we 
proceeded to measure specific thrombin activity in preterm BALF. Due to limited 
sample volume, most of the samples included in the convertase experiment (figure 
5.10) could not be used for this. However, thrombin activity was measured in samples 
collected from the other preterm infants who were part of the same cohort but not 
included in this study. 
As shown in figure 5.20, peak thrombin activity was significantly higher in infants with 
CLD (median 15.1 mIU/ml, IQR 3.8 – 52.2 mIU/ml) compared to the No CLD infants 
(median 0.0 mIU/ml, IQR 0.0 – 11.9 mIU/ml; p = 0.03). 
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 Figure 5-20: Activity of thrombin in preterm BALF. Peak thrombin activity 
(mIU/ml) in BALF from No CLD (red circles) and CLD (green squares) infants. Points 
plotted are from individual infants and bars are at medians. (* = p < 0.05) 
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5.13. Discussion 
 
5.13.1. Summary 
This is the first report of IL-877 expression in the lungs of preterm infants. 
Although total IL-8 and IL-877 concentration were significantly increased in infants who 
developed CLD, the majority of the IL-8 expressed seemed to be the more potent 
shorter isoforms. Resident (adult) and infiltrating (term newborn) cells in the lung 
express a significant proportion of IL-8 as the 77 a.a. isoform. I have demonstrated a 
significant, but inhibitable, capacity of proteases in the preterm BALF to convert IL-877 
to its shorter isoforms. Specifically, conversion by proteinase-3 resulted in shorter 
isoforms with increased functional activity.     
 
5.13.2. Expression of IL-8 isoforms in preterm BALF 
Persistent, neutrophil-driven inflammation has been strongly implicated in the 
pathogenesis of CLD with IL-8 being a key chemokine involved in the process.  My 
results are in keeping with previous data that IL-8 is significantly increased in the lungs 
of infants developing CLD (Ambalavanan et al., 2009, Munshi et al., 1997, Kotecha et 
al., 1995). This reflects the pattern of lung inflammation observed in preterm infants 
developing CLD: persistent acute inflammation, with a poorly-resolving neutrophilia 
(Kotecha et al., 2003). IL-877 was detected as a minor proportion of total IL-8, which 
agrees with my hypothesis that the shorter, and more potent isoforms, constitute the 
majority of the IL-8 in preterm BALF; this was observed in both groups of infants. 
In a recent report (Maheshwari et al., 2009), IL-877 was described as the major 
isoform in the preterm circulation (60%). This was found to decrease at term to 15% 
and then to a minor fraction in adults (8%). If the same proportions were to be 
reflected in the preterm lungs, it could have a profound impact on the function of IL-8 
and on inflammation. The authors (Maheshwari et al., 2009) demonstrated increased 
transcription of IL-8 in endothelial cells compared to monocytes in an in vitro porcine 
cellular model, suggesting that endothelial cells in foetal life may be the major source 
of IL-8. It is already known that the major isoform of IL-8 expressed from endothelial 
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cells is IL-877 (Gimbrone et al., 1989, Hebert et al., 1990a). Monocytes, which are the 
major source of IL-872 (Lindley et al., 1988a, Van Damme et al., 1989b), are known to 
go through a “maturation” phase during foetal life (Schibler et al., 1993) but at 
inflammatory sites, as in the ventilated preterm lung, it is more likely that 
inflammatory cells (mononuclear and polymorphonuclear) are major sources of IL-8 
production. However, foetal inflammation is an associated factor in preterm deliveries 
since chorioamnionitis has been identified as a major cause leading to preterm labour 
(Goldenberg et al., 2000). Thus, some degree of inflammation can be expected in 
preterm infants, except if they are delivered for maternal reasons. Maheshwari and 
colleagues (Maheshwari et al., 2009) have not specified reasons for prematurity in the 
cohort of infants examined in their study. Following-on from their observation, I 
measured the concentration and proportion of IL-877 in preterm BALF on the first day 
of life to reflect in-utero concentrations as closely as possible. No correlation was 
observed in either the concentration or proportion of IL-877 in BALF with the birth 
gestation of infants.  
Taken together, the above observation suggests that in the inflamed preterm 
lungs, inflammatory cells (mononuclear and polymorphonuclear) may be the major 
producer of IL-8 (as shorter isoforms predominate), although most other cell-types in 
the lungs can express IL-8. Another possibility was that immune cells other than 
monocytes and lung epithelial-cells express significant proportions of IL-877, but it gets 
converted to the more potent shorter isoforms by one or several proteases. I first 
looked at the expression of IL-877 from individual cell types.  
 
5.13.3. Expression of IL-877 from individual cell types 
Pulmonary epithelial cell lines are known to express IL-8 on stimulation 
(Standiford et al., 1990, Leverence et al., 2011); however, expression of IL-877 has not 
been described before. My results show for the first time that a significant proportion 
of IL-8 is expressed as the 77 a.a. isoform by a variety of adult airway cell-lines and 
primary small airway cells, both in the un-stimulated state and in the presence of 
inflammatory stimuli.  
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Another abundant cell type in the preterm lungs are neutrophils and 
monocytes/macrophages. Previously, IL-877 expression has been reported to range 
from 17–38% of total IL-8 from adult monocytes (Yoshimura et al., 1989b, Lindley et 
al., 1988b) and mixed mononuclear cells (Van Damme et al., 1989a), and about 60% of 
total IL-8 from PMNs (Padrines et al., 1994b). I have described for the first time 
expression of IL-877 from term neonatal cord-blood PMNs and monocytes. My results 
are similar with adult data published previously.  
Taken together, this data shows that both non-immune and immune cells in the 
lung can potentially express significant quantities of IL-877, especially when stimulated. 
However, the proportion of IL-877 I recovered from preterm BALF was uniformly low. 
This suggested that known proteases or other unknown convertases could be involved 
in the preterm lung to convert the IL-877 to shorter isoforms. I next looked at the 
possibility of this in the preterm BALF samples.  
 
5.13.4. Conversion of IL-877 by preterm BALF: effect of neutrophil serine 
proteases 
BALF from ventilated preterm infants is known to contain several inflammatory 
mediators (Ryan et al., 2008, Bose et al., 2008) including an imbalance in neutrophil 
proteases and anti-protease (Speer, 2006).  Matrix metalloproteinase-9 (MMP-9) has 
also recently been recovered in preterm BALF (Davies et al., 2010). Since all of these 
proteases are known converters of IL-877 to shorter and more potent isoforms (Van 
den Steen et al., 2000, Padrines et al., 1994a), I looked for specific convertase activity 
in preterm BALF. Indeed, when known quantities of exogenous rhIL-877 was incubated 
with preterm BALF, significant conversion was noted (71% recovery of original 
protein). Conversion was more pronounced in the CLD infants.  
To study the specific mechanisms of conversion, the same samples were pre-
incubated with specific anti-proteases before rhIL-877 was added. Protection from 
conversion by -1 antitrypsin (AAT, 88% recovery) and anti-thrombin III (ATIII, 88% 
recovery) suggested neutrophil serine proteases and thrombin were involved in the 
conversion process. However, AAT or ATIII were not able to completely inhibit the 
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conversion of rhIL-877 by BALF. Phenylmethanesulfonylfluoride (PMSF, recovery 95%) 
provided greater protection as it is known to inhibit a wider range of enzymes, 
including both neutrophil serine proteases and thrombin. Metallo-proteases were not 
involved in the convertase activity, as suggested by the lack of any protection in the 
presence of 1-10 phenanthroline, a non-specific inhibitor of metallo-proteases (68% 
recovery).  
  Early studies in preterm infants have suggested the involvement of neutrophil 
proteases in contributing to inflammation and lung damage (Merritt et al., 1983, 
Ogden et al., 1984a) although this has not been corroborated by more recent studies 
(Sveger et al., 2002).  An imbalance between matrix-metallo-proteases and their 
inhibitors in the lungs of preterm infants has been noted (Cederqvist et al., 2001, 
Ekekezie et al., 2004, Sweet et al., 2004). This imbalance has the potential of damaging 
the lung with long-term consequences (Speer, 2006). Our group have recently 
reported the contribution of elastase and MMP-9 in the development of CLD (Davies et 
al., 2010). Similar imbalances have been suggested in cystic fibrosis, another 
neutrophilic lung disease (Griese et al., 2008, Gaggar et al., 2011). Apart from the 
direct effect of proteases, post-translational modification of chemokines (Mortier et 
al., 2011b) can also influence local immune function and have an impact on tissue 
injury. This effect is particularly important for IL-8 as cleavage by proteases results in 
enhanced functional activity.  
The neutrophil serine proteases themselves have been shown to induce IL-8 
expression from lung epithelial cells (Nakamura et al., 1992, Chen et al., 2004, 
Kuwahara et al., 2006) and endothelial cells (Berger et al., 1996). Some investigators 
have suggested the existence of a positive-feedback loop whereby proteases released 
from the initial influx of PMNs both induce an increase in IL-8 production from 
epithelial cells and also cleaves potential longer isoforms of IL-8 to shorter isoforms. 
Such a loop, if unchecked, has significant potential to cause lung damage.  
Since protection from cleavage of IL-877 in BALF was achieved by AAT and PMSF, 
I looked at the processing of IL-877 by the three main serine proteases from 
neutrophils. Proteinase-3 is able to convert IL-877 to IL-870 (Padrines et al., 1994b) as 
shown previously, but the authors found that elastase and cathepsin G were not 
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involved in the conversion. I have shown that all three of the main serine proteases in 
PMNs can convert IL-877 to shorter isoforms. This is effective both over time and over a 
dose range. Cathepsin G seems to be the most potent in this regard with elastase the 
least potent among the three. Interestingly, with longer incubation periods, there was 
a decrease in the amount of total IL-8 recovered, which was statistically significant 
with proteinase-3. This would suggest that there are several potential cleavage sites 
for the enzymes on the IL-8 molecule which are distal from the NH2 terminal (Padrines 
et al., 1994b), producing smaller peptides which are undetectable by ELISA for IL-8. 
Elastase has previously been reported to abolish IL-8 activity by a similar process 
(Leavell et al., 1997), although the authors found no such effect of cathepsin G 
(proteinase-3 was not studied). They suggested that cleavage of IL-8 by proteases 
could be a mechanism by which activity of this chemokine is abolished. I have found 
evidence that all the three PMN serine proteases have this effect when present at an 
excess compared to substrate. Further studies need to be conducted to confirm the 
clinical implications of this effect in vivo.  
Although I have shown that all three of the neutrophil serine proteases can 
convert IL-877 to shorter forms efficiently, only conversion by proteinase-3 resulted in 
proteins which were functionally more potent than IL-877. In a detailed in vitro study of 
chemically synthesised IL-8 isoforms (Clark-Lewis et al., 1991), isoforms of IL-8 which 
were shorter than 72 a.a. were found to be more potent than IL-872 itself. This was 
validated in a more recent study, where the authors defined three different categories 
of IL-8 isoforms based on functional potency (Mortier et al., 2011b). Thus, the most 
abundant and well studied isoform, IL-872, may not be the most potent. My results 
suggest that proteinase-3 could be an important modulator of IL-8 function in preterm 
lung by post-translation modification of long isoforms. Processing of both IL-877 and IL-
872 by proteinase-3 resulted in loss of protein (as determined by immune assay) after 
incubation for up to 24 hours. Although I have not been able to show a clear functional 
correlation of this observation, it has been previously shown that a similar effect by 
elastase can result in abolition of activity (Leavell et al., 1997). Elastase remains the 
most extensively studied neutrophil serine protease in the lungs. However, my analysis 
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suggests that proteinase-3 may be more relevant in modulation of IL-8 biology in the 
preterm lungs and more research is merited to explore this. 
 Alpha-1 antitrypsin (Alpha-1 proteinase inhibitor, AAT) has been assessed as a 
therapeutic intervention in two randomised controlled trials by the same group of 
investigators (Shah and Ohlsson, 2001). When all the infants and all doses of AAT were 
pooled together, there was a reduction in incidence of CLD defined as oxygen 
requirement at 28 days of age (short-term outcome). However, no other statistically 
significant benefits were observed in any of the outcomes recorded, including 
prevention of CLD at 36-weeks corrected gestational age or long-term neuro-
developmental outcome. As the total number of infants included in these two trials is 
small (195), this may have masked a true effect. 
 AAT has been in use in adults as a treatment for AAT deficiency since initial 
studies conducted in the 1980s (Wewers et al., 1987, Gadek et al., 1981). Although the 
authors demonstrated safety and biochemical efficacy, this study was not designed to 
look for clinical effectiveness.  Evidence for clinical effectiveness of AAT in genetically 
deficient individuals have been mainly from observational studies and small 
randomised-controlled trials, long after the molecule was licensed for clinical use. 
Results from these trials and reports have been conflicting at best; more often they 
have failed to show clear clinical benefits (Dickens and Lomas, 2011) and as such has 
not been recommended for use (Gotzsche and Johansen, 2010). Several theories have 
been proposed to explain this apparent lack of effect. Polymers formed by abnormal 
AAT alleles have been shown to be pro-inflammatory and result in chronic 
inflammation in the lungs and slow, but persistent, damage to the liver (Dickens and 
Lomas, 2011), and an approach using small molecules to block this polymerisation has 
been proposed (Mallya et al., 2007). Moreover, as AAT is an acute-phase reactant, 
episodic administration could be more relevant for clinical effectiveness than a steady-
state concentration. Using alternative delivery techniques like nebulisation could also 
prove to be both effective and economic (Siekmeier, 2010). Elafin is a potent 
endogenous inhibitor of elastase and proteinase-3 (Shaw and Wiedow, 2011). In a 
recent trial on an animal model of CLD, intra-tracheal instillation of recombinant elafin 
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in mechanically ventilated newborn mice was shown to reverse histological changes in 
lung compared to vehicle-treated controls (Hilgendorff et al., 2011).   
 The above evidence, along with my analysis, suggests that using antiproteases 
could have clinical benefits in attenuating lung inflammation and injury in preterm 
ventilated infants and merit assessment in well-powered clinical trials.  
 
5.13.5. Conversion of IL-877 by preterm BALF: effect of thrombin and the 
coagulation cascade  
Links between inflammation and the coagulation cascade have recently come to 
light. Inflammatory cytokines (IL-6, TNF-, IL-1, MCP-1, CRP) increase expression of 
tissue factor on endothelial cells and monocytes (Lipinski et al., 2011, Mackman, 2009) 
leading to triggering of the coagulation cascade (Levi, 2010). Cytokines also dampen 
anti-coagulation by various mechanisms (Lipinski et al., 2011) and suppress fibrinolysis 
(Levi and van der Poll, 2008). Thrombin itself has been shown to increase expression of 
IL-8 from endometrial stromal cells through stimulation of MAPK (Kawano et al., 2011). 
Thus there is ample evidence of a pro-coagulant state during active inflammation with 
evidence of cross-talk between the two systems.  
An imbalance in the coagulation: anticoagulation balance has been observed in 
lavage fluid from preterm ventilated infants (Viscardi et al., 1992). Initiation of the 
coagulation cascade, as demonstrated by elevated thrombin activity, was shown in 
BALF from a lamb model of preterm RDS (Jaarsma et al., 2001). To my knowledge, only 
one previous group of investigators have reported measurement of thrombin activity 
in BALF from preterm ventilated infants, where it was shown to be the major 
mitogenic stimulus in BALF for fibroblasts in culture (Dik et al., 2003). However, in this 
study, thrombin activity was found to be lower in infants who subsequently developed 
CLD compared to those who don’t. My results show a significant increase in thrombin 
activity in BALF from preterm ventilated infants who develop CLD (figure 5.20). In a 
recent in vitro model, activation of the coagulation cascade by CLD-BALF was shown to 
promote fibrotic responses (Kambas et al., 2011). Importantly, the authors 
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demonstrated the beneficial effects of suppression of fibrosis mediators by blocking 
the extrinsic pathway of coagulation with ATIII in their model. 
Activation of the clotting cascade has been shown to contribute to fibrotic lung 
diseases in adults (Scotton et al., 2009, Imokawa et al., 1997), where thrombin is part 
of the final common pathway. My analysis suggests that thrombin is involved in 
modulating lung inflammation in ventilated preterm infants by post-translational 
modification of IL-8, thus attracting increased numbers of neutrophils into the lungs 
which express serine proteases and other inflammatory mediators. Recently, inhibition 
of neutrophil serine proteases has been shown to improve lung growth in a murine 
model of BPD (Hilgendorff et al., 2011). Thus, inhibition of specific proteases could 
regulate IL-8 activity and curtail pulmonary inflammation in preterm infants at risk of 
BPD, with possible clinical benefits.  
Protease-activated receptors (PAR) are a group of G-protein coupled cell-
membrane proteins involved in intracellular signalling (Ossovskaya and Bunnett, 2004). 
To date, four such receptors (1 - 4) have been characterised. A variety of cell types 
express these receptors including platelets, epithelial and endothelial cells, fibroblasts 
and neural cells. Several proteases can activate these receptors but thrombin is the 
best characterised among them, which can activate PAR1, PAR3 and PAR4 (van der 
Poll, 2008). Among the neutrophil proteases, cathepsin G has been suggested to be an 
activator of PAR4 (Sambrano et al., 2000). In the airways, PAR1 and PAR2 are 
expressed on epithelial, endothelial and smooth muscle cells (Ossovskaya and Bunnett, 
2004). Activation of PAR1, PAR2 and PAR4 on airway epithelial cells stimulate 
expression of inflammatory cytokines (Asokananthan et al., 2002). Activation of 
coagulation (Scotton et al., 2009, Imokawa et al., 1997), and more specifically 
thrombin (Howell et al., 2002) has been shown to be associated with fibrotic diseases 
of the lungs. In summary, these groups of receptors and their protease activators may 
have important roles to play in lung inflammation. A clear understanding of their role 
in the preterm infants and may suggest novel approaches towards lung inflammation.   
The pathology of CLD has evolved over the years and can be subdivided into 
three broad eras. Early descriptions of CLD from the 1960s to the 1970s (Northway et 
al., 1967, Bonikos et al., 1976, Reid, 1979, Stocker, 1986) involving relatively late 
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preterm infants (by today’s standards) were characterised by severe epithelial 
changes, extensive fibroproliferation and smooth muscle hyperplasia with 
hypertensive changes in the vasculature. Improvements in clinical practice in the 
1980s, even before the era of exogenous surfactant replacement and antenatal 
steroids (Taghizadeh and Reynolds, 1976), resulted in survival of more immature 
infants who had lungs characterised by less epithelial and vascular changes, variable 
degrees of fibrosis and more simplified airspaces (Erickson et al., 1987). In the few 
infants with reported lung histology who received exogenous surfactant replacement 
(Husain et al., 1998), the major pathology was an arrest of acinar development. 
However, septal fibrosis was still noted among some of these infants. No reports of 
lung histology describing CLD from extremely premature infants who received both 
antenatal steroids and post-natal exogenous surfactant replacement therapy are 
available, presumably because most of them die before developing CLD, and very few 
die thereafter. However, in the face of significant and persistent inflammation 
documented in the lungs of these infants, healing with some degree of fibrosis is 
almost inevitable. Part of this effect will be contributed by activation of the clotting 
cascade, as noted in adult diseases (Scotton et al., 2009, Imokawa et al., 1997), and 
merits further research.     
 
 
5.14. Limitations 
I acknowledge certain limitations of this study. I was unable to confirm 
previously reported increased expression of IL-877 in preterm circulation (Maheshwari 
et al., 2009) as I did not have access to matched blood samples from the infants in my 
study. The airway cell-lines and primary cells used in my experimental models are all 
from adult populations and may not reflect conditions in the preterm lung accurately. I 
believe that the future use of appropriate animal models may enable us to overcome 
some of these difficulties.  
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5.15. Summary 
My data show that in the lungs of ventilated preterm infants, the majority of IL-
8 expression seems to be the shorter (more potent) isoforms; this is also supported by 
the pattern of cellular infiltration into the lungs. The expression of IL-877 is low, 
although several individual cell-types present in the lungs can potentially express 
significant quantities of the protein. This difference in proportion could be due to 
conversion of IL-877 to shorter isoforms extracellularly. Imbalances in protease-
antiprotease ratio could contribute to this conversion. Knowledge about intra-cellular 
post-transcriptional modifications during IL-8 production may lead to novel 
approaches toward limiting inflammation.  
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6. Final Summary 
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6.1. Introduction 
 
Chronic lung disease (CLD) remains the most common respiratory sequelae of 
premature birth, especially among the extremely premature and low birth weight 
infants (Ali et al., 2013). Currently, CLD is a descriptive term used for a spectrum of 
clinical respiratory illness, from mild to severe (Jobe and Bancalari, 2001a). No single 
cause have been identified so far which leads to the development of CLD, apart from 
extreme prematurity and low birth weight, which remain the two consistent risk 
factors (Chakraborty et al., 2010). The cumulative effect of CLD has important medium-
term health implications including respiratory (Gough et al., 2012, Kotecha et al., 2013) 
and neuro-developmental (Doyle and Anderson, 2009) morbidity. Although we are still 
in the process of understanding the long-term implications of CLD in the current 
population of infants born extremely preterm and who survived, our current 
knowledge informs us that CLD is a condition with significant short- and long-term 
morbidities. A better understanding of the condition, including the mechanisms and 
pathways involved, is essential for planning therapeutic strategies. 
Lung inflammation involving the innate immune system has been strongly 
implicated and extensively studied in preterm infants developing CLD/BPD (Ryan et al., 
2008, Chakraborty et al., 2010). A common pattern of inflammation in the lungs of 
preterm infants who develop CLD later is a persistent and poorly resolving 
neutrophilia. The chronic nature of insult to the preterm lung ensures persistence of 
this acute inflammation. In parallel, low numbers of mononuclear cells precludes 
adequate resolution of the acute inflammation. While a large body of evidence exists 
regarding inflammatory mediators in the preterm lungs, studies on resolution of 
inflammation are limited. Modulation of inflammatory process to counter acute 
inflammation or to initiate resolution could have profound influences on lung growth 
and development in preterm infants and may result in improved clinical outcomes. 
This forms the overall hypothesis of my research work.  
Association of inflammatory mediators in the preterm lung with CLD are 
inconsistent, with IL-8 being a notable exception (Ryan et al., 2008, Ambalavanan et 
al., 2009). IL-8 is a key chemokine involved in attracting and activating neutrophils at 
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sites of inflammation (Remick, 2005). Significantly higher concentrations of IL-8 in 
lungs or BALF of preterm ventilated infants developing CLD has been reported in the 
literature; this is reflected in the neutrophilic lung inflammation observed in infants 
developing CLD. This led me to study two different pathways of possible resolution of 
lung inflammation in preterm infants: modulation of expression (by IL-6 trans-
signalling responses) and function (by different isoforms) of IL-8 in BALF from a cohort 
of preterm ventilated infants. The study was planned to initiate with observational 
data, and then proceed to develop in vitro models to study mechanisms of each of 
these two pathways. 
 
6.2. Modulation of inflammation by IL-6 trans-signalling 
 
Interleukin-6 (IL-6) is a critical cytokine involved in acute inflammation. 
Although the majority of the pro-inflammatory functions of IL-6 are mediated by 
signalling through its cognate receptor, IL-6R (Jones, 2005), the pro-inflammatory 
effects of IL-6 trans-signalling have been studied in various diseases and disease 
models and blocking the effects of IL-6 trans-signalling in rheumatoid arthritis (Choy et 
al., 2002) and Crohn’s disease (Ito et al., 2004) have resulted in therapeutic benefits.  
More relevant to my research are the pro-resolution effects of IL-6 trans-
signalling in innate immunity, as summarised in figure 6.1 and supported by 
experimental data from animal models of inflammation (Hurst et al., 2001, McLoughlin 
et al., 2004, Chalaris et al., 2007). Since the pattern of inflammation noted in these 
animal models reflect preterm lung inflammation closely, this led me to my first 
hypothesis for my research project: non-resolution of lung inflammation in preterm 
infants could be due to a lack of the effects of IL-6 trans-signalling.  
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Figure 6-1: Regulation of innate and acquired immunity by IL-6 trans-signalling. (With 
permission from (Jones, 2005)) Copyright 2005. The American Association of 
Immunologists, Inc. 
 
6.2.1. Data from the baboon model of BPD 
 
Non-human primates share genetic and physiological characteristics with 
humans. They also have common susceptibilities to infection and other chronic 
diseases. The baboon model of BPD closely reflects the condition in human preterm 
infants (Coalson et al., 1999b), and has been used by several investigators to study 
mechanisms of the disease (Subramaniam et al., 2007, Viscardi et al., 2006a, Afshar et 
al., 2003, Yoder et al., 2003b, Awasthi et al., 2001) and trial therapeutic interventions 
(McCurnin et al., 2009, Thomson et al., 2006, McCurnin et al., 2005a, McCurnin et al., 
2005c, Thomson et al., 2004, Yoder et al., 2000b). Baboons were delivered at 2/3 of 
term gestation (equivalent to 24-26 weeks in human infants) by Caesarean section, 
after receiving antenatal steroids at least 48 hours before delivery. Preterm newborn 
baboons received exogenous surfactant replacement and were gently ventilated on 
pressures and oxygen concentrations that reflects current clinical practice in preterm 
human infants.  
To establish proof of concept, I utilised tracheal aspirate fluid (TAF) from 
preterm baboons, included in the control arms of therapeutic trials, to collect 
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observational data. I confirmed the expression of IL-6 and its soluble receptors, and 
the chemokines IL-8 & MCP-1, in the TAF of preterm ventilated baboons. Expression of 
the soluble receptors sIL-6R and sgp130 is being reported for the first time in this 
model.   
Apart from sIL-6R, the pattern of expression of the other cytokines and 
chemokines showed dynamic changes usually reaching a peak (median concentration) 
on day 6-7 before showing signs of resolution. Similarly, the cellular infiltrate into the 
lungs (total and differential), as recovered in TAF, did not change significantly over the 
study period. Since the source of sIL-6R has been suggested to be mainly inflammatory 
cells, this could be a possible reason why this cytokine concentration remained 
unchanged.  
The relative expression of the cytokines suggested a lack of any IL-6 trans-
signalling activity in the preterm baboon lungs. This was reflected by a small, but 
significant, change in the pattern of recruited cells into the lungs with a predominance 
of mononuclear cells towards the end of the study period. Thus, data from the preterm 
baboons confirmed dynamic expression of the IL-6 trans-signalling molecules in the 
lungs of these animals, although suggesting lack of any significant IL-6 trans-signalling 
effects in preterm ventilated baboon TAF.  
 
6.2.2. Data from human preterm infants    
While data from the preterm baboons confirmed expression of the IL-6 trans-
signalling molecules in the lungs, interestingly it revealed a significant increase of  
sgp130, the specific inhibitor of IL-6 trans-signalling. Observational data from the 
human preterm infants also showed a significant increase in expression of sgp130 and 
a trend towards increased expression of IL-6 and sIL-6R in bronchoalveolar lavage fluid 
(BALF) of preterm ventilated infants who develop CLD compared to those who do not. 
Anti trans-signalling potential (sgp130/sIL-6R) was higher in the CLD infants suggesting 
abrogation of IL-6 trans-signalling effects, my primary hypothesis.  
As previously reported in the literature, expression of IL-8 was significantly 
higher in the CLD infants of my cohort. However, while IL-6 has been reported in 
increased concentration from CLD infants previously (Kotecha et al., 1996b), my 
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analysis showed a non-significant rise. This could be due to the limited number of 
infants included in each group of my cohort. However, a shift in the pattern of lung 
inflammation, due to changes in clinical practice, cannot be ruled out, although 
consistent data to support this is lacking. 
The similarities and contrasting features in the data from baboons and human 
infants are interesting. While both are observational, the baboon data is from a cohort 
study while the human data is from a prospective case-control study. Thus, direct 
comparison between the two sets of data is not possible. However, some cautious 
inferences regarding the pattern of expression of molecules can be drawn from them. 
1) Significant modulation of sgp130 concentration was noted in the lungs of 
both species. Concentration of sgp130 was in excess of both sIL-6R and IL-6 
concentration in both species. This remains the key finding from my work. 
2) The relative expression of sIL-6R, compared to IL-6 expression, in the 
baboons was noted to be different from the human infants. While sIL-6R concentration 
was lower than IL-6 concentration in all samples of TAF from the preterm baboons 
(table 3.1), they were comparable in preterm BALF from the human infants (table 3.5). 
Understandably, this resulted in differences in the IL-6 trans-signalling potential (as 
calculated from the ratio of the molecules) between the two species. Differences in 
the method of sample collection (TAF vs BALF), and lack of non-human primate specific 
ELISAs for baboons, may be possible explanations for this difference. The pattern of 
expression of these two molecules set up an environment where functional IL-6 trans-
signalling would be unable to proceed in the lungs of either species.  
3) While significant changes in the expression of IL-6 was noted in the baboon 
lungs, no significant differences were noted between the two groups of human infants. 
 
6.2.3. Data from the IL-6 functional assay    
To understand the functional implications of the previous observations, I 
modified a cell-base IL-6 functional assay, using mouse B9 cells, to measure specific IL-
6 trans-signalling. My strategy to measure specific IL-6 trans-signalling activity was by 
using a monoclonal anti-mouse antibody against IL-6R (2B10), to inhibit IL-6 cis-
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signalling. Thus, any proliferation of cells in the presence of the 2B10 antibody would 
be due to the effects of IL-6 trans-signalling. Key findings from my work are: 
1. I have demonstrated the successful modification of the B9 cell assay to 
measure specific IL-6 trans-signalling using the above strategy. This can be used 
for clinical samples where IL-6 trans-signalling is thought to be involved in 
pathogenesis. 
2.  BALF samples from both groups of infants resulted in comparable proliferation 
of B9 cells. This suggests the presence of “free” IL-6 in the samples. 
3. The significantly higher concentration of sgp130 did not seem to have an effect 
on the IL-6 cis- or trans-signalling activity.  
 
My data and analysis suggests that IL-6 trans-signalling may not be a major 
pathway involved in inflammation in the preterm lungs. This inference can be drawn 
from the observational data in TAF from the preterm baboons and in BALF from 
preterm human infants, primarily due to the relative low concentrations of sIL-6R in 
samples from both species. An excess of sIL-6R, relative to IL-6, have been found in all 
diseases and disease models which seem to respond to therapeutic blockade of IL-6 
trans-signalling (implicating IL-6 trans-signalling as a pro-inflammatory process) 
(Desgeorges et al., 1997, Kotake et al., 1996, Uson et al., 1997, Peake et al., 2006, 
Mitsuyama et al., 1995, Doganci et al., 2005). Binding studies conducted in vitro 
(Gaillard et al., 1999) also suggest that concentration of the sIL-6R/IL-6 complex is 
primarily dependent on the concentration of sIL-6R, and increases when sIL-6R is in 
excess relative to IL-6.  
The results of the functional assay, which were designed to confirm the above 
observation, needs careful interpretation. I have demonstrated successfully that the 
B9 cells can be modified to act as a functional assay for IL-6 trans-signalling. This 
particular strategy seems to work well with hyper IL-6 (H IL-6, a synthetic stable 
complex of sIL-6R/IL-6), but no activity was noted with in presence of the natural 
complex (formed in the presence of recombinant IL-6 and sIL-6R). Although 
recombinant human IL-6 (used as a positive control in the assay) and sIL-6R (used for 
IL-6 trans-signalling in rheumatoid arthritis synovial fibroblasts, figure 4.10) were both 
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individually functionally active, no B9 cell proliferation was noted in the presence of 
their natural complex. Difference in functional potency between the stable (H IL-6) and 
natural complex, as well as inadequate concentration of the natural complex, could be 
possible explanations for this observation. Such a difference in potency between cis- 
and trans-signalling has been suggested previously in the case of signalling by the 
complex of IL-11 and sIL-11R, which was less potent than signalling by IL-11 through 
the cell-surface receptor (Curtis et al., 1997). It is also possible that the strategy of 
using an antibody to inhibit IL-6 cis-signalling (2B10) in order to measure IL-6 trans-
signalling, may not be appropriate for clinical samples in this assay. Concentrations of 
IL-6 had to be kept “low” in all of these experiments to prevent “breakthrough” IL-6 
signalling; possibly leading to inadequate complex formation. To overcome this specific 
limitation, the ideal modification should be to prevent expression of the IL-6 cognate 
receptor on the B9 cells (IL-6R). This can be achieved either by “knockdown” of IL-6R 
using translation blockers like short interfering RNA (siRNA), but more definitively by 
genetic “knockout” of the IL-6 receptor gene (e.g. by zinc-finger proteases). Although 
the BAF-B03 cells express the same phenotype (IL-6R- gp130+), they only respond to 
supra-physiologic concentration of IL-6 and sIL-6R, making it unsuitable for use with 
clinical samples. Thus, I have not been able to definitively confirm or refute my 
hypothesis, and my work highlights need for further research in the development of a 
specific IL-6 trans-signalling assay.      
 
6.2.4. Role of sgp130 
The role of sgp130 in the preterm infant lung remains unknown. I have found 
significantly higher concentrations of sgp130 in preterm infants developing CLD, 
apparently without an obvious function. The precise mechanisms of regulation of 
expression of cell-surface gp130 and sgp130 in health and disease has not yet been 
fully elucidated. Recent evidence from a large cohort study of adults at risk for 
coronary artery disease found that circulatory concentration of sgp130, but not cell-
surface expression, is predicted by a specific polymorphism, G148C, on the gp130 gene 
(Wonnerth et al., 2014). This is intriguing, more so because polymorphisms have been 
suggested as a genetic risk-factor for development of CLD previously (Bhandari and 
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Gruen, 2006), although a genome wide association study (GWAS) did not find 
significant associations between CLD and single nucleotide polymorphisms (SNP) 
(Wang et al., 2013). On the other hand, a separate GWAS identified novel SNPs in the 
IL-6ST (IL-6 signal transducer: gp130) gene as risk loci for rheumatoid arthritis (Stahl et 
al., 2010), a dsease where IL-6 trans-signalling is involved in the pathogenesis. Taken 
together, sgp130 polymorphisms could explain the difference in concentration noted 
in BALF, and suggest novel genetic risk loci for CLD.   
There are several other cytokines which belong to the IL-6 family (signal 
through gp130 signal transducer) including IL-11, leukaemia inhibitory factor (LIF), 
ciliary neurotrophic factor (CNTF), cardiotrophin-1 (CT-1), cardiotrophin like cytokine 
(CLC) and oncostatin-M (OSM). Like IL-6, IL-11 uses a homo-dimer of gp130 for intra-
cellular signalling (along with a cognate -receptor) while LIF, CNTF, CT-1, CLC and 
OSM signal through a gp130 hetero-dimer receptor (only one receptor subunit is 
gp130). The role of these cytokines, if any, on the development of CLD in preterm 
infants remain unknown. In a recent study on the growth of foetal rat lung explants, IL-
6 and IL-11 (which signal through a homo-dimer of gp130) were found to enhance 
growth and differentiation of lungs throughout foetal life, while CNTF, CLC, CT-1 and 
OSM (which signal through a hetero-dimer of gp130) inhibited lung growth. It is 
possible that other members of the IL-6 family have a yet unknown role in the preterm 
lungs and in the development of CLD. Soluble gp130 (sgp130) can inhibit LIF- and OSM-
induced cartilage injury (Hui et al., 2000); while IL-11 trans-signalling has been 
described (Curtis et al., 1997, Dams-Kozlowska et al., 2012), it remains unknown 
whether sgp130 has a similar inhibitory role as for IL-6 trans-signalling. Thus, the 
significantly high levels of sgp130 noted in preterm infants who later develop CLD 
could be involved in signalling by other members of the IL-6 family. This is another 
significant new area of research highlighted as a result of my work.  
The question regarding the effects of IL-6 trans-signalling in the preterm lungs 
remains unresolved. IL-6 being such an important cytokine in innate and acquired 
immunity, is almost certainly involved in inflammatory process in the preterm lungs. 
My data seems to suggest that IL-6 trans-signalling currently may not be an effective 
pathway; however there is possibility of exploring its effect by using hyper IL-6 (H IL-6) 
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in an appropriate animal model. This is supported by convincing experimental 
evidence of the pro-resolution effects of IL-6 trans-signalling (Hurst et al., 2001, 
McLoughlin et al., 2004, Chalaris et al., 2007). It remains to be seen whether the 
elevated concentration of sgp130 is able to inhibit effects of H IL-6 in vivo.  
In summary, this part of my work has confirmed some of my hypotheses, but 
raised several new research questions which needs to be addressed in future studies. 
 
6.3. Modulation of inflammation by IL-8 isoforms 
 
Interleukin-8 (IL-8) is a key chemokine in acute inflammation, involved in 
recruiting and activating neutrophils at sites of inflammation down a concentration 
gradient. It is ubiquitously expressed by almost all cell types at sites of inflammation, 
and increased IL-8 expression has been consistently reported in lungs of preterm 
infants who develop CLD, compared to those who do not. Elevated IL-8 expression 
could be partly responsible for the persistent neutrophilia observed in the lungs of 
preterm infants; however, other factors including poor resolution of inflammation 
likely contributes to this effect. Although IL-8 has been consistently reported in the 
literature in association with CLD, several other biological molecules which can attract 
and activate neutrophils are likely involved in lung inflammation in preterm infants. 
Some chemokines, like GRO-α, GRO-β and ENA-78, share receptors with IL-8, while 
other chemokines, like MIP-1α and RANTES, have separate receptors. Additionally, 
there are several other peptide molecules (e.g. complement anaphylatoxins: C5a) and 
lipid-derived mediators (e.g. leukotrienes and platelet activating factor) which have 
similar effects on neutrophils (Sadik et al., 2011). This redundancy would suggest that 
targeting any one of these mediators in isolation may not have a major clinical effect. 
However, IL-8 is the prototypical neutrophil activating chemokine and many of the 
other major chemokines share receptors with IL-8. Since its discovery, IL-8 has been 
the best studied chemokine in acute inflammation, and is known to be expressed early 
in the lungs of preterm infants before an influx of neutrophils (Munshi et al., 1997).  
Longer isoforms of IL-8 (IL-877) are functionally less potent compared to shorter 
isoforms (IL-872) in terms of neutrophil chemotaxis and degranulation. Although the 
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shorter isoform is the better studied molecule in the context of inflammation, IL-877 
expression is best characterised in non-leukocytic cells. IL-877 is also the most abundant 
isoform present in the preterm circulation (up to 60%), in contrast to term infants and 
adults (Maheshwari et al., 2009), raising the question of whether this is also the 
dominant isoform in the preterm lungs. My hypothesis for this part of the project was 
that persistent influx of neutrophils into the lungs of preterm infants suggests shorter, 
and functionally more potent, isoforms of IL-8 are the dominant molecules. 
IL-8 is the link between the two parts of my thesis and research work. In my 
earlier work, I have already shown that total IL-8 is present at a significantly higher 
concentration in the lung fluid of preterm ventilated infants who develop CLD, 
compared to preterm infants who do not. In this part of my work, I have looked at the 
modulation of the effects of IL-8 by IL-6 trans-signalling, as IL-8 has been shown to be 
down-regulated by the pro-resolution effects of IL-6 trans-signalling. In the second part 
of my work, I intended to address modulation of IL-8 activity due to expression of its 
functionally different isoforms.  
My data and analysis shows that as hypothesised, IL-877 is a minor proportion of 
total IL-8 in broncho-alveolar lavage fluid (BALF) from preterm ventilated infants. 
Although all the major cell populations could experimentally express significant 
quantities of IL-877 in vitro, this isoform was a minor proportion in lung fluid seemingly 
due to post-translational modification by neutrophil serine proteases and thrombin in 
preterm BALF, which retained significant enzymatic activity to cleave IL-877 to shorter 
isoforms. Conversion by proteinase-3 (Pr-3) resulted in a functionally more potent 
isoform, making Pr-3 an attractive target for therapeutic intervention. Thrombin had a 
similar effect on IL-877 as Pr-3, also making it a potential target in the preterm lung. 
Strategies to inhibit activity of serine proteases in the preterm infant lung has 
the potential to modulate inflammation by preventing post-translational modification 
of IL-877 and attenuating influx of neutrophils into the lungs. It is also thought that 
inhibition of proteases could attenuate direct lung injury caused by these proteases. 
Although laboratory studies have established this association between an imbalance in 
the protease-antiprotease concentration and the development of CLD (Davies et al., 
2010) with beneficial results in experimental CLD (Hilgendorff et al., 2011), a meta-
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analysis of clinical trials using AAT in preterm infants at risk of CLD was unable to 
demonstrate any significant benefit (Shah and Ohlsson, 2001).  
My study has identified two new modulation mechanisms of IL-8 in the preterm 
lungs: proteinase-3 (PR-3) and thrombin. While elastase and metallo-proteases have 
been previously studied in preterm infants in the context of CLD, this is the first time 
Pr-3 has been measured in the preterm lung fluid and a potential link established with 
neutrophil-driven inflammation. Clear links have been found between enzymes of the 
coagulation cascade, including thrombin, and inflammation (Lipinski et al., 2011). 
Although clinical evidence from adult trials is in is still at an early stage (Lipinski et al., 
2011, Wang et al., 2013b), this is clearly an under-researched area in the field of 
inflammation. Although anticoagulation may not be a valid option in preterm infants at 
risk of serious adverse effects (intra-ventricular and pulmonary haemorrhage), 
modified forms of antithrombin, which lacks anticoagulant properties but retains anti-
inflammatory properties (Wang et al., 2013b), may offer new therapeutic 
opportunities. 
 
 
6.4. Limitations and unresolved questions 
 
My study originates as observations in samples collected from human infants, 
which leads to in vitro experiments. Correlation of my conclusions in vivo in preterm 
infants is difficult and appropriate animal models need to be used for this purpose. 
However, the fact remains that a model for current CLD, where infants with lungs in 
the saccular stage of development are born through chorioamnionitis after receiving a 
course of antenatal steroids, receive exogenous surfactant replacement, are ventilated 
for a variable period of time in variable concentration of oxygen, and go on to develop 
CLD at the time-point where alveolarisation should start, does not exist. Importantly, I 
have studied two specific pathways to modulate neutrophil influx in the preterm lung. 
Inflammation at any site is characterised by redundancy, with several different 
pathways converging to produce similar effects. Thus, experimental findings described 
here are unlikely to reflect the full clinical picture.  Nevertheless, by undertaking 
203 
 
detailed functional studies such as this, we can begin to unpick the precise molecular 
events taking place in the preterm lung and leading to CLD.  
To look at expression of IL-8 from cells, I have used adult cell-lines and term 
newborn cells. Although preterm cells are known to be transcriptionally active, we do 
not know whether they would express similar proportions of IL-877. Lack of preterm 
lung cell-lines is a limitation of my study. Choosing an appropriate animal model for IL-
8 work is not straightforward. Common murine models are inappropriate as they do 
not express IL-8. KC (mice) and CINC-1 (rats) are considered to be functional 
homologues of human IL-8; however, it is not known whether isoforms of these 
molecules exist. The closest animal model of CLD is the preterm baboon model. Again, 
isoforms of IL-8 have not been studied in this model.  
For IL-6 trans-signalling, I have used a modified functional assay using the 
mouse B9 cells. Although lower sensitivity of IL-6 trans-signalling in functional assays is 
well known, I have had concerns whether I have used sufficient cytokine 
concentrations to form a stable sIL-6R/IL-6 complex. My approach has been to use an 
antibody for the membrane IL-6R to inhibit classical IL-6 signalling. Because of the 
sensitivity of these cells to IL-6, this approach only worked in the presence of a low 
concentration of IL-6 (< 10 pg/ml). Breakthrough signalling was observed at 
concentrations above this, even in the presence of the 2B10 antibody. Thus, the 
exquisite sensitivity of these cells to IL-6, which makes it an ideal model for use with 
clinical samples, may have proved to be the limiting factor in measuring IL-6 trans-
signalling. Whether this reflects a physiologically relevant difference in the relative 
sensitivity of cells to cis- and trans-signalling event remains to be seen, however 
further work in this area would be revealing and important for therapies targeting 
these distinct pathways.  Strategies to completely abolish classical signalling in this cell-
line by appropriate modifications may prove to be useful in the future. 
In the simplified experimental conditions of the laboratory, associations 
between a single risk-factor and a disease could become established. For the same 
reason, monotherapies may prove to be beneficial, when tested in the experimental 
models. A complex disease like CLD results from a combination of several risk factors. 
As is well established, nature has built-in several redundancies in the inflammatory 
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cascade, the factor which is strongly implicated in the development of CLD. Thus, in 
actual clinical situations monotherapies, especially those directed towards countering 
inflammation, are unlikely to demonstrate similar efficacy as under experimental 
conditions. Advances in clinical medicine depend on detailed research, which begins in 
the laboratory, progresses in animal models (which are more complex than in vitro 
conditions, but are still controlled situations) and then trialled on human patients. 
Many therapies, which initially show promise in the laboratory, fail on the last hurdle. 
However, most research advances our knowledge and understanding of diseases, and 
hopefully will lead to more directed interventions. 
 
6.5. Scientific uncertainties surrounding CLD/BPD 
 
Due to the prevalence of this condition in ex-preterm infants, CLD is commonly 
used in research studies as a marker of respiratory outcome. However, clinicians and 
researchers are still unable to fully agree on the definition of the term. In the past, 
CLD/BPD has been defined as a requirement for respiratory support at 28 days of life 
after preterm birth (Bancalari et al., 1979). This definition was changed in 1988 after a 
follow-up study by Shennan and colleagues who showed that the long-term respiratory 
outcomes of ex-preterm infants was best correlated with the need for respiratory 
support at 36 weeks of corrected gestational age (Shennan et al., 1988). These two 
clinical definitions of CLD/BPD remained in common use in the literature for a number 
of years; however, they were inconsistently applied by researchers in outcome studies. 
Predictably, comparison between studies were complicated by the lack of a consistent 
definition. Moreover, two major advances in neonatology – use of antenatal 
corticosteroids and exogenous surfactant replacement – became more common in the 
early to mid 1990s, leading to a shift in the natural history of the disease. Increased 
numbers of extremely preterm infants have survived since the routine use of these 
interventions (Roberts and Dalziel, 2006, Soll, 2000, Soll and Ozek, 2010), thus 
increasing the population of infants who are at highest risk of CLD. It was also noted 
that some preterm infants seem to need respiratory support, even if they have not 
been mechanically ventilated (Jobe, 1999). This led to a workshop to rethink the 
205 
 
definition of CLD and a new definition, stratified to gestation at birth and graded for 
severity, was proposed (Jobe and Bancalari, 2001a). A further refinement, using a 
room air saturation test to determine requirement for supplemental oxygen (Walsh et 
al., 2003), is also gaining popularity among researchers and epidemiologists. However, 
the definition of CLD remains a work in progress and universal acceptance is yet to be 
reached. 
As the name implies, CLD describes a clinical condition in ex-preterm infants. 
Although early studies have extensively described the pathology of BPD in preterm 
infants (Northway et al., 1967, Bonikos et al., 1976), the advent of antenatal 
corticosteroids and exogenous surfactant replacement have resulted in a change in 
pattern of the disease (Jobe, 1999). As mortality from BPD/CLD is rare in the current 
population of preterm infants (Jobe, 1999), only limited information is available on 
lung pathology from them. One study has looked at a small number of lung specimens 
from human infants with CLD, who received exogenous surfactant replacement at 
birth (Husain et al., 1998); we have also gained useful information from a primate 
model of BPD (Coalson et al., 1999b, Coalson, 2003, Coalson, 2006). Due to the low 
rates of mortality from this condition, these studies probably describe changes from 
the severe end of the spectrum. Thus, for the majority of infants with CLD/BPD, the 
pathological changes in the lung are yet to be characterised. 
Apart from extreme prematurity and low birth weight, several other risk factors 
have been implicated to contribute towards the development of CLD. Starting from 
antenatal infection, mechanical ventilation, postnatal infection, use of oxygen and 
patent ductus arteriosus are some of the common risk factors which have been 
extensively studied in the literature, although none of them have been established as 
having a cause-and-effect relationship with CLD. Indeed, contradictory results 
regarding contribution of each of these risk factors towards the development of CLD 
have been reported by researchers. However, lung inflammation has been proposed as 
the final common pathway involved in lung injury in preterm infants leading to the 
development of CLD (Speer, 2006, Ryan et al., 2008, Chakraborty et al., 2010). 
Lung inflammation involving the innate immune system has been extensively 
studied in preterm infants developing CLD/BPD (Ryan et al., 2008). Pathways of 
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inflammation in the preterm lung, as in other inflammatory diseases, is characterised 
by redundancy. Thus, activation of several different pathways of the innate immune 
system including cytokines, chemokines and proteases has been reported in the 
preterm lung. As with the risk factors mentioned previously, consistent associations of 
inflammatory mediators in the preterm lung with CLD are lacking, with IL-8 being a 
notable exception. Moreover, the mechanism of how lung inflammation leads to 
pathological changes (a temporary growth arrest in the alveolar development) is not 
yet clear. While the majority of research in inflammation has been observational, there 
is limited evidence in animal models of BPD regarding the efficacy of interventions in 
countering lung inflammation to prevent CLD (Auten et al., 2001, Hilgendorff et al., 
2011). This is in sharp contrast to intervention studies in human infants, none of which 
are yet to demonstrate any clear efficacy (Chakraborty et al., 2010).  
As discussed previously, lung inflammation has been strongly implicated as a 
final common pathway leading to the development of CLD. Evidence for this process 
has been accumulated from a large number of studies looking at many different 
pathways of inflammation. Most of these studies have taken a reductionist approach 
to a complex disease, and implicated candidate molecules to be involved in lung injury. 
While it is true that these molecules contribute to the process, due to the redundancy 
in inflammatory pathways, it is unlikely that targeting single molecules or pathways in 
human preterm infants would result in significant clinical benefit. This is borne out by 
the lack of any effective therapy for the treatment of CLD (Chakraborty et al., 2010). 
Interestingly, introduction of a package of interventions as a quality improvement 
programme may result in decreasing incidence of CLD, in keeping with its multi 
factorial pathogenesis (Pfister and Goldsmith, 2010). Prematurity being the primary 
risk factor for CLD, strategies to reduce or prevent preterm delivery would be the most 
definitive way to reduce CLD. So far, only one therapeutic intervention, progesterone 
replacement, has shown some benefit in reducing preterm delivery (Iams, 2014b, Iams, 
2014a).   
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6.6. Key points 
 
Key findings of my research: 
 Significant elevation of sgp130 concentration in BALF from preterm ventilated 
infants developing CLD later. 
 Possible lack of IL-6 trans-signalling activity in the preterm lungs. 
 Proteinase-3 and thrombin are key regulators of IL-877 function in the preterm 
lungs. 
 
Key areas of further research 
 Further modifications to B9 cells for measuring specific IL-6 trans-signalling. 
This could have application in several other diseases where IL-6 trans-signalling 
has been implicated in the pathogenesis. 
 Research into other members of the IL-6 family in the preterm lungs. 
 In vivo experiments involving IL-6 trans-signalling (both augmenting and 
inhibiting) in animal models to clarify its role. 
 Clinical trials of inhibition of proteinase-3 and thrombin in the preterm lungs.  
 Links between inflammation and interruption of lung growth in preterm 
infants.  
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8.2. Parent Information Leaflets and Consent Forms 
8.2.1. BALF Collection from Preterm Infants 
INFORMATION SHEET FOR PARENTS/GUARDIANS Ver 2.0 
 
Principle Investigators: Professor Sailesh Kotecha, Consultant Neonatologist 
Contact Details: Neonatal Unit, 029 20 74 3374 
 
1. Study Title 
Ex-vivo study to determine the efficacy of recombinant alpha 1-antitrypsin to redress proteolytic activity 
in lung lavage fluid obtained from preterm infants 
 
2. Invitation 
You are being invited to take part in a research study.  Before you decide it is important for you to 
understand why the research is being done and what it will involve.  Please take time to read the 
following information carefully and discuss it with others if you wish.  Ask us if there is anything that is 
not clear or if you would like more information.  Take time to decide whether or not you wish to take 
part. 
 
Thank you for reading this leaflet. 
 
3. What is the purpose of the study? 
Chronic Lung Disease of prematurity (CLD) which is also often called BPD (for bronchopulmonary 
dysplasia) is a common disease of premature babies. Babies with CLD require oxygen for prolonged 
periods and are sometimes discharged home on oxygen. Our research is trying to understand why some 
babies develop CLD. Our work has shown that babies who develop CLD have inflammation (redness and 
soreness) in their lungs. A cell type called neutrophil is responsible for the inflammation and these cells 
produce proteins called elastase which “dissolve” the lung tissues. Elastase is usually prevented from 
causing too much destruction in the lung tissue by another protein called alpha 1-antitrypsin or AAT. In 
babies who develop CLD, the balance between elastase and AAT is such that there is insufficient AAT 
thus resulting in elastase causing lung damage which may be one reason why babies develop CLD.  
 
Arrive Pharmaceuticals in the United States of America have developed AAT (called recombinant AAT or 
rAAT) in their laboratories. Before moving to a clinical study to examine if rAAT can be used to treat 
premature babies to prevent CLD, we wish to determine if rAAT can neutralise the excess elastase 
activity in lung fluid obtained from babies who need help with their breathing with mechanical 
ventilators.  
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4.  Why has my baby been chosen? 
We wish to obtain lung lavage fluid samples from two groups of babies: 
(a) babies who are born at or less than 32 weeks gestation and who need help with their 
breathing with breathing machines because of under-developed lungs, or 
(b) babies who need help with their breathing with breathing machines because of non-
breathing problems e.g. surgery. 
 
As your baby may fall into one of these two groups, we would like to invite you to take part in our study. 
 
5. Does my baby have to take part?  
It is up to you to decide whether or not you want your baby to take part. If you do decide that your baby 
can take part, you will be given this information sheet to keep and be asked to sign a consent form. If 
you decide for your baby to take part, you are still free to withdraw your baby at any time and without 
giving a reason. A decision to withdraw at any time, or a decision not to take part, will not affect the 
standard of care that your baby receives.  
 
6. What is the drug being tested? 
The drug is called recombinant alpha 1-antitrypsin or rAAT is developed by Arriva Pharmaceuticals. Our 
ultimate aim is to determine if this drug can decrease the rate of CLD in premature babies. Before we 
proceed to a clinical trial, we want to determine in the laboratory if rAAT can “neutralise” the elastase in 
lung fluid obtained from babies at risk of developing CLD.  
 
7.  What will happen if my baby takes part? 
We would like to obtain lung fluid from your baby whilst the baby remains on a breathing machine. The 
fluid will be obtained daily for the first week and twice weekly thereafter or until your baby is removed 
from the breathing machine, whichever occurs first. The breathing tube is often sucked out by the 
nurses to prevent it from blocking. We would replace this suctioning wherever possible so it does not 
need to be performed twice. In order to compare the results with other baby’s results, we have 
standardised this method of suctioning: we place the baby on his/her back and turn the head to the left 
side to encourage the suction tube to go down the right lung. We will then gently place a suction tube 
through the breathing tube into the lungs and through the tube insert saline (salt water). The amount of 
saline is based on the baby’s weight using 1 ml for each kilogram of the baby’s weight (one teaspoon is 5 
ml). After instilling the saline we will suck up as much fluid as possible and repeat the procedure once 
more. The returned fluid will consist of the saline and will also have the baby’s lung fluid which we can 
use for our research.  
 
We will monitor the baby’s heart rate and oxygen saturation during the procedure and sometime may 
need a little more oxygen (usually 5 – 10%) for a short period of time.  
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8. What will happen to the samples collected? 
We will use the fluid obtained from your babies to determine the amount of elastase activity and add 
rAAT to the fluid in the laboratory to determine if we can neutralise the elastase activity. The optimum 
dose of rAAT needed to neutralise the elastase activity will also be determined. If any fluid remains then 
we shall use this to measure the total amount of elastase and AAT as well as agents which promote or 
inhibit inflammation (named as IL-1, IL-6, TNF, IL-4, IL-10). We will analyse any cells obtained in the fluid 
sample for the presence of infection as infection has been shown to increase lung inflammation.  
9. What are the risks of my baby taking part? 
Babies who receive mechanical ventilation are monitored closely for their heart rate and oxygen levels. 
The risks are similar to those of routine suctioning that the baby may have. Sometimes the babies may 
need extra oxygen, typically 5 – 10%, for 5 – 10 minutes and sometimes especially when the suction 
tube is placed the heart rate may drop for a few seconds (usually less than 30 seconds). We would 
monitor the baby throughout the procedure and stop it if the baby becomes unwell in any way.  
 
10. What if something goes wrong? 
If your baby is harmed by taking part in this research project, there are no special compensation 
arrangements.  If your baby is harmed due to someone’s negligence, then you may have grounds for a 
legal action but you may have to pay for it.  Regardless of this, if you wish to complain, or have any 
concerns about any aspect of the way you or your baby have been approached or treated during the 
course of this study, the normal National Health Service complaints mechanisms should be available to 
you. 
 
11. Will my baby’s taking part be kept confidential? 
All information which is collected about your baby during the course of the research will be kept strictly 
confidential.  Any information about your baby which leaves the hospital/surgery will have your name 
and address removed so that you cannot be recognised from it. The company sponsoring this study will 
only have access to data from which your baby’s name, address and date of birth are removed. We will 
assign a number to each baby and use this to label the samples obtained for the study.  
 
12. What will happen to the results of the study? 
We will publish the results in reputable medical journals and will write a report on the study for the 
sponsors of the study. We will also present the data at scientific and medical meetings. Your baby’s 
name and details will NOT be revealed at any stage. Please let us know if you would like a copy of the 
report.  
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13. Who is paying for the study? 
The study is sponsored by Arriva Pharmaceuticals from California in the United States of America.  
 
14. Who had reviewed the study? 
This study has been reviewed by the South East Wales Research Ethics Committee and also by an expert 
group convened by Arriva Pharmaceuticals.  
 
15. Who can I contact for further information? 
You may contact Dr Phil Davies or Professor Sailesh Kotecha by asking one of the staff on the neonatal 
unit or by telephoning 029 20 74  3374 or by email (DavieP@Doctors.org.uk or 
KotechaS@Cardiff.ac.uk) or by mail to: 
 
Professor Sailesh Kotecha, Neonatal Unit, Heath Hospital, Heath Park, Cardiff CF14 4XN.  
 
 
Thank you for taking time to read this information leaflet at such a difficult time. Please do not 
hesitate to ask Dr Phil Davies or Professor Sailesh Kotecha if you would like to discuss anything 
further.  
 
 
Dr Philip Davies     Professor Sailesh Kotecha 
Clinical Research Fellow    Consultant in Neonatal Medicine 
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(Form to be on headed paper) 
Patient Identification Number for this trial: 
CONSENT FORM 
Ex-vivo study to determine the efficacy of recombinant alpha 1 - antitrypsin to redress proteolytic 
activity in lung lavage fluid obtained from preterm infants 
Name of Researcher:  Professor Sailesh Kotecha, Consultant Neonatologist, 
Neonatal Unit, Heath Hospital, Cardiff CF14 4XN 
 
       Please initial box 
 
1. I confirm that I have read and understand the information sheet dated .15th January 2005  
 (version 1.0) for the above study and have had the opportunity to ask questions. 
 
2. I understand that my baby’s participation is voluntary and that I am free to withdraw my baby  
 at any time, without giving any reason, without my baby’s medical care or legal rights being affected. 
 
3. I understand that sections of any of my baby’s medical notes may be looked at by    
 The research individuals I give permission for these individuals to have access to my  
 baby’s records. 
 
4. I agree for my baby to take part in the above study.       
 
 
________________________ ________________ ____________________ 
Name of Parent/Guardian Date Signature 
 
 
_________________________ ________________ ____________________ 
Name of Person taking consent Date Signature 
(if different from researcher) 
 
 
_________________________ ________________ ____________________ 
Researcher Date Signature 
 
 
 
 
 1 for patient, 1 for researcher, 1 to be kept with hospital notes. 
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8.2.2. Cord Blood Collection from Term Infants 
 
INFORMATION SHEET FOR PARENTS/GUARDIANS Version 4 (17th February 2010) –  
TERM BABIES 
 
Principle Investigators: Professor Sailesh Kotecha, Consultant Neonatologist 
Contact Details: Neonatal Unit, 029 20 74 3374 
 
Study Title 
 Developmental regulation of neonatal neutrophils and monocytes function. 
 
Invitation 
You are being invited to take part in a research study.  Before you decide it is important for you to 
understand why the research is being done and what it will involve.  Please take time to read the 
following information carefully and discuss it with others if you wish.  Please ask us if there is anything 
that is not clear or if you would like more information.  Take time to decide whether or not you wish to 
take part. 
 
Part 1 of this leaflet tells you the purpose of this study and what will happen if you decide to take part. 
Part 2 gives you more detailed information about the study. 
 
Thank you for reading this leaflet. 
 
Part 1 
 
1.1. What is the purpose of the study? 
We are trying to understand why some premature babies develop the disease called chronic lung 
disease of prematurity or CLD. Lung inflammation (redness and soreness) is common in babies who 
develop CLD. However, some of our work has shown that an under-developed immune system may be 
one reason why premature babies develop CLD. We wish to examine blood cells (which cause lung 
inflammation in babies who develop CLD) from babies born on time or prematurely to determine if their 
cell function is under-developed when compared to similar cells from healthy adults.  
 
1.2. Why have I and/or my baby been chosen? 
We wish to obtain samples from three groups: 
a) Babies born on time who are being delivered by an elective caesarean section 
b) Babies who are born prematurely (i.e. less than 32 weeks gestation) 
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c) Healthy adult donors 
 
Because your baby is due to be delivered on time by caesarean section, we would like to invite you to 
join our study. After the baby and placenta (after-birth) are delivered, we would like to obtain blood 
from the placenta to use for our studies.  
 
1.3. Does my baby have to take part?  
It is up to you to decide whether or not you want your baby to take part. If you do decide that your baby 
can take part, you will be given this information sheet to keep and be asked to sign a consent form. If 
you decide for your baby to take part, you are still free to withdraw your baby at any time and without 
giving a reason. A decision to withdraw at any time, or a decision not to take part, will not affect the 
standard of care that your baby receives.  
 
1.4. What will happen if my baby takes part? 
We would like to obtain blood (usually between 5-20 mls) from the placenta after the baby is born and 
the after-birth (placenta) is delivered. 
 
1.5. Will this affect my or my baby’s treatment? 
The medical care of you or your baby will not be affected by this study. The information from this study 
will not be used to diagnose or treat you or your baby. 
 
1.6. What are the risks of my baby taking part? 
The cord blood sample will be taken from the placenta after the umbilical cord has been cut and is not 
harmful or painful for you or your baby.  
 
1.7. What are the benefits of my baby taking part? 
We cannot promise that the study will help your baby but the information we get from this study may 
help us to improve the treatment of premature babies in the future. 
  
1.8. What if there is a problem? 
Any complaint about the way you or your baby have been dealt with during the study or any possible 
harm your baby might suffer will be addressed. The detailed information on this is given in Part 2. 
 
1.9. Will my baby’s taking part be kept confidential? 
Yes. We will follow ethical and legal practice and all information about you will be handled in 
confidence. The details are included in Part 2. 
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If the information in Part 1 has interested you and you are considering participation, please read the 
additional information in Part 2 before making a decision. 
 
Part 2 
 
2.1. What will happen if I don’t want my baby to carry on with the study? 
If you decide to withdraw from the study, we would like to use the data collected up to your withdrawal. 
Any stored blood or fluid samples that can be identified as your baby’s will be destroyed if you wish. 
 
2.2. What if there is a problem? 
If you are harmed by taking part in this research project, there are no special compensation 
arrangements.  If you are harmed due to someone’s negligence, then you may have grounds for a legal 
action against Cardiff University but you may have to pay for it.  Regardless of this, if you wish to 
complain, or have any concerns about any aspect of the way you have been approached or treated 
during the course of this study, the normal National Health Service complaints mechanisms should still 
be available to you. 
 
2.3. What will happen to the results of the study? 
We will publish the results in reputable medical journals and present the data at scientific and medical 
meetings. Your baby’s name and details will NOT be revealed at any stage. Please let us know if you 
would like a copy of the report.  
 
2.4. What will happen to the samples collected? 
From the blood samples we will separate the blood cells and the fluid (plasma). We will determine if 
there are differences in the function of the blood cells, including their survival, production of products 
which promote inflammation or tissue injury and their ability to kill germs.  
Sometimes we may have some of the blood sample left over after our initial tests. We would like to ask 
you if we may use any remaining sample for future studies. We would have to re-apply to the ethics 
committee to use the sample for any new studies. If you are happy for us to use the sample in the 
future, you will be asked to sign a separate consent form. If you do not agree to future use of the sample 
then we shall destroy any remaining sample at the end of this study. 
 
2.5. Will my baby’s taking part be kept confidential? 
All information which is collected about your baby during the course of the research will be kept strictly 
confidential. All data collected will be processed on a secure, password-protected computer at Cardiff 
University. Any information about your baby which leaves the hospital will have your and the baby’s 
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name and address removed so that you cannot be recognised from it. We will assign a number to each 
baby and use this to label the samples obtained for the study.  
 
2.6. Who is paying for the study? 
The studies are being funded by the Wellcome Trust and Arriva Pharmaceuticals.  
 
2.7. Who has reviewed the study? 
All research in the NHS is looked at by an independent group of people, called a Research Ethics 
Committee, to protect your and your baby’s safety, rights, wellbeing and dignity. This study has been 
reviewed and given a favourable opinion by the South East Wales Research Ethics Committee. 
 
2.8. Who can I contact for further information? 
You may contact Professor Sailesh Kotecha by asking one of the staff on the delivery suite or by 
telephoning 029 20 74 4187 or by email (KotechaS@Cardiff.ac.uk) or by mail to: 
Professor Sailesh Kotecha, Neonatal Unit, Heath Hospital, Heath Park, Cardiff CF14 4XN.  
 
Thank you for taking time to read this information leaflet. Please do not hesitate to ask Professor 
Sailesh Kotecha or Dr Mallinath Chakraborty if you would like to discuss anything further.  
 
 
Dr Mallinath Chakraborty    Professor Sailesh Kotecha 
Clinical Research Fellow     Consultant in Neonatal Medicine 
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CONSENT FORM – TERM BABIES 
 
Developmental regulation of neonatal neutrophils and monocytes function. 
 
Name of Researcher:   Professor Sailesh Kotecha, Consultant Neonatologist, 
Neonatal Unit, Heath Hospital, Cardiff CF14 4XN 
                      
 Please 
initial box 
1. I confirm that I have read and understand the information sheet dated 17th February 2010   
(version 4) for the above study and have had the opportunity to ask questions. 
 
2. I understand that my baby’s participation is voluntary and that I am free to withdraw my    
baby at any time, without giving any reason, without my baby’s medical care or legal rights 
being affected. 
 
3.  I consent to my baby’s cord blood being used        
 
4. I understand that sections of any of my baby’s medical notes may be looked at by the    
research individuals I give permission for these individuals to have access to my baby’s records.  
 
 
 
 
 
________________________ ________________ ____________________ 
Name of Parent/Guardian Date Signature 
 
 
_________________________ ________________ ____________________ 
Name of Person taking consent Date Signature 
(if different from researcher) 
 
 
_________________________ ________________ ____________________ 
Researcher Date Signature 
  
  1 for patient, 1 for researcher, 1 to be kept with hospital notes. 
 
 
 
 
